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uridines as MraY inhibitors: synthesis, biological
evaluation and molecular modeling†
Mickaël J. Fer,a Ahmed Bouhss,b Mariana Patrão,a Laurent Le Corre,a
Nicolas Pietrancosta,a Ana Amoroso,c Bernard Joris,c Dominique Mengin-Lecreulx,b
Sandrine Calvet-Vitale*a and Christine Gravier-Pelletier*a
The straightforward synthesis of 5’-methylene-[1,4]-triazole-substituted aminoribosyl uridines is
described. Two families of compounds were synthesized from a unique epoxide which was regioselec-
tively opened by acetylide ions (for compounds II) or azide ions (for compounds III). Sequential diastereo-
selective glycosylation with a ribosyl ﬂuoride derivative, Cu(I)-catalyzed azide–alkyne cycloaddition
(CuAAC) with various complementary azide and alkyne partners aﬀorded the targeted compounds after
ﬁnal deprotection. The biological activity of the 16 resulting compounds together with that of 14 pre-
viously reported compounds I, lacking the 5’ methylene group, was evaluated on the MraY transferase
activity. Out of the 30 tested compounds, 18 compounds revealed MraY inhibition with IC50 ranging from
15 to 150 µM. A molecular modeling study was performed to rationalize the observed structure–activity
relationships (SAR), which allowed us to correlate the activity of the most potent compounds with an
interaction involving Leu191 of MraYAA. The antibacterial activity was also evaluated and seven compounds
exhibited a good activity against Gram-positive bacterial pathogens with MIC ranging from 8 to 32 µg
mL−1, including the methicillin resistant Staphylococcus aureus (MRSA).
Introduction
In view of the increasing resistance1 of bacteria to commonly
used antibiotics and the emergence of multidrug resistant bac-
terial strains, it is of prime importance to develop antibiotics
with new mechanisms of action. Several strategies have been
developed for discovering new antibiotics; they notably include
the identification of new antibacterial targets by genomics
approaches and the screening of synthetic libraries on these
targets.2 However, a main drawback of the latter strategy lies in
the limited chemical diversity of the available libraries and in
the use of non-validated and isolated bacterial targets.3 A
complementary approach deals with the manipulation of
genes encoding enzymes involved in polyketides and non-
ribosomal peptides, in order to generate new derivatives.4
Indeed, many useful antibiotics belong to the latter two bio-
synthetic classes. New targets are also looked for in already
known biological processes such as, for example, folate bio-
synthesis,5 fatty acid biosynthesis,6 peptide deformylase7 and
transfer ribonucleic acid synthetases.8 The bacterial cell wall is
also particularly interesting in this respect. Indeed, the mul-
tiple enzymes involved in peptidoglycan biosynthesis,9 which
are essential and specific to the bacterial world, constitute
ideal targets in the search for new antibiotics, the inhibition of
any step in this pathway provoking an arrest of growth and cell
lysis. Thus, β-lactams and lipoglycopeptides are well-known
antibiotics which interfere with the late polymerization steps
of peptidoglycan biosynthesis. However, the ever increasing
number of resistance mechanisms developed or acquired by
pathogens towards these antibacterial agents10 forces us to
focus on upstream biosynthetic steps as potential alternative
drug targets. For several years, our group focused on the MraY
transferase, an integral membrane protein that is not targeted
by any drug in clinical use so far, a major advantage expected
to delay the emergence of resistance. The 3D structure of MraY
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was unknown until recently, due principally to its trans-
membrane nature. Nevertheless, the challenge has recently
been addressed and the 3D crystal structure of MraY from
Aquifex aeolicus (MraYAA) has been determined,
11 confirming
key structural features that had been previously identified.12,13
This enzyme, which catalyzes the first membrane-associated
step of peptidoglycan biosynthesis, has been demonstrated to
be essential14 and is ubiquitous in the bacterial kingdom.
It transfers the phospho-N-acetylmuramoyl-pentapeptide
(P-MurNAc-pentapeptide) moiety from the cytoplasmic precur-
sor UDP-MurNAc-pentapeptide to the membrane lipid acceptor
undecaprenyl-phosphate (C55-P), generating C55-pyrophos-
phoryl-MurNAc-pentapeptide (lipid I) and uridine monophos-
phate (UMP) (Fig. 1).12
In addition to a few non-nucleosidic compounds recently
described,15 several families of natural nucleoside antibiotics
such as FR-900493,16 liposidomycins,17 caprazamycins18 and
muraymycins19 (Fig. 2) have been identified as MraY inhibitors
and display interesting antibacterial activities.20 Elegant
synthetic approaches toward these compounds have been
reported.21,22 The common aminoribosyl-O-uridine scaﬀold
shared by the natural nucleoside inhibitors has been proven to
be essential for biological activity.23
Based on this aminoribosyl-O-uridine frame, our goal was
to develop powerful MraY inhibitors, displaying simplified
structure as compared to that of natural inhibitors and
endowed with antibacterial activity.
We report here the diversity-oriented synthesis of new MraY
inhibitors (Fig. 3), containing either a C-triazole (compounds
II) or an N-triazole (compounds III). Both families exhibit a
supplementary methylene group between the aminoribosyl
uridine scaﬀold and the triazole linker as compared to the
5′-triazole-substituted aminoribosyl uridines (compounds I) we
previously described.24 The enhanced flexibility of compounds
II and III was expected to improve the positioning of the result-
ing inhibitors within the active site of MraY and to result in a
better inhibitory activity.25 Identical R groups were used in
both series allowing a comparison of the respective impacts of
C- and N-triazole linkers. The in vitro and in cellulo biological
activity of compounds I, II and III was evaluated and a mole-
cular modeling study was performed to rationalize the
obtained in vitro activities.
Results and discussion
Chemical synthesis
The retrosynthesis we designed (Fig. 4) towards the targeted
inhibitors II and III relies on the Cu(I)-catalyzed azide–alkyne
cycloaddition26 (CuAAC) involving individual azides or alkynes
and complementary 5′-alkynylmethylenyl-aminoribosyl uridine
Fig. 1 Reaction catalyzed by the bacterial transferase MraY. The protein
is represented according to PDB code 4J72 of MraYAA, including the
catalytic magnesium (yellow ball).
Fig. 2 MraY natural inhibitors.
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A or 5′-azidomethylenyl-aminoribosyl uridine B, respectively.
These building blocks A and B could result from O-glycosy-
lation of the corresponding homopropargylic alcohol C or azi-
domethyl alcohol D by a known anomerically activated and
amine protected 5-amino-5-deoxy-D-ribofuranoside. Both alco-
hols C and D could come from a unique epoxide E.
We recently described the multi-gram scale synthesis of
epoxide 1 and its regioselective opening by various carbo- and
hetero-nucleophiles.27 In particular, nucleophilic opening of
the epoxide 1 by lithium trimethylsilylacetylide in the presence
of BF3·Et2O furnished the corresponding trimethylsilyl homo-
propargylic alcohol27 that was deprotected in the presence of
potassium carbonate in methanol to give 2 in 71% overall
yield (Scheme 1). In a complementary manner, opening of the
epoxide 1 by sodium azide in the presence of ammonium
chloride aﬀorded the azido alcohol 327 in 85% yield. Both alco-
hols 2 and 3 were next subjected to glycosylation with the
known amino ribose derivative 4,24 activated as a fluoride in
anomeric position and protected at C5′ as a phthalimido group
to prevent any side reaction during further CuAAC reaction.
This reaction was carried out in the presence of boron trifluor-
ide etherate28 at −78 °C in CH2Cl2 to provide the phthalimido-
ribosyl uridine derivatives 5 and 6 in 61% and 41% isolated
yields, with a good β/α diastereoselectivity (80/20 and 85/15,
respectively) thanks to the isopentylidene protective group of
the diol, hindering the α face of the ribosyl donor. Assignment
Fig. 3 Overall structure of targeted inhibitors.
Fig. 4 Retrosynthetic analysis.
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of anomers for compounds 5 and 6 was made according to dis-
tinguishing characteristic 1H NMR signals for H1″ (a singlet at
5.24 ppm for the major β anomers 5 and 6 and a doublet at
5.29 and 5.33 ppm (3JH1″–H2″ = 2.5 Hz) for their corresponding
minor α anomers, respectively).
With these key intermediates in hand, we next turned to
the preparation of the complementary fragments for CuAAC,
azido and alkynes building blocks with various structures and
polarity (Fig. 4). Thus, apolar aliphatic or aromatic azides and
alkynes 7a–b and 8a–b and polar hydroxylalkyl azides and
alkynes with various chain lengths 7c–d and 8c–d were
selected. Highly hydrophilic PEG-containing azide and alkyne
7e and 8e, prone to enhance water solubility, and phthalimido-
alkyl azide and alkyne 7f and 8f, as masked primary amines,
were also chosen. In addition, a few benzophenone containing
azides and alkynes 7g–h24 and 8g–h were included in the
series. Indeed, the related compounds I (Fig. 3) bearing such a
photoactivable group revealed promising inhibition of MraY
activity24 and the benzophenone moiety could further be
exploited to promote, upon irradiation, the formation of a
covalent linkage with the enzyme. Such an irreversible MraY-
inhibitor complex should enhance the stability of the protein
and promote its crystallization that would be a major leap for
rational drug design of new antibiotics. All these complemen-
tary fragments (Fig. 5) were either purchased from commercial
sources or synthesized in a few steps from alcohols or bromide
derivatives.
The synthesis of azides 7b,d,f and alkynes 8b–d,f–h is
depicted in Scheme 2. From the mesylate 9, readily obtained
from phenyl decanol in 91% yield, the azide 7b was prepared
by direct nucleophilic substitution by sodium azide, while the
nucleophilic substitution of the mesylate by lithium trimethyl-
silyl acetylide was revealed to be unsuccessful. Alkyne intro-
duction required the intermediate formation of the
corresponding bromide 10 followed by its substitution by
lithium acetylide leading to 11 and subsequent TMS de-
protection to provide the alkyne 8b in 62% overall yield from
9. The azide 7d resulted from bromodecanol by sodium azide
substitution. The phthalimidoalkyl azide 7f resulted from
dimesylate 1229 followed by nucleophilic substitution with
sodium azide to give 13 and subsequent phthalimide introduc-
tion. The alkynes 8c,d,f,h were obtained from the corres-
ponding dibromoalkane through substitution with lithium
Scheme 1 Synthesis of alkyne 5 and azide 6. Reagents and conditions: (a) trimethylsilylacetylene, n-BuLi, BF3·OEt2, THF, −78 °C to −10 °C, 16 h,
77%; (b) K2CO3, MeOH, 92%; (c) 4, BF3·EtO2, M.S. 4 Å, CH2Cl2, −78 °C, 81% as a 80/20 β/α mixture, 61% isolated for 5, 55% as a 85/15 β/α mixture,
41% isolated for 6; (d) NaN3, NH4Cl, DMF, 70 °C, 16 h, 85%.
Fig. 5 Structure of complementary azides 7a–h and alkynes 8a–h
fragments.
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trimethylsilyl acetylide which intermediately gave 14 and 15.
The bromo derivative 14 was substituted by potassium acetate
to aﬀord 16 that was deprotected by potassium carbonate in
methanol to furnish the alcohol 8c. In the same manner, the
bromo derivative 15 led to the alcohol 8d through the acetate
17. The phthalimido alkyne 8f and the benzophenone 8h were
respectively prepared by nucleophilic substitution of the
bromo derivative 15 with phthalimide potassium salt giving 18
and by 4-hydroxy-benzophenone in the presence of potassium
carbonate leading to 19, followed by TBAF deprotection.
Attempts to prepare the alkyne 21 from the bromo derivative
2024 by nucleophilic substitution with sodium acetylide or
lithium trimethylsilylacetylide resulted either in recovery of
unchanged starting material or complete degradation. Finally,
the alkyne 8g was synthesized from bromide 20, by copper-
promoted coupling30 with trimethylsilyl acetylene leading to
alkyne 21, followed by TMS deprotection in the presence of
potassium carbonate in methanol. It is noteworthy that TBAF
deprotection exclusively led to the formation of allene 22.
We next turned to the synthesis of the triazole-containing
targeted compounds 25a–h and 26a–h (Scheme 3).
Thus, azido and alkyne building blocks 5 and 6 were sub-
jected to CuAAC conditions with their complementary partner
7a–h and 8a–h, respectively. The reaction was carried out in
the presence of catalytic copper(I) in situ generated from
copper sulphate and sodium ascorbate26 in a 3/1 tert-BuOH/
H2O mixture with diisopropylethylamine as a base and
aﬀorded the expected C- and N-triazoles 23a–h and 24a–h in
yields ranging from 43 to 68% (Table 1). Amine and alcohols
deprotection were successively performed by methylamine in
Scheme 2 Synthesis of azides 7b, 7d, 7f and alkynes 8b–d, 8f–h. Reagents and conditions: (a) MsCl, TEA, DCM; (b) LiBr, acetone, reﬂux, 1.5 h; (c)
TMS-acetylene, BuLi, HMPA, THF, −78 °C, r.t., 16 h; (d) TBAF, THF, r.t., 1 h; (e) NaN3, NaI, DMF, 75 °C, 18 h; (f ) NaN3, CH3CN, reﬂux, 18 h; (g) PhthNK,
DMF, 80 °C, 18 h; (h) AcOK, DMF, 80 °C, 16 h; (i) K2CO3, MeOH, H2O, r.t., 6 h; ( j) PhthNK, DMF, r.t., 16 h; (k) 4-HO-BP, K2CO3, DMF, r.t., 16 h; (l) CuI,
TBAI, K2CO3, TMS-acetylene, CH3CN.
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methanol and acidic hydrolysis to give the targeted inhibitors
25a–h and 26a–h that were purified by preparative C-18 HPLC
and isolated as their TFA salts in 34–72% yield over two steps.
No trace of degradation product resulting from acidic cleavage
of the glycosidic bond was detected.
To perform a SAR study of these triazole-containing com-
pounds as inhibitors of the MraY activity, biological activity of
the C- and N-triazoles 25a–h and 26a–h (compounds II and III)
was evaluated (Table 2) and compared to that of the previously
described compounds I24 (Table 3) displaying a triazole linker
directly connected on the aminoribosyl uridine scaﬀold. The
structures of the related compounds 27a–n are depicted in
Fig. 6.
Furthermore, to assess the impact of the polarity and the
structure of the triazole substituent on the inhibitory activity,
the unprotected alkynes 28 and 34 and azide 29 were syn-
thesized as reference compounds (Scheme 4). On the one
hand, alkyne 28 and azide 29 were readily prepared by amine
and alcohols deprotection of alkyne 5 and azide 6 according to
the same conditions as those described above for compounds
25 and 26. On the other hand, the alkyne 34 was obtained in
three steps involving glycosylation of the propargylic alcohol
3131 with 5-azidoribosyl fluoride 3028 as a ribosyl donor to give
32, azide reduction under Staudinger conditions leading to 33
and acidic hydrolysis of ketal protective groups.
Biological evaluation
The inhibitory activity of compounds I (27a–n), II (25a–h), III
(26a–h) and their unprotected precursors (34, 28, 29) was eval-
uated on purified MraY transferase. Concerning compounds I
(Table 2), the introduction on the triazole of a short alkyl
chain bearing a polar group such as a hydroxyl (27e,f ), an
amino group (27g), an imidazolyl (27i), a hindered cycloheptyl
moiety (27b) or a more complex piperazinopyridine chain (27j)
was revealed to be detrimental to the inhibitory activity (IC50 >
1000 µM), as compared to that of the parent compound 34
(IC50 = 100 µM). Indeed, in this series the best inhibitors were
those containing either a benzophenone moiety (27k–n) or an
alkyl chain (27a,h) with IC50 ranging from 50 to 150 µM,
showing that a hydrophobic chain of suﬃcient length per-
mitted us to maintain the enzyme inhibition in the 100 µM
range. As exemplified for compounds 27c and 27d, a shorter or
a more rigid hydrophobic R group led to weaker activities (IC50
of 250 and 400 µM, respectively).
Interestingly, the mode of inhibition was investigated and
demonstrated to be competitive towards the nucleotide sub-
Scheme 3 Synthesis of targeted compounds 25a–h and 26a–h. Reagents and conditions: (a) 7a–h (R-N3) or 8a–h (R- ), DIPEA, CuSO4·5H2O
(0.1 equiv.), sodium ascorbate (0.3 equiv.), tert-BuOH/H2O 3 : 1, r.t., 16 h; (b) CH3NH2, MeOH, r.t., 5 h and then TFA/H2O 3 : 1, 0 °C, 10 min, and r.t.,
18 h.






23 25 24 26
7a a: 58 a: 62 8a a: 55 a: 56
7b b: 57 b: 53 8b b: 60 b: 52
7c c: 56 c: 38 8c c: 53 c: 34
7d d: 59 d: 65 8d d: 66 d: 42
7e e: 43 e: 52 8e e: 44 e: 69
7f f: 61 f: 41 8f f: 68 f: 45
7g g: 67 g: 64 8g g: 67 g: 72
7h h: 57 h: 69 8h h: 58 h: 64
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strate as exemplified for compound 27k (Fig. 7) with a Ki value
of 80 µM.
The in vitro activity of compounds II and III is depicted in
Table 3. Commercially available tunicamycin from Strepto-
myces sp. was used as a positive control in the test and resulted
in an IC50 value equal to 0.012 µM. From a general point of
view, the inhibitory activity of compounds II and III on the
MraY transferase was better than that of compounds I. Fur-
thermore, the general tendency showed that the C-triazole-
containing compounds II were more potent than the corres-
ponding N-triazole-containing compounds III. The inhibitors
bearing the longest alkyl chains (25d, 26d) were more potent
than their shorter homologs (25c, 26c). For a same length, the
compounds containing a hydroxyl group (25d, 26d) were more
active than those containing an amino group (25f, 26f). In spite
of their enhanced hydrosolubility, PEG-containing inhibitors
(25e, 26e) appeared to be poorly active. However, the introduc-
tion of a long hydrophobic chain on the triazole drastically
Scheme 4 Synthesis of reference compounds 28, 29 and 34. Reagents
and conditions: (a) CH3NH2, MeOH, 5 h, r.t. and then TFA/H2O: 3/1, 0 °C,
10 min, and r.t., 18 h, 31% for 28, 52% for 29; (b) BF3·Et2O, M.S., CH2Cl2,
−78 °C, 75% as a 13/1 β/α mixture, 45% isolated for 32; (c) PPh3, THF/
H2O: 6/1, 86%; (d) TFA/H2O: 3/1, 0 °C, 10 min and then r.t., 1.5 h, 99%.



















a The activities of the compounds were tested against purified MraY
from Bacillus subtilis. The assay was performed in a reaction mixture of
10 µL containing, in final concentrations, 100 mM Tris-HCl, pH 7.5,
40 mM MgCl2, 1.1 mM C55-P, 250 mM NaCl, 0.25 mM UDP-MurNAc-
[14C]pentapeptide (337 Bq), and 8.4 mM N-lauroyl sarcosine. The
reaction was initiated by the addition of MraY enzyme (50 ng), and the
mixture was incubated for 30 min at 37 °C under shaking. The
reaction was stopped by heating at 100 °C for 1 min and the
radiolabeled substrate (UDP-MurNAc-pentapeptide) and reaction
product (lipid I) were separated by TLC on silica gel plates. The
radioactive spots were located and quantified with a radioactivity
scanner. Data represent the mean of independent triplicate
determinations. b The activities were tested against purified MraY from
Aquifex aeolicus. Bp = benzophenone.
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improved the inhibitory activity, yielding IC50 ranging from 15 to
25 µM for compounds II (25a,b,g,h) and from 25 to 100 µM for
compounds III (26a,b,g,h). For these compounds, in both series,
the introduction of a substituted C or N-triazole improved by upFig. 6 Structure of compounds 27a–n.
Fig. 7 Analysis of MraY inhibition by compound 27k. Double reciprocal
plot of initial velocity versus UDP-MurNAc-pentapeptide. Compound
27k concentration was varied in the range 0–250 µM as indicated on
the right (µM).
Table 3 Inhibitory activity of compounds II (25a–h), III (26a–h), 28 and 29 against MraY
R1 Compound IC50
a (µM) Compound IC50
a (µM)
28 150 — —
–N3 — — 29 >1000
R Compounds II Compounds III
25a 15 26a 35
25b 20 26b 30
25c 400 26c 400
25d 40 26d 75
25e 750 — —
— — 26e 450
25f 200 26f 250
25g 20 26g 100
25h 25 26h 25
a The activities of the compounds were tested against purified MraY from Aquifex aeolicus. The assay was performed as described in Table 2.
Data represent the mean of independent triplicate determinations. Bp = benzophenone.
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to 10–40 fold the inhibitory potency as compared to that of the
parent compounds (28, 29). The promising results obtained for
the inhibitors 25g,h and 26g,h demonstrated a tolerance for
rather bulky groups such as benzophenone moieties.
The antibacterial activity of compounds I, II, and III was
evaluated and the data are shown in Table 4. Several Gram-
negative (E. coli ATCC 8730, C. freundii ATCC8090 and P. aerugi-
nosa ATCC 27853) and Gram-positive pathogenic bacterial
strains (S. aureus ATCC 25923, E. faecium ATCC 19434) were
selected, including a methicillin resistant strain (S. aureus
MRSA ATCC 43300). Piperacillin and vancomycin were used as
the positive control in the tests. Interestingly, 9 out of the
33 tested compounds revealed antibacterial activity with
minimum inhibitory concentration (MIC) values of 8–64 µg
mL−1 on the three Gram-positive pathogens and on the Gram-
negative P. aeruginosa. The best antibacterial activities were
observed for compounds 26h and 27m bearing a hydrophobic
decyloxybenzophenone R group with IC50 values of 25 and 100
µM, respectively (Tables 2 and 3). These promising antibacter-
ial activities were obtained against S. aureus MRSA and the
MIC values were 8 µg mL−1. Despite the simplicity of the 5′
substituent borne by the aminoribosyl uridine scaﬀold, it is
noteworthy that these antibacterial activities are comparable
with that reported for muraymycins, natural MraY inhibitors
with a much more complex structure.
Molecular modeling
Our SAR study revealed that a hydrophobic moiety was crucial
for the inhibitory activity. To better understand how the syn-
thesized compounds interact with the MraY protein and to
evaluate the role of this hydrophobic counterpart, we took
advantage that the X-ray crystal structure of MraY from Aquifex
aeolicus (MraYAA, PDB code: 4J72) had been recently solved,
11
paving the way for molecular docking studies. This structure
revealed an active site opened towards the cytoplasm. It com-
prises a magnesium cation, 10 trans-membrane helices
(TM1–10) and a deep hydrophobic pocket localized in the
trans-membrane domain and surrounded by TM5 and TM9
(Fig. 8). We thus anticipated that this hydrophobic groove
could play a major role in the interaction of our compounds,
through their hydrophobic tail, within the enzyme active site.
After the preparation of both protein and ligands (com-
pounds 25–27), we performed a blind docking study of all
compounds in the putative ligand binding site centered on the
magnesium ion (i.e. Mg2+, and key residues characterized by
Bouhss et al.13 such as Asp117 and Asp118). In parallel, all
compounds were divided into three batches according to their
in vitro potency: active compounds with an IC50 below or equal
to 25 µM (compounds 25a,b,g,h and 26h), weakly active com-
pounds which have no activity at 250 µM (compounds 25c,e,
26c,e and 27b,d–g,i,j) and an intermediate set (compounds
25d,f, 26a,b,d,f,g and 27a,c,h,k–n) with IC50 values ranging
from 25 to 250 µM. 200 conformers of compounds were gener-
ated using the Caesar protocol of Discovery Studio 4.1 soft-
ware32 and have been docked using the cDOCKER protocol.33
Finally, 5840 poses were generated after conformers docking
and were analysed based on their interactions with hydro-
phobic groove residues. In particular, we monitored poses in
which compounds bind with the key leucine residue (Leu191)
Table 4 Antibacterial activity of compounds I, II and III
Compound R
MICa (µg mL−1)



















Piperacillin 4 4 8 4 >128 4
Vancomycin — — — 1 1 0.5
27l –(CH2)5OBP >128 >128 >128 >128 64 >128
27m –(CH2)10OBP >128 >128 >128 8 8 >128
27n –
CH2PhCH2OBP
>128 >128 >128 >128 32 >128
25a –(CH2)9CH3 >128 >128 >128 128 64 >128
25b –(CH2)10Ph >128 >128 >128 32 16 64
25g –
CH2PhCH2OBP
>128 >128 >128 64 32 >128
26a –(CH2)9CH3 >128 >128 128 16 64 >128
26b –(CH2)10Ph >128 >128 64 64 16 32
26h –(CH2)10OBP >128 >128 >128 16 8 128
aDetermination of the antibacterial activity was performed on microtitric plates, in 200 µL (final volume) of Müeller–Hinton broth (MHB),
following the EUCAST (European Committee on Antimicrobial Susceptibility testing)/CLSI (Clinical and Laboratory Standard Institute)
recommended procedure. Compounds were solubilized in DMSO and then diluted in MHB just before utilization. Inocula were prepared for each
strain, resuspending isolated colonies from 18 h cultured plates. Equivalents of 0.5 McFarland turbidity standard (approximately 1 × 108 CFU
mL−1) were prepared in saline solution (NaCl 0.085%) and then diluted 200 fold in MHB. MIC values were determined as the lowest dilution of
product showing no visual turbidity.
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localized at the entrance of the groove (Fig. 8). Comparison
using the scoring function appeared to be inappropriate in our
case because of the micromolar activities of our compounds
(IC50 > 10 µM), so we selected the best interaction energy poses
(based on cDOCKER Interaction Energy33) for our binding
studies. Interestingly, our study revealed that an interaction
with Leu191, and consequently with the hydrophobic groove,
was suﬃcient to discriminate between active compounds and
others, either intermediate or weakly active, as illustrated by
compounds 25a and 25f (Fig. 9).
Furthermore, the results of docking experiments showed
that active compounds bound according to two modes. These
two binding modes are illustrated with compound 25a
(Fig. 10). Both of them revealed a good interaction between
the amino-ribosyl part of inhibitor 25a and the Mg2+ cation
(green ball, Fig. 10) as well as a varied and complex network
of low electrostatic interactions with residues located in the
active site and known to be important for substrate reco-
gnition,13 such as Asp265 or Lys121. A major diﬀerence
between both modes of interaction is the positioning of
Fig. 8 The active site of MraYAA. Molecular surface of MraY was obtained by the superimposition of atom-centered spheres, where the spheres’
radii are given by the atomic van der Waals radii. The putative active site (red circle) described by Chung et al.11 is located predominantly in the cyto-
solic extra-membrane portion and partially into the trans-membrane domain of the protein. The catalytic Mg2+ is represented by a green sphere and
the hydrophobic groove is shown by a blue arrow. The access of this cleft is monitored by the Leu191 (in yellow).
Fig. 9 Interaction of active compound 25a (IC50 = 15 µM) and analog 25f from the intermediate set (IC50 = 200 µM) with the hydrophobic groove.
Both docked compounds 25a and 25f (red stick) bind to MraY and chelate the magnesium (green ball) via a hydroxyl group of the ribose. However,
25a only interacts with Leu191 (yellow).
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active compounds within the active site. Indeed, the inter-
action with the hydrophobic groove can involve the hydro-
phobic tail of the active inhibitors (Mode A, Fig. 10A), as one
can expect, or, more surprisingly, their uracil moiety (Mode B,
Fig. 10B).
The eﬀect of introducing a hydrophobic moiety on an
aminoribosyl scaﬀold has already been reported.34,35 On the
one hand, Dini et al.34 reported an interesting SAR study of
aminoribosyl uridine derivatives lacking the hydroxyl group at
C-3′ and bearing various substituents at C-5′. Their study
showed that the introduction of a hydrophobic chain at C-5′
led to a five- to ten-fold increase of in vitro potency compared
to that of the parent compound. These results are in good
agreement with a positioning of the inhibitors according to
the mode A suggested by our docking experiments. On the
other hand, Matsuda et al.35 reported the synthesis of muray-
mycins analogues with an elaborate urea-dipeptide motif intro-
duced on an amino acid at the C-5′ position of an
aminoribosyl uridine scaﬀold. Biological evaluation of several
analogs diﬀering in the hydrophobic chain introduced on this
urea-dipeptide was also reported and showed that the presence
of a long hydrophobic chain decreased the inhibitory activity
by a factor 30, while the antibacterial activity was improved
due to a better membrane penetration. According to the
authors, this urea-dipeptide moiety could interact with the
carbohydrate recognition domain in the cytoplasmic loop 5,
while the aminoribosyl moiety could interact with the
vicinal Asp located on the cytoplasmic loop 2, close to the
magnesium cation. The resulting positioning, locating the
uracil moiety next to the hydrophobic groove, would be in
good agreement with our binding mode B. Thus, the two
modes of binding revealed by our docking study could explain
the contrasting conclusions of the SAR reported by Dini34 and
Matsuda.35
Conclusion
We report the synthesis of 16 inhibitors of the bacterial trans-
ferase MraY displaying a 5′-methylene-[1,4]-triazole-substituted
aminoribosyl uridine structure from a conveniently protected
epoxyuridine derivative. Key steps of the synthesis involved the
regioselective opening of this epoxide by acetylide or azide
ions followed by a sequential β-selective glycosylation with a
ribosyl donor, Cu(I)-catalyzed azide–alkyne cycloaddition with
various complementary azide and alkyne partners, to intro-
duce chemical and structural diversity, and deprotection to
aﬀord C-triazole (compounds II) or a N-triazole (compounds
III). The biological activity of the 16 resulting compounds was
evaluated in vitro on purified MraY and in cellulo on diﬀerent
Gram (+) and Gram (−) bacterial strains and was compared to
that of 14 previously synthesized compounds lacking the 5′
methylene group (compounds I). The latter was revealed to be
weakly active on MraY, except those bearing either a benzo-
phenone moiety, for which the IC50 ranged from 50 to 125 µM,
or a hydrophobic chain with an IC50 of about 150 µM. In con-
trast, all compounds II and III proved to be inhibitors of the
enzymatic activity of MraY, with IC50 ranging from 15 to 25 µM
for the most potent, showing a meaningful improvement of
the inhibitory activity related to the enhanced flexibility of
compounds II and III as compared to that of compounds I. A
slight superiority of compounds II as compared to compounds
III was observed, revealing the influence of the positioning of
the triazole ring within the active site, the mode of inhibition
of these inhibitors having been demonstrated to be competi-
tive towards the nucleotide substrate. The introduction of a
long hydrophobic chain on the triazole drastically improved
the inhibitory activity. A molecular modeling study was per-
formed to rationalize the observed structure–activity relation-
ships (SAR), which allowed us to correlate the activity of the
most potent compounds with an interaction involving Leu191
of MraYAA and which was consistent with two possible modes
of positioning for the most active inhibitors within the enzy-
matic active site, with either the hydrophobic chain in the
hydrophobic groove or the uracil moiety. The antibacterial
activity was also evaluated, and out of the 30 tested com-
pounds, seven of them exhibited a good activity against Gram-
positive bacterial pathogens with MIC ranging from 8 to 32 µg
mL−1, including methicillin resistant Staphylococcus aureus
(MRSA).
Fig. 10 Docking modes of compound 25a: mode A (with the hydrophobic tail into the hydrophobic groove, in contact with Leu191) and mode B
(with the uracil moiety into the hydrophobic groove, in contact with Leu191).
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When needed, reactions were carried out under an argon
atmosphere. They were monitored by thin-layer chromato-
graphy with precoated silica on aluminium foil. Flash
chromatography was performed with silica gel 60 (40–63 μm);
the solvent systems are given in v/v. Spectroscopic 1H and 13C
NMR, MS and/or analytical data were obtained using
chromatographically homogeneous samples. 1H NMR
(500 MHz) and 13C NMR (125 MHz) spectra were recorded in
CDCl3 unless otherwise indicated. Chemical shifts (δ) are
reported in ppm and coupling constants are given in Hz. For
each compound, detailed peak assignments have been made
according to COSY, HSQC and HMBC experiments. The num-
bering of molecules is indicated in the ESI.† Optical rotations
were measured with a sodium (589 nm) lamp at 20 °C. Melting
points were measured on a hot bench. IR spectra were
recorded on an FT-IR spectrophotometer and the wavelengths
are reported in cm−1. Purification of tested compounds was
achieved by either recrystallization or semi-preparative reverse
phase HPLC (column: Cluzeau, C18-stability, 10 µm, 250 mm ×
20 mm). Unless otherwise indicated, methods used for purifi-
cation were: method A: flow rate: 15 mL min−1, H2O–TFA
0.1%/MeOH (60/40 to 10/90 v/v in 12 min); method B: flow
rate: 15 mL min−1, H2O–TFA 0.1%/MeOH (60/40 for 5 min to
10/90 v/v in 10 min). Purity of tested compounds (>95%) was
controlled by analytical reverse phase HPLC (column: Cluzeau,
C18-stability, 5 µm, 250 mm × 4.6 mm). Unless otherwise indi-
cated, methods used were: method C: flow rate: 1 mL min−1,
H2O–TFA 0.1%/MeOH (60/40 to 10/90 v/v in 12 min) or
method D: flow rate: 1 mL min−1, H2O–TFA 0.1%/MeOH
(60/40 for 5 min to 10/90 v/v in 10 minutes). Products were
detected at 254 nm; low resolution mass spectra (LRMS) were
recorded with an ion trap mass analyzer under electrospray
ionization (ESI) in positive ionization mode detection or
atmospheric pressure chemical ionization (APCI). High
resolution mass spectra (HRMS) were recorded with a TOF
mass analyzer under electrospray ionization (ESI) in positive
ionization mode detection, atmospheric pressure chemical
ionization or atmospheric pressure photoionization (APPI).
For MraY activity, the radioactive spots were located and quan-




uridine 2. At −78 °C, to a solution of ethynyltrimethylsilane
(2.29 g, 23.35 mmol, 4 equiv.) in dry THF (35 mL) was drop-
wise added n-BuLi (1.9 M in hexane, 12.3 mL, 23.35 mmol,
4 equiv.). The resulting solution was stirred at −78 °C for 1 h.
At −78 °C, to this resulting solution were successively added
dropwise a solution of epoxide 1 (2.83 g, 5.84 mmol, 1 equiv.)
in freshly distilled THF (35 mL) and BF3·Et2O (2.9 mL,
23.35 mmol, 4 equiv.). The resulting solution was allowed to
warm from −78 °C to −10 °C and the mixture was diluted in
DCM. Saturated aqueous solution of NH4Cl was then added
(20 mL) and the aqueous phase was extracted with DCM (3 ×
40 mL). The combined organic phases were dried over Na2SO4,
filtered and concentrated in vacuo. Flash chromatography of
the residue (cyclohexane/EtOAc = 8/2 to 7/3) aﬀorded the
desired homopropargylic alcohol as a white powder (2.63 g,
77% yield). This compound (2.6 g, 4.46 mmol, 1 equiv.) was
then dissolved in methanol (52 mL) and potassium carbonate
(3.1 g, 22.3 mmol, 5 equiv.) was added. The mixture was
stirred at r.t. for 2.5 h and quenched by addition of saturated
aqueous solution of NH4Cl (30 mL). After removal of volatiles
in vacuo, the aqueous phase was extracted with EtOAc (5 ×
50 mL) and the combined organic layers were dried over
Na2SO4, filtered and concentrated in vacuo. Flash chromato-
graphy (cyclohexane/EtOAc 6/4) of the residue aﬀorded alcohol
2 as a white solid (2.1 g, 92% yield): Rf 0.30 (cyclohexane/
EtOAc 1/1); mp 198–204 °C; [α]D −11 (c 1.0, CH2Cl2); IR (film)
3474br, 2857m, 1693s, 1158w; 1H NMR δ 8.54–8.38 (m, 1H,
NH), 7.58 (d, 1H, JH6–H5 = 8.5 Hz, H6), 5.73 (dd, 1H, JH5–H6 =
8.5 Hz, JH5–NH = 2.5 Hz, H5), 5.46 (d, 1H, JH1′–H2′ = 6.0 Hz, H1′),
4.59 (dd, 1H, JH2′–H1′ = 6.0 Hz, JH2′–H3′ = 4.0 Hz, H2′), 4.18–4.16
(m, 2H, H3′, H4′), 3.88–3.85 (m, 1H, H5′), 3.58–3.47 (br s, 1H,
OH), 2.58 (ddd, 1H, JH6′a–H6′b = 16.5 Hz, JH6′a–H5′ = 7.5 Hz,
JH6′a–H8′ = 2.5 Hz, H6′a), 2.44 (ddd, 1H, JH6′b–H6′a = 16.5 Hz,
JH6′b–H5′ = 7.5 Hz, JH6′b–H8′ = 2.5 Hz, H6′b), 2.08 (t, 1H, JH8′–H6′a =
JH8′–H6′b = 2.5 Hz, H8′), 0.92 (s, 9H, –C(CH3)3), 0.87 (s, 9H,
–C(CH3)3), 0.16 (s, 9H, –Si–(CH3)3), 0.09, 0.06, 0.01 (3s, 12H, –Si–
t-Bu–(CH3)2);
13C NMR δ 162.8 (C4), 150.4 (C2), 143.4 (C6), 102.4
(C5), 94.1 (C1′), 86.6 (C4′), 80.6 (C7′), 73.1, 73.1 (C2′, C3′), 71.0
(C8′), 69.7 (C5′), 26.0, 25.9 (–C(CH3)3), 24.5 (C6′), 18.2, 18.1 (–
C(CH3)3), −4.3, −4.4, −4.5, −4.8 (–Si–t-Bu–(CH3)2); HRMS ESI+
calcd for C24H43N2O6Si2
+ (M + H)+ 511.2654, found 511.2650.
1″,5″-Dideoxy-2″,3″-O-isopentylidene-5″-phthalimido-1″-
[2 ′,3 ′-O-isopropylidene-5′(S)-acetylenylmethyl-uridinyl ]-
β-D-ribofuranose 5. Fluoride 4 (684 mg, 1.96 mmol, 2 equiv.)
and alkyne 2 (500 mg, 0.98 mmol, 1 equiv.) were dried together
by coevaporation with toluene (3 × 10 mL) and dissolved in
DCM (26 mL). The flask was flushed with argon and molecular
sieves 4 Å was added (5 g) in one portion. The suspension was
stirred at r.t. for 1 h and then cooled to −78 °C. Boron trifluor-
ide diethyletherate (248 µL, 1.96 mmol, 2 equiv.) was added at
−78 °C and the reaction medium was stirred at this tempera-
ture for 10 min and was then allowed to warm to r.t. for 16 h.
The reaction mixture was filtered on a celite pad and the cake
was washed with DCM (50 mL). The reaction was quenched by
addition of a saturated aqueous NaHCO3 solution (50 mL) and
the aqueous phase was extracted with DCM (5 × 60 mL). The
combined organic layers were dried (Na2SO4), filtered and con-
centrated in vacuo. The resulting white foam was purified by
flash chromatography (toluene/acetone 95/5) to give the
phthalimido-ribosyl-uridine 5 as a β/α mixture (β/α = 85/15) as
a white foam (668 mg, 81% combined yield). After crystalliza-
tion in a minimum amount of cyclohexane/EtOAc 9/1, the
β-anomer was isolated with 61% yield: Rf 0.26 (cyclohexane/
EtOAc 6/4); m.p. 122–125 °C; [α]D −34 (c 1.0, CH2Cl2); IR (film)
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3268br, 2857w, 1774w, 1718s, 1696m, 1394m; 1H NMR δ 8.47
(br s, 1H, NH), 7.90–7.87 (m, 2H, H11″), 7.84 (d, 1H, JH6–H5 =
8.0 Hz, H6), 7.78–7.74 (m, 2H, H12″), 6.17 (dd, 1H, JH5–H6 = 8.0
Hz, JH5–NH = 2.0 Hz, H5), 5.92 (d, 1H, JH1′–H2′ = 4.5 Hz, H1′),
5.24 (s, 1H, H1″), 4.75 (d, 1H, JH2″–H3″ = 6.0 Hz, H2″), 4.64 (d,
1H, JH3″–H2″ = 6.0 Hz, H3″), 4.53 (dd, 1H, JH4″–H5″b = 10.5 Hz,
JH4″–H5″a = 6.0 Hz, H4″), 4.47 (dd, 1H, JH4′–H5′ = 1.0 Hz, JH4′–H3′ =
4.5 Hz, H4′), 4.18 (t, 1H, JH2′–H3′ = JH2′–H1′ = 4.5 Hz, H2′), 4.02 (t,
1H, JH3′–H2′ = JH3′–H4′ = 4.5 Hz, H3′), 3.87 (ddd, 1H, JH5′–H4′ = 1.0
Hz, JH5′–H6′a = 4.5 Hz, JH5′–H6′b = 11.0 Hz, H5′), 3.81 (dd, 1H,
JH5″a–H5″b = 13.5 Hz, JH5″a–H4″ = 6.0 Hz, H5″a), 3.77 (dd, 1H,
JH5″b–H5″a = 13.5 Hz, JH5″b–H4″ = 10.5 Hz, H5″b), 2.98 (ddd, 1H,
JH6′a–H6′b = 16.5 Hz, JH6′a–H5′ = 4.5 Hz, JH6′a–H8′ = 2.5 Hz, H6′a),
2.66 (ddd, 1H, JH6′b–H6′a = 16.5 Hz, JH6′b–H5′ = 11.0 Hz, JH6′b–H8′ =
2.5 Hz, H6′b), 2.06 (t, 1H, JH8′–H6′a = JH8′–H6′b = 2.5 Hz, H8′),
1.72–1.60 (m, 2H, H7″), 1.56–1.48 (m, 2H, H7″), 0.94 (s, 9H,
–C(CH3)3), 0.91 (s, 9H, –C(CH3)3), 0.88 (t, 3H, JH8″–H7″ = 7.5 Hz,
H8″), 0.82 (t, 3H, JH8″–H7″ = 7.5 Hz, H8″), 0.13, 0.10 (2s, 12H, –Si–
t-Bu–(CH3)2);
13C NMR δ 168.2 (C9″), 163.3 (C4), 150.3 (C2), 139.8
(C6), 134.5 (C12″), 131.9 (C10″), 123.9 (C11″), 117.7 (C6″), 112.5
(C1″), 102.8 (C5), 88.6 (C1′), 86.3 (C3″), 84.6 (C4″), 83.8 (C4′), 82.1
(C2″), 79.6 (C5′), 79.4 (C7′), 75.6 (C2′), 72.2 (C3′), 71.4 (C8′), 40.4
(C5″), 29.4, 28.9 (C7″), 25.9, 25.9 (–C(CH3)3), 22.8 (C6′), 18.2
(–C(CH3)3), 8.5, 7.4 (C8″), −3.9, −4.3, −4.6, −4.6 (–Si–t-Bu–
(CH3)2); HRMS ESI
+ calcd for C42H62N3O11Si2




6. Fluoride 4 (1.19 g, 3.39 mmol, 2.1 equiv.) and azide
3 (852 mg, 1.61 mmol, 1 equiv.) were dried together by co-evap-
oration with toluene (3 × 10 mL) and dissolved in DCM
(26 mL). The flask was flushed with argon and molecular
sieves 4 Å was added (8 g) in one portion. The suspension was
stirred at r.t. for 1 h and then cooled to −78 °C. Boron trifluor-
ide diethyletherate (426 µL, 3.39 mmol, 2.1 equiv.) was added
at −78 °C and the reaction medium was stirred at this tempera-
ture for 10 min and was then allowed to warm to r.t. for 16 h.
The reaction mixture was filtered on a celite pad and the cake
was washed with DCM (50 mL). The reaction was quenched by
addition of a saturated aqueous NaHCO3 solution (50 mL) and
the aqueous phase was extracted with DCM (5 × 60 mL). The
combined organic layers were dried (Na2SO4), filtered and con-
centrated in vacuo. The resulting white foam was purified by
flash chromatography (toluene/acetone 95/5) to give the
phthalimido-ribosyl-uridine 6 as a β/α mixture (β/α = 85/15) as
a white foam (761 mg, 55% combined yield). The β-anomer
was isolated with 41% yield: Rf 0.52 (toluene/acetone 8/2);
m.p. 102–106 °C; [α]D −9 (c 0.6, CH2Cl2); IR (film) 2928br,
2856br, 1715s, 1698m, 1394m; 1H NMR δ 8.45 (br s, 1H, NH),
7.91–7.89 (m, 2H, H11″), 7.85 (d, 1H, JH6–H5 = 8.5 Hz, H6),
7.79–7.76 (m, 2H, H12″), 6.14 (dd, 1H, JH5–H6 = 8.5 Hz, JH5–NH =
1.0 Hz, H5), 5.85 (d, 1H, JH1′–H2′ = 4.0 Hz, H1′), 5.24 (s, 1H, H1″),
4.75 (d, 1H, JH2″–H3″ = 5.5 Hz, H2″), 4.65 (d, 1H, JH3″–H2″ = 5.5
Hz, H3″), 4.55 (dd, 1H, JH4″–H5″b = 10.5 Hz, JH4″–H5″a = 5.5 Hz,
H4″), 4.25 (dd, 1H, JH4′–H5′ = 1.5 Hz, JH4′–H3′ = 4.0 Hz, H4′), 4.19
(t, 1H, JH2′–H3′ = JH2′–H1′ = 4.0 Hz, H2′), 4.04 (t, 1H, JH3′–H2′ = JH3′–
H4′ = 4.0 Hz, H3′), 3.88–3.70 (m, 4H, H5′, H6′a, H5″a, H5″b), 3.60
(dd, 1H, JH6′b–H6′a = 12.5 Hz, JH6′b–H5′ = 9.0 Hz, H6′b), 1.73–1.64
(m, 2H, H7″), 1.55–1.49 (m, 2H, H7″), 0.94 (s, 9H, –C(CH3)3),
0.92 (s, 9H, –C(CH3)3), 0.88 (t, 3H, JH8″–H7″ = 7.5 Hz, H8″), 0.83
(t, 3H, JH8″–H7″ = 7.5 Hz, H8″), 0.16, 0.13, 0.13 (3s, 12H, –Si–t-
Bu–(CH3)2);
13C NMR δ 168.2 (C9″), 163.2 (C4), 150.2 (C2), 139.8
(C6), 134.6 (C12″), 131.9 (C10″), 123.9 (C11″), 117.8 (C6″), 112.5
(C1″), 102.6 (C5), 89.1 (C1′), 86.2 (C3″), 84.6 (C4″), 82.9 (C4′), 82.1
(C2″), 78.6 (C5′), 75.6 (C2′), 71.6 (C3′), 51.5 (C6′), 40.4 (C5″), 29.4,
28.9 (C7″), 25.9 (–C(CH3)3), 18.2, 18.2 (–C(CH3)3), 8.5, 7.5 (C8″),
−3.9, −4.2, −4.7, −4.7 (–Si–t-Bu–(CH3)2); HRMS ESI+ calcd for
C40H61N6O11Si2
+ (M + H)+ 857.3931, found 857.3945.
10-Phenyldecyl methanesulfonate 9. To a solution of
10-phenyldecanol (625 mg, 2.67 mmol, 1 equiv.) in dichloro-
methane (2 mL) was added triethylamine (593 µL, 4.26 mmol,
1.6 equiv.). At 0 °C, to this resulting solution was then added
dropwise methanesulfonyl chloride (310 µL, 4.0 mol,
1.5 equiv.). The mixture was stirred at 0 °C for 30 min and
then at r.t. for 2 h. The precipitate was filtered out and the fil-
trate was concentrated in vacuo. Flash chromatography of the
residue (cyclohexane/EtOAc 8/2 to 6/4) aﬀorded the mesylate 9
as a colorless oil (760 mg, 91% yield): Rf 0.52 (cyclohexane/
EtOAc 6/4); IR (film) 2854m 1354s, 1110s, 972m, 952m, 831w;
1H NMR δ 7.34–7.31 (m, 2H, H3), 7.24–7.24 (m, 3H, H2, H4),
4.28 (t, 2H, JHa–Hb = 6.5 Hz, Ha), 3.05 (s, 3H, CH3), 2.66 (t, 2H,
JHj–Hi = 7.5 Hz, Hj), 1.82–1.77 (m, 2H, Hi), 1.69–1.64 (m, 2H,
Hb), 1.47–1.42 (m, 2H, Hc), 1.39–1.30 (m, 10H, Hd, He, Hf, Hg,
Hh);
13C NMR δ 143.0 (C1), 128.5 (C3), 128.4 (C2), 125.7 (C4),
51.7 (Ca), 37.5 (CH3), 36.1 (Cj), 31.6 (Ci), 26.6, 29.4, 29.3, 28.9,
26.9 (Cb, Cc, Cd, Ce, Cf, Cg, Ch); HRMS ESI
+ calcd for
C17H28O3SNa
+ (M + Na)+ 335.1651, found 335.1652.
1-Bromo-10-phenyl-decane 10. To a solution of mesylate 9
(150 mg, 0.48 mmol, 1 equiv.) in acetone (3.0 mL) was added
lithium bromide (84 mg, 0.96 mmol, 2.0 equiv.). The mixture
was refluxed for 2 h, cooled to r.t., and concentrated in vacuo.
The residue was filtered through a silica gel pad and washed
with DCM (50 mL) to furnish 10 as a colorless oil (137 mg,
96% yield): Rf 0.62 (cyclohexane/EtOAc 9/1); IR (film) 3026w,
2925s, 2853m, 1603w, 1453m, 699s; 1H NMR δ 7.30–7.27 (m,
2H, H3), 7.19–7.17 (m, 3H, H2, H4), 3.42 (t, 2H, JHa–Hb = 7.0 Hz,
Ha), 2.62 (t, 2H, JHj–Hi = 7.5 Hz, Hj), 1.86 (qt, 2H, JHb–Ha = JHb–Hc =
7.0 Hz, Hb), 1.66–1.58 (m, 2H, Hi), 1.46–1.40 (m, 2H, Hc),
1.36–1.28 (m, 10H, Hd, He, Hf, Hg, Hh);
13C NMR δ 143.0 (C1),
128.5 (C3), 128.4 (C2), 125.7 (C4), 36.1 (Cj), 34.2 (Ca), 32.8 (Cb),
31.6 (Ci), 29.6, 29.6, 29.4, 28.9, 28.3 (Cc, Cd, Ce, Cf, Cg, Ch);
HRMS APPI calcd for C16H25Br
+ (M)+ 296.1140, found
296.1130. Spectral data were in agreement with the literature.36
12-Phenyl-1-trimethylsilyl-dodec-1-yne 11. A flame dried
flask flushed with argon was cooled to −78 °C and charged
with a solution of ethynyltrimethylsilane (413 mg, 4.21 mmol,
2.5 equiv.) in dry THF (10 mL). The mixture was stirred at
−78 °C for 5 min and n-BuLi was then added dropwise (2.5 M
in hexane, 1.69 mL, 4.21 mmol, 2.5 equiv.). The medium was
stirred at −78 °C for 1 h and HMPA (731 µL, 4.21 mmol,
1 equiv.) was then added. Finally, at −78 °C, to this resulting
solution was added dropwise a solution of freshly purified
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1-bromo-10-phenyl-decane 10 (500 mg, 1.68 mmol, 1 equiv.) in
THF (5 mL). The resulting orange solution was stirred at
−78 °C and then at r.t. for 16 h, quenched with a saturated
aqueous solution of NH4Cl (10 mL) and volatiles were removed
in vacuo. The aqueous phase was extracted with DCM (3 ×
20 mL) and the combined organic layers were dried over
Na2SO4, filtered and concentrated in vacuo. Flash chromato-
graphy of the residue (cyclohexane) aﬀorded alkyne 11 as a
colorless oil (387 mg, 73% yield): Rf 0.24 (cyclohexane);
IR (film) 2928m, 2848m, 2167w, 1448w, 843m, 744s; 1H NMR
δ 7.28–7.24 (m, 2H, H3ar), 7.16–7.14 (m, 3H, H2ar, H4ar), 2.58 (t,
2H, JHa–Hb = 7.5 Hz, Ha), 2.19 (t, 2H, JHj–Hi = 7.5 Hz, Hj),
1.62–1.56 (m, 2H, Hb), 1.49 (qt, 2H, JHi–Hj = JHi–Hh = 7.5 Hz, Hi),
1.38–1.23 (m, 12H, Hc, Hd, He, Hf, Hg, Hh);
13C NMR δ 143.1
(C1ar), 128.5 (C3ar), 128.4 (C2ar), 125.7 (C4ar), 107.9 (C2), 84.4
(C1), 36.1 (Ca), 31.7 (Cb), 29.6, 29.6, 29.5, 29.2, 28.9, 28.8, 25.5
(Cc, Cd, Ce, Cf, Cg, Ch, Ci), 20.0 (Cj); HRMS APPI calcd for
C18H26
+ (M − TMS + H)+ 242.2035, found 242.2028.
10-Azido-decyl methanesulfonate 13. To a suspension of
dimesylate 1229 (1 g, 3.03 mmol, 1 equiv.) in acetonitrile
(16 mL) was added sodium azide (197 mg, 3.03 mmol, 2.5
equiv.). The mixture was refluxed for 18 h and cooled to r.t.
The precipitate was then filtered out and the filtrate was con-
centrated in vacuo. Flash chromatography of the residue (cyclo-
hexane/EtOAc 8/2) aﬀorded the starting material 12 as a white
solid (254 mg, 25%) and azido mesylate 13 as a colorless oil
(354 mg, 42%, 56% yield based on the recovered starting
material): Rf 0.35 (cyclohexane/EtOAc 8/2); IR (film) 2096s,
1350s, 1169m, 955m; 1H NMR δ 4.22 (t, 2H, JHa–Hb = 6.5 Hz,
Ha), 3.26 (t, 2H, JHj–Hi = 7.0 Hz, Hj), 2.99 (s, 3H, CH3),
1.77–1.72 (m, 2H, Hb), 1.62–1.56 (m, 2H, Hi), 1.42–1.27 (m,
12H, Hc, Hd, He, Hf, Hg, Hh);
13C NMR δ, 70.3 (Ca), 51.6 (Cj),
37.5 (CH3), 29.4, 29.4, 29.2, 29.2, 29.1, 28.9, 26.8, 25.5 (Cb, Cc,
Cd, Ce, Cf, Cg, Ch, Ci); HRMS ESI
+ calcd for C11H24NO3S
+ (M −
N2 + H)
+ 250.1471, found 250.1469.
7-Bromo-1-trimethylsilyl-hept-1-yne 14. A flame dried flask
flushed with argon was cooled to −78 °C and charged with a
solution of ethynyltrimethylsilane (178 mg, 1.81 mmol,
1 equiv.) in dry THF (5 mL). The mixture was stirred at −78 °C
for 5 min and n-BuLi was then added dropwise (2.5 M in
hexane, 724 µL, 1.81 mmol, 1 equiv.). The medium was stirred
at −78 °C for 1 h and HMPA (315 µL, 1.81 mmol, 1 equiv.) was
then added. Finally, at −78 °C, to this resulting solution was
added dropwise a solution of 1,5-dibromopentane (500 mg,
2.17 mmol, 1.2 equiv.) in THF (5 mL). The mixture was stirred
at −78 °C for 5 min and then at r.t. for 16 h, quenched with a
saturated aqueous solution of NH4Cl (10 mL) and volatiles
were removed in vacuo. The aqueous phase was extracted with
DCM (3 × 20 mL) and the combined organic layers were dried
over Na2SO4, filtered and concentrated in vacuo. Flash
chromatography of the residue (cyclohexane) aﬀorded 14 as a
white fine powder (270 mg, 60% yield): Rf 0.22 (cyclohexane);
m.p. 72 °C; IR (film) 1556m, 1274w, 1262w, 829m, 749s; 1H
NMR δ 3.42 (t, 2H, JHa–Hb = 6.5 Hz, Ha), 2.27–2.23 (m, 2H, He),
1.93–1.86 (m, 2H, Hb), 1.57–1.54 (m, 4H, Hc, Hd), 0.16 (s, 9H,
(–Si–(CH3)3));
13C NMR δ 107.2 (C2), 84.9 (C1), 33.7 (Ca), 32.4
(Cb), 27.8 (Cd), 27.5 (Cc), 19.9 (Ce), 0.3 (–Si–(CH3)3); HRMS APPI
calcd for C7H11Br
+ (M − TMS + H)+ 174.0044, found 174.0042.
12-Bromo-1-trimethylsilyl-dodec-1-yne 15. A flame dried
flask flushed with argon was cooled to −78 °C and charged
with a solution of ethynyltrimethylsilane (208 mg, 2.12 mmol,
1 equiv.) in dry THF (3 mL). The mixture was stirred at −78 °C
for 5 min and n-BuLi was then added dropwise (2.5 M in
hexane, 847 µL, 2.12 mmol, 1 equiv.). The medium was stirred
at −78 °C for 1 h and HMPA (368 µL, 2.12 mmol, 1 equiv.) was
then added. Finally, at −78 °C, to this resulting pale yellow
solution was added dropwise a solution of 1,10-dibromo-
decane (953 mg, 3.18 mmol, 1.5 equiv.) in THF (3 mL). The
mixture was stirred at −78 °C for 16 h, quenched with a satu-
rated aqueous solution of NH4Cl (10 mL) and volatiles were
removed in vacuo. The aqueous phase was extracted with DCM
(3 × 20 mL) and the combined organic layers were dried over
Na2SO4, filtered and concentrated in vacuo. Flash chromato-
graphy of the residue (cyclohexane) aﬀorded 15 as a colorless
oil (413 mg, 41% yield): Rf 0.19 (cyclohexane); IR (film) 2174w,
1248m, 702s, 840s, 759w; 1H NMR δ 3.42 (t, 2H, JHa–Hb =
6.5 Hz, Ha), 2.21 (t, 2H, JHj–Hi = 7.0 Hz, Hj), 1.87 (qt, 2H, JHb–Ha =
JHb–Hc = 7.0 Hz, Hb), 1.52 (qt, 2H, JHi–Hj = JHi–Hh = 6.5 Hz, Hi),
1.46–1.40 (m, 2H, Hc), 1.40–1.38 (m, 2H, Hh), 1.34–1.28
(m, 8H, Hd, He, Hf, Hg), 0.16 (s, 9H, (–Si–(CH3)3));
13C NMR
δ 107.9 (C2), 84.5 (C1), 34.2 (Ca), 32.9 (Cb), 29.5, 29.2, 28.9,
28.8, 28.3 (Cc, Cd, Ce, Cf, Cg, Ch, Ci), 20.0 (Cj), 0.4 (–Si–(CH3)3);
HRMS APPI calcd for C12H21Br
+ (M − TMS + H)+ 244.0827,
found 244.0822. Spectral data were in agreement with the
literature.37
7-O-Acetyl-1-trimethylsilyl-hept-1-yne 16. Potassium acetate
(595 mg, 6.07 mmol, 15 equiv.) was added to a solution of
alkyne 14 (100 mg, 0.40 mmol, 1 equiv.) in DMF (6 mL). The
reaction mixture was stirred at 80 °C for 12 h, cooled to r.t.
and quenched by addition of a saturated aqueous solution of
NaHCO3 (10 mL). The aqueous phase was extracted with ether
(4 × 20 mL) and the combined organic layers were dried over
Na2SO4, filtered and concentrated in vacuo. Flash chromato-
graphy of the residue (cyclohexane/EtOAc 9/1) aﬀorded 16 as a
colorless oil (65 mg, 71% yield): Rf 0.10 (cyclohexane/EtOAc
9/1); IR (film) 2956w, 2174w, 1742s, 1365w, 1248s, 1049w,
838s, 759m; 1H NMR δ 4.05 (t, 2H, JHa–Hb = 6.5 Hz, Ha), 2.22 (t,
2H, JHe–Hd = 7.0 Hz, He), 2.03 (s, 3H, –OCOCH3), 1.64 (qt, 2H,
JHb–Ha = JHb–Hc = 6.5 Hz, Hb), 1.57–1.49 (m, 2H, Hd), 1.48–1.42
(m, 2H, Hc), 0.13 (s, 9H, (–Si–(CH3)3));
13C NMR δ 171.2
(–OCOCH3), 107.2 (C2), 84.8 (C1), 64.5 (Ca), 28.3 (Cb), 28.2 (Cd),
25.2 (Cc), 21.1 (–OCOCH3), 19.8 (Ce), 0.3 (–Si–(CH3)3; HRMS
APCI+ calcd for C12H22NaO2Si
+ (M + Na)+ 249.1281, found
249.1283. Spectral data were in agreement with the literature.38
12-O-Acetyl-1-trimethylsilyl-dodec-1-yne 17. Potassium acetate
(360 mg, 3.64 mmol, 15 equiv.) was added to a solution of
alkyne 15 (77 mg, 0.24 mmol, 1 equiv.) in DMF (1 mL). The
reaction mixture was stirred at 80 °C for 12 h, cooled to r.t.
and quenched by addition of saturated aqueous solution of
NaHCO3 (10 mL). The aqueous phase was extracted with ether
(4 × 15 mL) and the combined organic layers were dried over
Na2SO4, filtered and concentrated in vacuo. Flash chromato-
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graphy of the residue (cyclohexane/EtOAc 98/2) aﬀorded 17 as
a colorless oil (45 mg, 63% yield): Rf 0.37 (cyclohexane/EtOAc
98/2); IR (film) 2929w, 1742m, 1247m, 1236m, 838s; 1H NMR
δ 4.06 (t, 2H, JHa–Hb = 7.0 Hz, Ha), 2.21 (t, 2H, JHj–Hi = 7.0 Hz,
Hj), 2.04 (s, 3H, –OCOCH3), 1.62 (qt, 2H, JHb–Ha = JHb–Hc = 7.0
Hz, Hb), 1.52 (qt, 2H, JHi–Hj = JHi–Hh = 7.0 Hz, Hi), 1.39–1.26
(m, 12H, Hc, Hd, He, Hf, Hg, Hh), 0.15 (s, 9H, (–Si–(CH3)3));
13C NMR δ 171.4 (–OCOCH3), 107.9 (C2), 84.4 (C1), 64.8 (Ca),
29.6, 29.5, 29.4, 29.2, 28.9, 28.8, 26.1 (Cb, Cc, Cd, Ce, Cf, Cg, Ch,
Ci), 21.2 (–OCOCH3), 19.9 (Cj), 0.3 (–Si–(CH3)3); HRMS, ESI
+
calcd for C17H33O2Si
+ (M + H)+ 297.2244, found 297.2248.
12-N-Phthalimido-1-trimethylsilyl-dodec-1-yne 18. To a solu-
tion of bromo alkyne 15 (111 mg, 0.35 mmol, 1 equiv.) in DMF
(3.5 mL) was added phthalimide potassium salt (194 mg,
1.05 mmol, 3 equiv.). The mixture was stirred at 80 °C for 16 h,
cooled to r.t., quenched with a saturated aqueous solution of
NH4Cl (10 mL) and extracted with DCM (3 × 10 mL). The com-
bined organic layers were dried over Na2SO4, filtered and con-
centrated in vacuo. Flash chromatography of the residue
(cyclohexane/EtOAc 95/5) aﬀorded 18 as a colorless oil
(115 mg, 86% yield). Additionally, partial deprotection of the
TMS group was observed, and thus terminal alkyne 8f was also
isolated in 3% yield. Data for 18: Rf 0.36 (cyclohexane/EtOAc
95/5); IR (film) 1713s, 1395m, 1247w, 842s; 1H NMR
δ 7.85–7.84 (m, 2H, H3ar), 7.72–7.70 (m, 2H, H4ar), 3.69 (t, 2H,
JHa–Hb = 7.5 Hz, Ha), 2.21 (t, 2H, JHj–Hi = 7.0 Hz, Hj), 1.70–1.65
(m, 2H, Hb), 1.52 (qt, 2H, JHi–Hj = JHi–Hh = 7.0 Hz, Hi), 1.39–1.25
(m, 12H, Hc, Hd, He, Hf, Hg, Hh), 0.15 (s, 9H, (–Si–(CH3)3);
13C
NMR δ 168.6 (C1ar), 133.9 (C4ar), 132.4 (C2ar), 123.3 (C3ar), 107.9
(C2), 84.4 (C1), 38.2 (Ca), 29.6, 29.3, 29.2, 28.9, 28.8, 28.8, 27.0
(Cb, Cc, Cd, Ce, Cf, Cg, Ch, Ci), 20.0 (Cj), 0.3 (–Si–(CH3)3); HRMS,
APCI+ calcd for C20H26NO2
+ (M − TMS + 2H)+ 312.1958, found
312.1963.
12-O-p-Benzophenonyl-1-trimethylsilyl-dodec-1-yne 19. To a
solution of bromo alkyne 15 (96 mg, 0.30 mmol, 2.4 equiv.) in
DMF (1 mL) was added 4-hydroxy-benzophenone (25 mg,
0.12 mmol, 1 equiv.) and potassium carbonate (87 mg,
0.63 mmol, 5 equiv.). The mixture was stirred at r.t. for 16 h,
quenched with a saturated aqueous solution of NH4Cl (10 mL)
and extracted with DCM (3 × 10 mL). The combined organic
layers were dried over Na2SO4, filtered and concentrated
in vacuo. Flash chromatography of the residue (cyclohexane/
DCM 6/4) aﬀorded 19 as a colorless oil (49 mg, 90% yield):
Rf 0.22 (cyclohexane/DCM 6/4); IR (film) 2174w, 1654w, 1600w,
1250s, 852s; 1H NMR δ 7.83–7.81 (m, 2H, H7ar), 7.77–7.75 (m,
2H, H3ar), 7.58–7.55 (m, 1H, H9ar), 7.49–7.46 (m, 2H, H8ar),
6.96–6.94 (m, 2H, H2ar), 4.04 (t, 2H, JHa–Hb = 7.0 Hz, Ha), 2.21
(t, 2H, JHj–Hi = 7.5 Hz, Hj), 1.82 (qt, 2H, JHb–Ha = JHb–Hc = 7.0
Hz, Hb), 1.52 (qt, 2H, JHi–Hj = JHi–Hh = 7.0 Hz, Hi), 1.49–1.45 (m,
2H, Hc), 1.35–1.26 (m, 10H, Hd, He, Hf, Hg, Hh), 0.16 (s, 9H,
(–Si–(CH3)3));
13C NMR δ 195.6 (C5ar), 163.0 (C1ar), 138.5 (C6ar),
132.7 (C3ar), 131.9 (C9ar), 130.0 (C4ar), 129.8 (C7ar), 128.3 (C8ar),
114.1 (C2ar), 107.8 (C2), 84.4 (C1), 68.4 (Ca), 29.6, 29.5, 29.5,
29.3, 29.2, 28.9, 28.7 (Cb, Cd, Ce, Cf, Cg, Ch, Ci), 26.1 (Cc), 19.9
(Cj), 0.3 (–Si–(CH3)3); HRMS ESI calcd for C28H39O2Si
+ (M + H)+
435.2714, found 435.2727.
1-Trimethylsilyl-3-[4-O-(benzophenonyl)-benzyl]-prop-1-yne
21. To a suspension of bromide derivative 2024 (100 mg,
0.26 mmol, 1 equiv.), copper iodide (50 mg, 0.26 mmol,
1 equiv.), TBAI (96 mg, 0.26 mmol, 1 equiv.), and potassium
carbonate (72 mg, 0.52 mmol, 2 equiv.) in dry acetonitrile
(1.5 mL) was added trimethylsilylacetylene (45 µL, 0.31 mmol,
1.2 equiv.). The mixture was stirred at 40 °C for 24 h, quenched
with a saturated aqueous solution of NH4Cl (10 mL) and
extracted with DCM (4 × 20 mL). The combined organic layers
were dried over Na2SO4, filtered and concentrated in vacuo.
Flash chromatography of the residue (cyclohexane/DCM 7/3 to
4/6) aﬀorded 21 as a colorless film (60 mg, 57% yield): Rf 0.39
(cyclohexane/DCM 1/1); IR (film) 2130m, 1632s, 1600w, 1250s,
855s; 1H NMR δ 7.85–7.83 (m, 2H, H3ar), 7.77–7.75 (m, 2H,
H7ar), 7.59–7.55 (m, 1H, H9ar), 7.49–7.46 (m, 2H, H8ar),
7.42–7.38 (m, 4H, Hc, Hd), 7.06–7.03 (m, 2H, H2ar), 5.14 (s, 2H,
Ha), 3.68 (s, 2H, Hf), 0.21 (s, 9H, (–Si–(CH3)3));
13C NMR
δ 195.6 (C5ar), 162.5 (C1ar), 138.4 (Ce), 136.7 (C6ar), 134.7 (Cb),
132.7 (C3ar), 132.0 (C9ar), 130.5 (C4ar), 129.9 (C7ar), 128.4 (C8ar),
128.3, 127.9 (Cc, Cd), 114.5 (C2ar), 104.1 (C2), 87.3 (C1), 70.1
(Ca), 26.1 (Cf), 0.2 (–Si–(CH3)3); HRMS ESI
+ calcd for
C26H27O2Si
+ (M + H)+ 399.1775, found 399.1768.
3-[4-O-(Benzophenonyl)-benzyl]-propadiene 22. To a solu-
tion of alkyne 21 (49 mg, 0.12 mmol, 1 equiv.) in dry THF
(1.5 mL) was added, at 0 °C, tetrabutyl ammonium fluoride tri-
hydrate. The flashing dark purple solution was stirred for
10 min at 0 °C and then at r.t. for 1 h. After removal of volatiles
in vacuo, the crude residue was purified by flash chromato-
graphy (cyclohexane/DCM = 9/1 to 7/3). Under these con-
ditions, allene 22 was obtained as a white powder (37 mg, 91%
yield): Rf 0.32 (cyclohexane/DCM 7/3); IR (film) 2859br, 1938w,
1728br, 1650s, 1597s, 1257s; 1H NMR δ 7.84–7.82 (m, 2H,
H3ar), 7.77–7.74 (m, 2H, H7ar), 7.59–7.55 (m, 1H, H9ar),
7.49–7.46 (m, 2H, H8ar), 7.39–7.37 (m, 2H, Hd), 7.34–7.31 (m,
2H, Hc), 7.05–7.02 (m, 2H, H2ar), 6.18 (t, 1H, JHf–H2 = 7.0 Hz,
Hf), 5.17 (d, 2H, JH2–Hf = 7.0 Hz, H2), 5.14 (s, 1H, Ha);
13C NMR
δ 210.1 (C1), 195.7 (C5ar), 162.5 (C1ar), 138.4 (Ce), 134.9 (C6ar),
134.2 (Cb), 132.7 (C3ar), 132.0 (C9ar), 130.5 (C4ar), 129.9 (C7ar),
128.3 (C8ar), 128.0 (Cc), 127.1 (Cd), 114.6 (C2ar), 93.7 (Cf), 79.1
(C2), 70.1 (Ca); HRMS, ESI
+ calcd for C23H19O2
+ (M + H)+
327.1380, found 327.1372.
1-Azido-10-phenyl-decane 7b. To a solution of mesylate 9
(220 mg, 0.70 mmol, 1 equiv.) in DMF (1.5 mL) were succes-
sively added sodium azide (114 mg, 13.2 mmol, 2.5 equiv.) and
sodium iodide (53 mg, 0.35 mmol, 0.5 equiv.). The mixture
was stirred at 75 °C for 18 h, cooled to r.t., and diluted with
Et2O (20 mL) and water (20 mL). The aqueous phase was
extracted with Et2O (3 × 20 mL) and the combined organic
layers were dried (Na2SO4), filtered and concentrated in vacuo.
Flash chromatography of the resulting pale yellow oil (cyclo-
hexane/EtOAc 95/5 to 9/1) aﬀorded azide 7b as a colorless oil
(168 mg, 92% yield): Rf 0.72 (cyclohexane/EtOAc 9/1); IR (film)
3026w, 2099s, 1603w, 746m; 1H NMR δ 7.28–7.25 (m, 2H, H3),
7.18–7.15 (m, 3H, H2, H4), 3.25 (t, 2H, JHa–Hb = 7.0 Hz, Ha), 2.59
(t, 2H, JHj–Hi = 7.5 Hz, Hj), 1.63–1.56 (m, 4H, Hb, Hi), 1.37–1.26
(m, 12H, Hc, Hd, He, Hf, Hg, Hh);
13C NMR δ 143.0 (C1), 128.5
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(C3), 128.4 (C2), 125.7 (C4), 70.3 (Ca), 37.5 (Cj), 36.1 (Ci), 31.6,
29.6, 29.5, 29.4, 29.3, 29.1, 25.5 (Cb, Cc, Cd, Ce, Cf, Cg, Ch);
HRMS ESI+ calcd for C16H26N
+ (M − N2 + H)+ 232.2060 found
232.2056. Spectral data were in agreement with the literature.39
10-Azido-decan-1-ol 7d. To a solution of 10-bromo-decan-1-ol
(633 mg, 2.40 mmol, 1 equiv.) in DMF (7.6 mL) was added
sodium azide (312 mg, 4.80 mmol, 2 equiv.) and sodium
iodide (180 mg, 1.20 mmol, 0.5 equiv.). The suspension was
stirred at 80 °C for 18 h, cooled to r.t. and diluted with ether
(20 mL) and water (20 mL). The aqueous phase was extracted
with Et2O (3 × 20 mL) and the combined organic layers were
washed with brine (2 × 20 mL) and water (20 mL), dried
(Na2SO4), filtered and concentrated in vacuo. Flash chromato-
graphy of the residue (cyclohexane/EtOAc 6/4) aﬀorded azide
7d as a colorless oil (469 mg, 98%): Rf 0.37 (cyclohexane/EtOAc
6/4); IR (film) 3056br, 2092m, 1276m, 1251m, 741s; 1H NMR
δ 3.66–3.62 (m, 2H, Hj), 3.28–3.24 (m, 2H, Ha), 1.63–1.54 (m,
4H, Hb, Hi), 1.37–1.29 (m, 12H, Hc, Hd, He, Hf, Hg, Hh);
13C
NMR δ 63.2 (Cj), 51.6 (Ca), 32.9 (Ci), 29.6, 29.5, 29.5, 29.3, 28.9,
26.8, 25.8 (Cb, Cc, Cd, Ce, Cf, Cg, Ch); HRMS ESI
+ calcd for
C10H22NO
+ (M − N2 + H)+ 172.1696, found 172.1694.
1-Azido-10-phthalimido-decane 7f. To a solution of azido
mesylate 13 (200 mg, 0.72 mmol, 1 equiv.) in DMF (2 mL) was
added potassium phthalimide (400 mg, 2.16 mmol, 3 equiv.).
The suspension was stirred at 80 °C for 18 h, cooled to r.t. and
diluted with ether (15 mL) and water (15 mL). The aqueous
phase was extracted with Et2O (3 × 15 mL) and the combined
organic layers were washed with brine (2 × 20 mL) and water
(20 mL), dried (Na2SO4), filtered and concentrated in vacuo.
Flash chromatography of the residue (cyclohexane/EtOAc 8/2)
aﬀorded azide 7f as a colorless oil (233 mg, 98%): Rf 0.49
(cyclohexane/EtOAc 7/3); IR (film) 2094w, 1708s, 1345m, 719m;
1H NMR δ 7.86–7.82 (m, 2H, H3), 7.72–7.69 (m, 2H, H4), 3.68 (t,
2H, JHj–Hi = 7.5 Hz, Hj), 3.25 (t, 2H, JHa–Hb = 7.0 Hz, Ha),
1.70–1.64 (m, 2H, Hi), 1.61–1.55 (m, 2H, Hb), 1.39–1.22 (m, 12H,
Hc, Hd, He, Hf, Hg, Hh);
13C NMR δ 168.6 (C1), 133.9 (C4), 132.4
(C2), 123.3 (C3), 51.6 (Ca), 38.2 (Cj), 29.5, 29.5, 29.2, 29.2, 28.9,
28.7, 26.9, 26.8 (Cb, Cc, Cd, Ce, Cf, Cg, Ch, Ci); HRMS APCI
+ calcd
for C18H25N2O2
+ (M − N2 + H)+ 301.1911, found 301.1911.
General procedure for TMS deprotection and preparation of
compounds 8b, 8f, 8h
To a solution of the silylated alkyne (1 equiv.) in THF (0.1 M)
was added in one portion tetrabutyl ammonium fluoride trihy-
drate (1.1 to 1.6 equiv.). The solution was stirred at r.t. for 1 h
and volatiles were removed in vacuo. Flash chromatography of
the residue aﬀorded the corresponding terminal alkyne.
12-Phenyl-dodec-1-yne 8b. Alkyne 8b was obtained from pro-
tected alkyne 11 (327 mg, 1.04 mmol, 1 equiv.) according to
the general procedure for terminal alkyne synthesis. Flash
chromatography of the residue (cyclohexane) aﬀorded 8b as a
colorless oil (223 mg, 89% yield): Rf 0.22 (cyclohexane); IR
(film) 3075m, 2140m, 1602m, 1452m, 1290m, 1253s, 1175w;
1H NMR δ 7.30–7.26 (m, 2H, H3ar), 7.20–7.17 (m, 3H, H2ar,
H4ar), 2.62 (t, 2H, JHa–Hb = 7.5 Hz, Ha), 2.19 (dt, 2H, JHj–Hi = 7.5
Hz, JHj–H2 = 3.0 Hz, Hj), 1.95 (t, 1H, JH2–Hj = 3.0 Hz, H2),
1.66–1.60 (m, 2H, Hb), 1.55 (qt, 2H, JHi–Hj = JHi–Hh = 7.5 Hz, Hi),
1.43–1.38 (m, 2H, Hc), 1.38–1.26 (m, 10H, Hd, He, Hf, Hg, Hh);
13C NMR δ 143.1 (C1ar), 128.5 (C3ar), 128.4 (C2ar), 125.7 (C4ar),
84.9 (C1), 68.2 (C2), 36.1 (Ca), 31.6 (Cb), 29.6, 29.5, 29.5, 29.5,
29.2, 28.9, 28.7 (Cc, Cd, Ce, Cf, Cg, Ch, Ci), 18.6 (Cj); HRMS APPI
calcd for C18H26
+ (M)+ 242.2035, found 242.2030.
Heptyn-1-ol 8c. To a suspension of ester 16 (71 mg,
0.31 mmol, 1 equiv.) in MeOH (2 mL) and water (0.2 mL) was
added potassium carbonate (216 mg, 1.57 mmol, 5 equiv.).
The reaction mixture was stirred at r.t. for 5 h and then
quenched by addition of saturated aqueous solution of NH4Cl
(10 mL). The aqueous phase was extracted with EtOAc (4 ×
15 mL) and the combined organic layers were dried over
Na2SO4, filtered and concentrated in vacuo. Flash chromato-
graphy of the residue (cyclohexane/EtOAc 8/2) aﬀorded 8c as a
white solid (29 mg, 82% yield): Rf 0.21 (cyclohexane/EtOAc
8/2); IR (film) 3061br, 2919w, 1278m, 1252m, 743s; 1H NMR
δ 3.66 (t, 2H, JHa–Hb = 6.5 Hz, Ha), 2.21 (dt, 2H, JHe–Hd = 7.0 Hz,
JHe–H2 = 2.5 Hz, He), 1.94 (t, 1H, JH2–He = 2.5 Hz, H2), 1.62–1.54
(m, 4H, Hb, Hd), 1.52–1.47 (m, 2H, Hc);
13C NMR δ 84.6 (C2),
68.5 (C1), 62.9 (Ca), 32.4 (Cb), 28.4 (Cd), 25.1 (Cc), 18.5 (Ce);
HRMS, APCI+ calcd for C7H13O
+ (M + H)+ 113.0966, found
113.0961. Spectral data were in agreement with the literature.40
Dodec-11-yn-1-ol 8d. To a suspension of ester 17 (36 mg,
0.12 mmol, 1 equiv.) in MeOH (1 mL) and water (0.1 mL) was
added potassium carbonate (84 mg, 0.61 mmol, 5 equiv.). The
reaction mixture was stirred at r.t. for 5 h and then quenched
by addition of saturated aqueous solution of NH4Cl (10 mL).
The aqueous phase was extracted with EtOAc (4 × 15 mL) and
the combined organic layers were dried over Na2SO4, filtered
and concentrated in vacuo. Flash chromatography of the
residue (cyclohexane/EtOAc 9/1) aﬀorded 8d as a white solid
(20 mg, 90% yield): Rf 0.12 (cyclohexane/EtOAc 9/1); m.p
26–28 °C; IR (film) 3065br, 2923w, 1275m, 1256m, 744s; 1H
NMR δ 3.49 (t, 2H, JHa–Hb = 7.0 Hz, Ha), 2.03 (dt, 2H, JHj–Hi =
7.0 Hz, JHj–H2 = 2.5 Hz, Hj), 1.79 (t, 1H, JH2–Hj = 2.5 Hz, H2),
1.45–1.35 (m, 4H, Hb, Hi), 1.28–1.11 (m, 12H, Hc, Hd, He, Hf,
Hg, Hh);
13C NMR δ 84.9 (C2), 68.2 (C1), 63.2 (Ca), 32.9 (Cb),
29.7, 29.6, 29.2, 28.9, 28.6, 25.8 (Cc, Cd, Ce, Cf, Cg, Ch, Ci), 18.5
(Cj); HRMS, APCI
+ calcd for C12H23O
+ (M + H)+ 183.1743,
found 183.1746. Spectral data were in agreement with the
literature.41
12-N-Phthalimido-dodec-1-yne 8f. Alkyne 8f was obtained
from protected alkyne 18 (114 mg, 0.29 mmol, 1 equiv.) accord-
ing to the general procedure for terminal alkyne synthesis.
Flash chromatography of the residue (cyclohexane/EtOAc 95/5)
aﬀorded 8f as a white film (51 mg, 55% yield): Rf 0.28 (cyclo-
hexane/EtOAc 95/5); IR (film) 2937s, 2100m, 1767w, 1710s,
1394m; 1H NMR δ 7.85–7.82 (m, 2H, H3ar), 7.72–7.68 (m, 2H,
H4ar), 3.67 (t, 2H, JHa–Hb = 7.5 Hz, Ha), 2.17 (dt, 2H, JHj–Hi = 7.0
Hz, JHj–H2 = 2.5 Hz, Hj), 1.93 (t, 2H, JH2–Hj = 2.5 Hz, H2),
1.69–1.64 (m, 2H, Hb), 1.51 (qt, 2H, JHi–Hj = JHi–Hh = 7.0 Hz, Hi),
1.40–1.26 (m, 12H, Hc, Hd, He, Hf, Hg, Hh);
13C NMR δ 168.6
(C1ar), 133.9 (C4ar), 132.3 (C2ar), 123.3 (C3ar), 107.9 (C2), 84.4
(C1), 68.2 (C2), 38.2 (Ca), 29.6, 29.5, 29.3, 29.2, 28.8, 28.7, 28.6,
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26.9 (Cb, Cc, Cd, Ce, Cf, Cg, Ch, Ci), 18.5 (Cj); HRMS, ESI
+ calcd
for C20H26NO2
+ (M + H)+ 312.1958, found 312.1961.
3-[4-O-(Benzophenonyl)-benzyl]-prop-1-yne 8g. To a suspen-
sion of protected alkyne 21 (100 mg, 0.25 mmol, 1 equiv.) in
methanol (3 mL) was added potassium carbonate in one
portion (173 mg, 1.25 mmol, 5 equiv.). The suspension was
stirred at r.t. for 5 h and the suspension was then diluted with
EtOAc (15 mL). After addition of saturated aqueous solution of
NH4Cl (10 mL), the aqueous phase was extracted with EtOAc
(3 × 25 mL). The combined organic layers were dried over
Na2SO4, filtered and concentrated in vacuo. Flash chromato-
graphy of the residue (cyclohexane to cyclohexane/EtOAc 95/5)
aﬀorded 8g as a white film (66 mg, 81% yield): Rf 0.42 (cyclo-
hexane/EtOAc 9/1); IR (film) 2325w, 1645s, 1602s, 1281s,
1173m; 1H NMR δ 7.77–7.74 (m, 2H, H3ar), 7.70–7.66 (m, 2H,
H7ar), 7.49 (t, 1H, JH9ar–H8ar = 7.0 Hz, H9ar), 7.39 (t, 2H,
JH8ar–H9ar = 7.0 Hz, H8ar), 7.34–7.31 (m, 4H, Hc, Hd), 6.97–6.94
(m, 2H, H2ar), 5.06 (s, 1H, Ha), 3.55 (d, 2H, JHf–H2 = 3.0 Hz, Hf),
2.13 (t, 2H, JH2–Hf = 3.0 Hz, Hf);
13C NMR δ 195.7 (C5ar), 162.5
(C1ar), 138.4 (Ce), 136.4 (C6ar), 134.9 (Cb), 132.7 (C3ar), 132.0
(C9ar), 130.5 (C4ar), 129.9 (C7ar), 128.4 (C8ar), 128.3, 127.9 (Cc, Cd),
114.6 (C2ar), 81.8 (C2), 70.7 (Ca), 70.1 (C1), 24.7 (Cf); HRMS, ESI
+
calcd for C23H19O2
+ (M + H)+ 327.1380, found 327.1374.
12-O-p-Benzophenonyl-dodec-1-yne 8h. Alkyne 8h was
obtained from protected alkyne 19 (54 mg, 0.12 mmol,
1 equiv.) according to the general procedure for terminal
alkyne synthesis. Flash chromatography of the residue (cyclo-
hexane/EtOAc 9/1) aﬀorded 8h as a white film (44 mg, 97%
yield): Rf 0.51 (cyclohexane/EtOAc 9/1); IR (film) 2919w, 1639s,
1602m, 1307s, 1290m, 1253s, 1175w; 1H NMR δ 7.84–7.81 (m,
2H, H3ar), 7.77–7.75 (m, 2H, H7ar), 7.59–7.55 (m, 1H, H9ar),
7.49–7.46 (m, 2H, H8ar), 6.96–6.94 (m, 2H, H2ar), 4.04 (t, 2H,
JHa–Hb = 6.5 Hz, Ha), 2.19 (dt, 2H, JHj–Hi = 7.0 Hz, JHj–H2 = 2.5
Hz, Hj), 1.82 (qt, 2H, JHb–Ha = JHb–Hc = 6.5 Hz, Hb), 1.54 (qt, 2H,
JHi–Hj = JHi–Hh = 7.0 Hz, Hi), 1.49–1.45 (m, 2H, Hc), 1.42–1.30
(m, 10H, Hd, He, Hf, Hg, Hh);
13C NMR δ 195.7 (C5ar), 163.0
(C1ar), 138.5 (C6ar), 132.7 (C3ar), 131.9 (C9ar), 130.1 (C4ar), 129.8
(C7ar), 128.3 (C8ar), 114.2 (C2ar), 84.9 (C1), 68.4 (Ca), 68.2 (C2),
29.6, 29.5, 29.5, 29.3, 29.2, 28.8, 28.6 (Cb, Cd, Ce, Cf, Cg, Ch, Ci),
26.1 (Cc), 18.5 (Cj); HRMS, ESI
+ calcd for C25H31O2
+ (M + H)+
363.2319, found 363.2313.
General procedure for Cu(I)-catalyzed azide–alkyne
cycloaddition: preparation of compounds 23a–h
To a solution of alkyne 5 (1 equiv.) and azide partner 7a–h
(1–2 equiv.) in tert-BuOH/H2O (1.5 mL/500 µL) were succes-
sively added CuSO4 (0.1 equiv.), sodium ascorbate (0.3 equiv.)
and N-diisopropylethylamine (2.2 equiv.). The suspension was
sonicated for 5 min to solubilise all reagents. The mixture was
stirred at r.t. for 18 h and diluted with DCM (30 mL) and
NH4Cl (15 mL). The aqueous phase was extracted with DCM
(6 × 30 mL) and the combined organic layers were washed with
10−3 M solution of tetra-sodium EDTA, dried (Na2SO4), filtered
and concentrated in vacuo. The residue was then purified by
flash chromatography to give the corresponding C-triazole
23a–h.
Compound 23a. Triazole 23a was synthesized according to
the general procedure for Cu(I)-catalyzed azide–alkyne cyclo-
addition from alkyne 5 (114 mg, 0.14 mmol) and azide 7a
(50 mg, 0.27 mmol, 2 equiv.). Flash chromatography (cyclo-
hexane/EtOAc 6/4) aﬀorded 23a as a white foam (81 mg, 58%
yield): Rf 0.28 (cyclohexane/EtOAc 6/4); m.p. 102–106 °C; [α]D
−30 (c 0.5, CH2Cl2); IR (film) 3060m, 2928m, 2856m, 1714s,
1386m; 1H NMR δ 8.76 (d, 1H, JNH–H5 = 2.0 Hz, NH), 7.90–7.84
(m, 3H, H11″, H6), 7.77–7.74 (m, 2H, H12″), 7.37 (s, 1H, H8′),
6.18 (dd, 1H, JH5–H6 = 8.0 Hz, JH5–NH = 2.0 Hz, H5), 5.95 (d, 1H,
JH1′–H2′ = 5.5 Hz, H1′), 5.34 (s, 1H, H1″), 4.77 (d, 1H, JH2″–H3″ =
6.0 Hz, H2″), 4.67 (d, 1H, JH3″–H2″ = 6.0 Hz, H3″), 4.52 (dd, 1H,
JH4″–H5″a = 7.0 Hz, JH4″–H5″b = 9.0 Hz, H4″), 4.35–4.25 (m, 2H,
H9′), 4.19–4.16 (m, 2H, H2′, H5′), 4.00 (t, 1H, JH3′–H2′ = JH3′–H4′ =
3.5 Hz, H3′), 3.88–3.82 (m, 3H, H5″a, H5″b, H4′), 3.49 (dd, 1H,
JH6′a–H6′b = 14.0 Hz, JH6′a–H5′ = 4.5 Hz, H6′a), 3.07 (dd, 1H,
JH6′b–H6′a = 14.0 Hz, JH6′b–H5′ = 10.5 Hz, H6′b), 1.91–1.81 (m, 2H,
H10′), 1.72–1.60 (m, 2H, H7″), 1.55–1.47 (m, 2H, H7″), 1.33–1.20
(m, 14H, H11′, H12′, H13′, H14′, H15′, H16′, H17′), 0.88 (t, 3H,
JH8″–H7″ = 7.5 Hz, H8″), 0.86 (t, 3H, JH18′–H17′ = 7.5 Hz, H18′), 0.85
(s, 9H, –C(CH3)3), 0.83 (s, 9H, –C(CH3)3), 0.81 (t, 3H, JH8″–H7″ =
7.5 Hz, H8″), 0.07, 0.07, 0.05, −0.02 (4s, 12H, –Si–t-Bu–(CH3)2);
13C NMR δ 168.2 (C9″), 163.3 (C4), 150.6 (C2), 142.9 (C7′), 139.9
(C6), 134.5 (C12″), 131.9 (C10″), 123.8 (C11″), 122.2 (C8′), 117.7
(C6″), 112.4 (C1″), 103.2 (C5), 87.7 (C1′), 86.4 (C3″), 84.5 (C4″),
84.3 (C4′), 82.6 (C2″), 80.8 (C2′), 75.4 (C5′), 72.6 (C3′), 50.5 (C9′),
40.5 (C5″), 31.9 (C10′), 30.5 (C7″), 29.6, 29.5, 29.5, 29.4, 29.1,
28.9, 28.9 (C7″, C6′, C11′, C12′, C13′, C14′, C15′, C16′), 25.9, 25.8
(–C(CH3)3), 22.8 (C17′), 18.1, 18.0 (–C(CH3)3), 14.2 (C18′), 8.4, 7.5
(C8″), −4.2, −4.5, −4.5, −4.6 (–Si–t-Bu–(CH3)2); HRMS, ESI+
calcd for C52H83N6O11Si2
+ (M + H)+ 1023.5653, found
1023.5652.
Compound 23b. Triazole 23b was synthesized according to
the general procedure for Cu(I)-catalyzed azide–alkyne cyclo-
addition from alkyne 5 (60 mg, 0.07 mmol) and azide 7b
(37.5 mg, 0.14 mmol, 2 equiv.). Flash chromatography (cyclo-
hexane/EtOAc 1/1) aﬀorded 23b as a white foam (45 mg, 57%
yield): Rf 0.25 (cyclohexane/EtOAc 1/1); m.p. 100–102 °C; [α]D
−27 (c 1.0, CH2Cl2); IR (film) 2929m, 1717s, 1696s, 1394w,
1088w, 838w; 1H NMR δ 8.30 (br s, 1H, NH), 7.90–7.88 (m, 3H,
H11″, H6), 7.77–7.75 (m, 2H, H12″), 7.36 (s, 1H, H8′), 7.28–7.25
(m, 2H, H20′), 7.18–7.15 (m, 3H, H21′, H22′), 6.20 (dd, 1H, JH5–H6 =
8.0 Hz, JH5–NH = 2.0 Hz, H5), 5.97 (d, 1H, JH1′–H2′ = 6.0 Hz, H1′),
5.36 (s, 1H, H1″), 4.79 (d, 1H, JH2″–H3″ = 6.0 Hz, H2″), 4.69 (d,
1H, JH3″–H2″ = 6.0 Hz, H3″), 4.55–4.52 (m, 1H, H4″), 4.35–4.26
(m, 2H, H9′), 4.19–4.17 (m, 2H, H2′, H5′), 4.00 (t, 1H, JH3′–H2′ =
JH3′–H4′ = 3.5 Hz, H3′), 3.89–3.84 (m, 3H, H5″, H4′), 3.50 (dd, 1H,
JH6′a–H6′b = 14.0 Hz, JH6′a–H5′ = 5.0 Hz, H6′a), 3.07 (dd, 1H, JH6′b–
H6′a = 14.0 Hz, JH6′b–H5′ = 11.0 Hz, H6′b), 2.59 (t, 2H, JH18′–H17′ =
7.5 Hz, H18′), 1.89–1.84 (m, 2H, H10′), 1.61–1.59 (m, 2H, H17′),
1.55–1.52 (m, 2H, H7″), 1.32–1.25 (m, 12H, H11′, H12′, H13′, H14′,
H15′, H16′), 0.89 (t, 3H, JH8″–H7″ = 8.0 Hz, H8″), 0.87 (s, 9H, –C
(CH3)3), 0.84 (s, 9H, –C(CH3)3), 0.83 (t, 3H, JH8″–H7″ = 8.0 Hz,
H8″), 0.08, 0.08, 0.07, −0.02 (4s, 12H, –Si–t-Bu–(CH3)2); 13C
NMR δ 168.3 (C9″), 163.1 (C4), 150.4 (C2), 143.0 (C19′), 142.9
(C7′), 139.9 (C6), 134.5 (C12″), 131.9 (C10″), 128.5 (C21′), 128.3
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(C20′), 125.7 (C22′), 123.8 (C11″), 122.1 (C8′), 117.7 (C6″), 112.4
(C1″), 103.2 (C5), 87.6 (C1′), 86.4 (C3″), 84.5 (C4″), 84.4 (C4′), 82.6
(C2″), 80.9 (C2′), 75.4 (C5′), 72.7 (C3′), 50.4 (C9′), 40.5 (C5″), 36.1
(C18′), 31.6 (C10′), 30.6 (C7″), 29.6, 29.6, 29.5, 29.5, 29.4, 29.1,
28.9, 26.6 (C7″, C6′, C11′, C12′, C13′, C14′, C15′, C16′, C17′), 25.9,
25.9 (–C(CH3)3), 18.1, 18.1 (–C(CH3)3), 8.5, 7.5 (C8″), −4.2, −4.5,
−4.5 (–Si–t-Bu–(CH3)2); HRMS, ESI+ calcd for C58H87N6O11Si2+
(M + H)+ 1099.5966, found 1099.5969.
Compound 23c. Triazole 23c was synthesized according to
the general procedure for Cu(I)-catalyzed azide–alkyne cyclo-
addition from alkyne 5 (72 mg, 0.086 mmol) and azidopenta-
nol 7c (22 mg, 0.17 mmol, 2 equiv.). Flash chromatography
(cyclohexane/EtOAc 3/7 to EtOAc) aﬀorded 23c as a white foam
(47 mg, 56% yield): Rf 0.40 (cyclohexane/EtOAc 1/9);
m.p. 104–108 °C; [α]D −27 (c 1.0, CH2Cl2); IR (film) 3046br,
2307w, 1715s, 1464m, 1169w; 1H NMR δ 8.77–8.37 (br s, 1H,
NH), 7.91–7.80 (m, 2H, H11″), 7.86 (d, 1H, JH6–H5 = 8.5 Hz, H6),
7.79–7.74 (m, 2H, H12″), 7.39 (s, 1H, H8′), 6.19 (d, 1H, JH5–H6 =
8.5 Hz, H5), 5.96 (d, 1H, JH1′–H2′ = 6.0 Hz, H1′), 5.35 (s, 1H, H1″),
4.77 (d, 1H, JH2″–H3″ = 6.0 Hz, H2″), 4.68 (d, 1H, JH3″–H2″ = 6.0
Hz, H3″), 4.53 (dd, 1H, JH4″–H5″a = 6.0 Hz, JH4″–H5″b = 10.0 Hz,
H4″), 4.39–4.29 (m, 2H, H9′), 4.20–4.17 (m, 2H, H2′, H5′), 4.00
(dd, 1H, JH3′–H2′ = 4.0 Hz, JH3′–H4′ = 3.0 Hz, H3′), 3.90–3.81 (m,
3H, H5″, H4′), 3.65 (t, 2H, JH13′–H12′ = 6.0 Hz, H13′), 3.48 (dd, 1H,
JH6′a–H6′b = 14.0 Hz, JH6′a–H5′ = 4.0 Hz, H6′a), 3.06 (dd, 1H,
JH6′b–H6′a = 14.0 Hz, JH6′b–H5′ = 10.5 Hz, H6′b), 1.92 (qt, 2H,
JH10′–H9′ = JH10′–H11′ = 7.0 Hz, H10′), 1.73–1.64 (m, 2H, H7″),
1.64–1.58 (m, 2H, H12′), 1.56–1.50 (m, 2H, H7″), 1.44–1.38 (m,
2H, H11′), 0.88 (t, 3H, JH8″–H7″ = 7.5 Hz, H8″), 0.87 (s, 9H,
–C(CH3)3), 0.84 (s, 9H, –C(CH3)3), 0.83 (t, 3H, JH8″–H7″ = 7.5 Hz,
H8″), 0.08, 0.07, −0.01 (3s, 12H, –Si–t-Bu–(CH3)2); 13C NMR
δ 168.3 (C9″), 163.2 (C4), 150.6 (C2), 143.1 (C7′), 140.0 (C6),
134.5 (C12″), 131.9 (C10″), 123.8 (C11″), 122.3 (C8′), 117.7 (C6″),
112.3 (C1″), 103.3 (C5), 87.6 (C1′), 86.4 (C3″), 84.6 (C4″), 84.4
(C4′), 82.3 (C2″), 80.8 (C2′), 75.3 (C5′), 72.7 (C3′), 62.5 (C13′), 50.2
(C9′), 40.5 (C5″), 31.9 (C7″), 30.2 (C10′), 29.5 (C11′), 28.9 (C6′), 28.9
(C7″), 25.8, 25.8 (–C(CH3)3), 22.9 (C12′), 18.1, 18.1 (–C(CH3)3),
8.4, 7.5 (C8″), −4.2, −4.8, −4.5 (–Si–t-Bu–(CH3)2); HRMS, ESI+
calcd for C47H73N6O12Si2
+ (M + H)+ 969.4820, found 969.4812.
Compound 23d. Triazole 23d was synthesized according to
the general procedure for Cu(I)-catalyzed azide–alkyne cyclo-
addition from alkyne 5 (62 mg, 0.074 mmol) and azidodecanol
7d (29 mg, 0.15 mmol, 2 equiv.). Flash chromatography (cyclo-
hexane/EtOAc 2/8) aﬀorded 23d as a white foam (45 mg, 59%
yield): Rf 0.40 (cyclohexane/EtOAc 2/8); m.p. 112–114 °C; [α]D
−28 (c 0.7, CH2Cl2); IR (film) 2931br, 2301m, 1711s, 1457w,
1262w; 1H NMR δ 8.17–8.80 (br d, 1H, NH), 7.90–7.80 (m, 2H,
H11″), 7.81 (d, 1H, JH6–H5 = 7.0 Hz, H6), 7.79–7.74 (m, 2H, H12″),
7.48–7.38 (br s, 1H, H8′), 6.18 (br d, 1H, JH5–H6 = 7.0 Hz, H5),
5.96 (d, 1H, JH1′–H2′ = 3.5 Hz, H1′), 5.35 (s, 1H, H1″), 4.78 (d, 1H,
JH2″–H3″ = 5.5 Hz, H2″), 4.68 (d, 1H, JH3″–H2″ = 5.5 Hz, H3″), 4.53
(dd, 1H, JH4″–H5″a = 3.0 Hz, JH4″–H5″b = 9.0 Hz, H4″), 4.37–4.29
(m, 2H, H9′), 4.25–4.17 (m, 2H, H2′, H5′), 4.00–3.90 (m, 1H,
H3′), 3.89–3.81 (m, 3H, H5″, H4′), 3.64 (t, 2H, JH18′–H17′ = 7.0 Hz,
H18′), 3.51–3.45 (m, 1H, H6′a), 3.14–3.06 (m, 1H, H6′b),
1.93–1.58 (m, 2H, H17′), 1.73–1.63 (m, 2H, H7″), 1.55–1.49 (m,
4H, H10′, H7″), 1.35–1.24 (m, 12H, H11′, H12′, H13′, H14′, H15′,
H16′), 0.89 (t, 3H, JH8″–H7″ = 7.0 Hz, H8″), 0.87 (s, 9H, –C(CH3)3),
0.85 (s, 9H, –C(CH3)3), 0.83 (t, 3H, JH8″–H7″ = 7.0 Hz, H8″), 0.08,
0.00 (2s, 12H, –Si–t-Bu–(CH3)2);
13C NMR δ 168.3 (C9″), 162.9
(C4), 150.4 (C2), 142.9 (C7′), 140.1 (C6), 134.5 (C12″), 131.9 (C10″),
123.8 (C11″), 122.3 (C8′), 117.7 (C6″), 112.4 (C1″), 103.3 (C5), 87.6
(C1′), 86.4 (C3″), 84.6 (C4″), 84.5 (C4′), 84.5 (C2″), 82.3 (C2′), 75.4
(C5′), 72.3 (C3′), 63.2 (C18′), 50.5 (C9′), 40.5 (C5″), 32.9 (C10′), 32.5
(C7″), 30.5 (C17′), 29.5, 29.5, 29.4, 29.1, 29.0, 29.0, 26.6 (C7″, C6′,
C11′, C12′, C13′, C14′, C15′, C16′), 25.9, 25.8 (–C(CH3)3), 18.1, 18.1
(–C(CH3)3), 8.5, 7.5 (C8″), −4.2, −4.4, −4.5 (–Si–t-Bu–(CH3)2);
HRMS, ESI+ calcd for C52H83N6O12Si2
+ (M + H)+ 1039.5602,
found 1039.5606.
Compound 23e. To a suspension of azide 7e (11.5 mg,
0.043 mmol, 1 equiv.), alkyne 5 (55 mg, 0.065 mmol, 1.5
equiv.), CuSO4·5H2O (1.1 mg, 0.004 mmol, 0.1 equiv.) in tert-
butanol/H2O (1.5 mL/500 µL) were successively added sodium
ascorbate (2.6 mg, 0.013 mmol, 0.3 equiv.) and diisopropyl-
ethylamine (16 µL, 0.09 mmol, 2.2 equiv.). The resulting brown
mixture was sonicated for 5 min, stirred at r.t. for 18 h and
diluted with DCM (30 mL) and NH4Cl (15 mL). The aqueous
phase was extracted with DCM (6 × 30 mL) and the combined
organic layers were washed with 10−3 M solution of tetra-
sodium EDTA, dried (Na2SO4), filtered and concentrated
in vacuo. The residue was then purified by flash chromato-
graphy (EtOAc/MeOH 100/0 to 90/10) to aﬀord 23e as a pale
red film (20.5 mg, 43% yield): Rf 0.10 (EtOAc/MeOH 90/10);
[α]D −23 (c 0.5, CH2Cl2); IR (film) 2930br, 2853w, 1713s,
1394w, 1100m; 1H NMR δ 8.55–8.45 (br m, 1H, NH), 7.92–7.89
(m, 2H, H11″), 7.86 (d, 1H, JH6–H5 = 7.0 Hz, H6), 7.79–7.75 (m,
2H, H12″), 7.64–7.54 (br s, 1H, H8′), 6.19 (br d, 1H, JH5–H6 = 6.5
Hz, H5), 6.06–5.95 (br s, 1H, H1′), 5.38 (s, 1H, H1″), 4.78 (d, 1H,
JH2″–H3″ = 6.0 Hz, H2″), 4.70 (d, 1H, JH3″–H2″ = 6.0 Hz, H3″),
4.60–4.48 (m, 3H, H9′, H4″), 4.28–4.17 (m, 2H, H2′, H5′),
4.06–3.98 (m, 1H, H3′), 3.90–3.77 (m, 5H, H5″, H4′, H10′),
3.77–3.48 (m, 18H, H6′a, H6′b, H11′, H12′, H13′, H14′, H15′, H16′,
H17′, H18′), 3.11–3.03 (br s, 1H, OH), 1.72–1.63 (m, 2H, H7″),
1.59–1.43 (m, 2H, H7″), 0.89 (t, 3H, JH8″–H7″ = 7.5 Hz, H8″), 0.87
(s, 9H, –C(CH3)3), 0.84 (s, 9H, –C(CH3)3), 0.83 (t, 3H, JH8″–H7″ =
7.0 Hz, H8″), 0.08, 0.07, −0.01 (3s, 12H, –Si–t-Bu–(CH3)2); 13C
NMR δ 168.3 (C9″), 163.2 (C4), 150.5 (C2), 140.1 (C7′), 140.0 (C6),
134.5 (C12″), 131.9 (C10″), 123.8 (C11″), 123.8 (C8′), 117.7 (C6″),
112.3 (C1″), 103.4 (C5), 87.3 (C1′), 86.4 (C3″), 84.6 (C4″), 84.5
(C4′), 82.4 (C2″), 80.8 (C2′), 75.3 (C5′), 73.0 (C3′), 72.8, 70.7, 70.6,
70.4, 69.6, 61.7 (CPEG), 50.5 (C9′), 40.5 (C5″), 29.5 (C7″), 28.9
(C7″), 25.9, 25.9 (–C(CH3)3), 18.1, 18.1 (–C(CH3)3), 8.5, 7.5 (C8″),
−4.2, −4.4, −4.5, −4.5 (–Si–t-Bu–(CH3)2); HRMS, ESI+ calcd for
C52H83N6O16Si2
+ (M + H)+ 1103.5399, found 1103.5425.
Compound 23f. Triazole 23f was synthesized according to
the general procedure for Cu(I)-catalyzed azide–alkyne cyclo-
addition from alkyne 5 (67 mg, 0.08 mmol) and azide 7f
(52.3 mg, 0.14 mmol, 2 equiv.). Flash chromatography (cyclo-
hexane/EtOAc 1/1) aﬀorded 23f as a white foam (57 mg, 61%
yield): Rf 0.20 (cyclohexane/EtOAc 1/1); m.p. 114–118 °C; [α]D
−29 (c 1.0, CH2Cl2); IR (film) 2930m, 1773w, 1701s, 1395m,
1086m, 837m, 721m; 1H NMR δ 8.56 (d, 1H, JNH–H5 = 2.0 Hz,
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NH), 7.89–7.87 (m, 3H, H11″, H6), 7.84–7.81 (m, 2H, H21′),
7.78–7.74 (m, 2H, H22′), 7.72–7.69 (m, 2H, H12″), 7.36 (s, 1H,
H8′), 6.20 (dd, 1H, JH5–H6 = 8.0 Hz, JH5–NH = 2.0 Hz, H5), 5.96 (d,
1H, JH1′–H2′ = 5.5 Hz, H1′), 5.35 (s, 1H, H1″), 4.78 (d, 1H, JH2″–H3″ =
6.0 Hz, H2″), 4.68 (d, 1H, JH3″–H2″ = 6.0 Hz, H3″), 4.54–4.51 (m,
1H, H4″), 4.34–4.25 (m, 2H, H9′), 4.19–4.16 (m, 2H, H2′, H5′),
3.99 (t, 1H, JH3′–H2′ = JH3′–H4′ = 3.5 Hz, H3′), 3.88–3.82 (m, 3H,
H5″, H4′), 3.68 (t, 2H, JH18′–H17′ = 7.0 Hz, H18′), 3.50 (dd, 1H,
JH6′a–H6′b = 14.0 Hz, JH6′a–H5′ = 5.0 Hz, H6′a), 3.07 (dd, 1H,
JH6′b–H6′a = 14.0 Hz, JH6′b–H5′ = 11.0 Hz, H6′b), 1.89–1.84 (m, 2H,
H10′), 1.69–1.62 (m, 4H, H17′, H7″), 1.55–1.57–1.42 (m, 2H, H7″),
1.24–1.19 (m, 12H, H11′, H12′, H13′, H14′, H15′, H16′), 0.82 (t, 3H,
JH8″–H7″ = 8.0 Hz, H8″), 0.79 (s, 9H, –C(CH3)3), 0.76 (s, 9H,
–C(CH3)3), 0.75 (t, 3H, JH8″–H7″ = 8.0 Hz, H8″), 0.01, 0.00, −0.01,
−0.1 (4s, 12H, –Si–t-Bu–(CH3)2); 13C NMR δ 168.6, 168.2 (C19′,
C9″), 163.2 (C4), 150.5 (C2), 142.9 (C7′), 139.9 (C6), 134.5 (C12″),
133.9 (C22′), 132.3 (C20′), 131.9 (C10″), 123.8 (C11″), 123.3 (C21′),
122.0 (C8′), 117.7 (C6″), 112.3 (C1″), 103.2 (C5), 87.6 (C1′), 86.4
(C3″), 84.5 (C4″), 84.3 (C4′), 82.2 (C2″), 80.8 (C2′), 75.4 (C5′), 72.7
(C3′), 50.4 (C9′), 40.5 (C5″), 38.2 (C18′), 30.5 (C7″), 29.5, 29.4,
29.4, 29.2, 29.1, 28.9, 28.7, 26.9, 26.6 (C7″, C6′, C10′, C11′, C12′,
C13′, C14′, C15′, C16′, C17′), 25.9, 25.8 (–C(CH3)3), 18.1, 18.1 (–
C(CH3)3), 8.4, 7.5 (C8″), −4.2, −4.5, −4.5, −4.6 (–Si–t-Bu–
(CH3)2); HRMS ESI
+ calcd for C60H86N7O13Si2
+ (M + H)+
1168.5817, found 1168.5839.
Compound 23g. Triazole 23g was synthesized according to
the general procedure for Cu(I)-catalyzed azide–alkyne cyclo-
addition from alkyne 5 (140 mg, 0.17 mmol) and azide 7g
(110 mg, 0.33 mmol, 2 equiv.). Flash chromatography (cyclo-
hexane/EtOAc 6/4) aﬀorded 23g as a white foam (133 mg, 67%
yield): Rf 0.26 (cyclohexane/EtOAc 6/4); m.p. 122–128 °C; [α]D
−26 (c 0.5, CH2Cl2); IR (film) 2930m, 2351w, 1710s, 1693s,
1393m; 1H NMR δ 8.22 (br d, 1H, JNH–H5 = 2.0 Hz, NH),
7.89–7.86 (m, 2H, H11″), 7.85–7.82 (m, 3H, H6, H17′), 7.77–7.74
(m, 4H, H12″, H22′), 7.58–7.55 (m, 1H, H23′), 7.48 (d, 2H,
JH21′–H22′ = 8.0 Hz, H21′), 7.45 (d, 2H, JH11′–H12′ = 8.5 Hz, H11′),
7.36 (s, 1H, H8′), 7.28 (d, 2H, JH12′–H11′ = 8.5 Hz, H12′), 7.03–6.99
(m, 2H, H16′), 6.17 (dd, 1H, JH5–H6 = 8.0 Hz, JH5–NH = 2.0 Hz,
H5), 5.95 (d, 1H, JH1′–H2′ = 6.0 Hz, H1′), 5.56 (d, 1H, JH9′a–H9′b =
15.0 Hz, H9′a), 5.47 (d, 1H, JH9′b–H9′a = 15.0 Hz, H9′b), 5.34 (s,
1H, H1″), 5.14 (s, 2H, H14′), 4.78 (d, 1H, JH2″–H3″ = 6.0 Hz, H2″),
4.67 (d, 1H, JH3″–H2″ = 6.0 Hz, H3″), 4.52 (dd, 1H, JH4″–H5″a = 6.5
Hz, JH4″–H5″b = 9.5 Hz, H4″), 4.20–4.17 (m, 2H, H2′, H5′), 4.00
(dd, 1H, JH3′–H2′ = 4.5 Hz, JH3′–H4′ = 3.0 Hz, H3′), 3.86 (dd, 1H,
JH4′–H3′ = 3.0 Hz, JH4′–H5′ = 2.0 Hz, H4′), 3.84–3.78 (m, 2H,
H5″a, H5″b), 3.47 (dd, 1H, JH6′a–H6′b = 14.0 Hz, JH6′a–H5′ = 5.0 Hz,
H6′a), 3.07 (dd, 1H, JH6′b–H6′a = 14.0 Hz, JH6′b–H5′ = 10.5 Hz,
H6′b), 1.71–1.62 (m, 2H, H7″), 1.55–1.50 (m, 2H, H7″), 0.88 (t,
3H, JH8″–H7″ = 7.5 Hz, H8″), 0.87 (s, 9H, –C(CH3)3), 0.84 (s, 9H,
–C(CH3)3), 0.81 (t, 3H, JH8″–H7″ = 7.5 Hz, H8″), 0.07, 0.07, 0.06,
−0.03 (4s, 12H, –Si–t-Bu–(CH3)2); 13C NMR δ 195.6 (C19′), 168.2
(C9″), 162.9 (C4), 162.3 (C15′), 150.4 (C2), 143.6 (C7′), 139.9 (C6),
138.3 (C20′), 137.1 (C13′), 134.8 (C10′), 134.4 (C12″), 132.7 (C17′),
132.1 (C23′), 131.9 (C10″), 130.7 (C18′), 129.9 (C21′), 128.4 (C22′),
128.3 (C11′), 128.3 (C12′), 123.9 (C11″), 122.3 (C8′), 117.7 (C6″),
114.9 (C16′), 112.5 (C1″), 103.2 (C5), 87.6 (C1′), 86.4 (C3″), 84.5
(C4″), 84.5 (C4′), 82.2 (C2″), 80.8 (C2′), 75.4 (C5′), 72.8 (C3′), 69.7
(C14′), 53.9 (C9′), 40.4 (C5″), 29.5 (C7″), 28.9 (C7″), 28.9 (C6′), 25.9,
25.8 (–C(CH3)3), 18.1, 18.1 (–C(CH3)3), 8.5, 7.5 (C8″), −4.2, −4.5,
−4.5, −4.5 (–Si–t-Bu–(CH3)2); HRMS ESI+ calcd for
C63H79N6O13Si2
+ (M + H)+ 1183.5238, found 1183.5230.
Compound 23h. Triazole 23h was synthesized according to
the general procedure for Cu(I)-catalyzed azide–alkyne cyclo-
addition from alkyne 5 (108 mg, 0.13 mmol) and azide 7h
(98 mg, 0.26 mmol, 2 equiv.). Flash chromatography (cyclo-
hexane/EtOAc 1/1) aﬀorded 23h as a white foam (90 mg, 57%
yield): Rf 0.27 (cyclohexane/EtOAc 1/1); m.p. 96–102 °C; [α]D
−25 (c 1.0, CH2Cl2); IR (film) 2930m, 1710s, 1696s, 1256s; 1H
NMR δ 8.63–8.60 (m, 1H, NH), 7.89–7.87 (m, 3H, H11″, H6),
7.83–7.80 (m, 2H, H21′), 7.77–7.74 (m, 4H, H12″, H25′), 7.57–7.54
(m, 1H, H27′), 7.47 (t, 2H, JH26′–H27′ = JH26′–H25′ = 8.0 Hz, H26′),
7.38 (s, 1H, H8′), 6.96–6.93 (m, 2H, H20′), 6.20 (dd, 1H, JH5–H6 =
8.0 Hz, JH5–NH = 2.0 Hz, H5), 5.97 (d, 1H, JH1′–H2′ = 5.5 Hz, H1′),
5.33 (s, 1H, H1″), 4.78 (d, 1H, JH2″–H3″ = 6.0 Hz, H2″), 4.68 (d,
1H, JH3″–H2″ = 6.0 Hz, H3″), 4.53 (dd, 1H, JH4″–H5″a = 7.0 Hz,
JH4″–H5″b = 9.0 Hz, H4″), 4.36–4.26 (m, 2H, H9′), 4.20–4.18 (m,
2H, H2′, H5′), 4.03 (t, 1H, JH18′–H19′ = 6.5 Hz, H18′), 4.00 (t, 1H,
JH3′–H2′ = JH3′–H4′ = 4.5 Hz, H3′), 3.92–3.83 (m, 3H, H5″a, H5″b,
H4′), 3.52 (dd, 1H, JH6′a–H6′b = 14.0 Hz, JH6′a–H5′ = 5.0 Hz, H6′a),
3.08 (dd, 1H, JH6′b–H6′a = 14.0 Hz, JH6′b–H5′ = 11.0 Hz, H6′b),
1.92–1.85 (m, 2H, H10′), 1.84–1.78 (m, 2H, H17′), 1.73–1.61 (m,
2H, H7″), 1.57–1.50 (m, 2H, H7″), 1.48–1.44 (m, 2H, H16′),
1.38–1.26 (m, 10H, H11′, H12′, H13′, H14′, H15′), 0.88 (t, 3H,
JH8″–H7″ = 8.0 Hz, H8″), 0.86 (s, 9H, –C(CH3)3), 0.84 (s, 9H,
–C(CH3)3), 0.82 (t, 3H, JH8″–H7″ = 8.0 Hz, H8″), 0.08, 0.08, 0.07,
−0.01 (4s, 12H, –Si–t-Bu–(CH3)2); 13C NMR δ 195.6 (C23′), 168.2
(C9″), 163.2 (C4), 162.9 (C19′), 150.5 (C2), 142.9 (C7′), 139.9 (C6),
138.5 (C24′), 134.5 (C12″), 132.7 (C21′), 131.9 (C27′), 132.2 (C21′),
130.1 (C10″), 129.8 (C25′), 128.3 (C26′), 123.8 (C11″), 122.2 (C8′),
117.7 (C6″), 114.9 (C20′), 112.4 (C1″), 103.2 (C5), 87.6 (C1′), 86.4
(C4′), 84.5 (C2″), 84.4 (C4″), 82.2 (C2′), 80.8 (C3″), 75.4 (C3′), 72.7
(C5′), 68.4 (C18′), 50.4 (C9′), 40.5 (C5″), 30.5 (C17′), 29.6, 29.5,
29.4, 29.2, 29.1, 28.9, 26.6, 26.1 (C6′, C10′, C11′, C12′, C13′, C14′,
C15′, C16′, C7″), 25.9, 25.8 (–C(CH3)3), 18.1, 18.1 (–C(CH3)3), 8.4,
7.4 (C8″), −4.2, −4.5, −4.5, −4.6 (–Si–t-Bu–(CH3)2); HRMS ESI+
calcd for C65H91N6O13Si2
+ (M + H)+ 1219.6177, found
1219.6187.
General procedure for the preparation of N-triazoles 24a–h
To a solution of azide 6 (1 equiv.) and alkyne partner 8a–h
(1 to 2 equiv.) in tert-BuOH/H2O (1.5 mL/500 µL) were succes-
sively added CuSO4 (0.1 equiv.), sodium ascorbate (0.3 equiv.)
and N-diisopropylethylamine (2.2 equiv.). The suspension was
sonicated for 5 min to solubilise all reagents. The mixture was
stirred at r.t. for 18 h and diluted with DCM (30 mL) and NH4Cl
(15 mL). The aqueous phase was extracted with DCM (6 × 30 mL)
and the combined organic layers were washed with 10−3 M solu-
tion of tetra-sodium EDTA, dried (Na2SO4), filtered and concen-
trated in vacuo. The residue was then purified by flash
chromatography to give the corresponding N-triazole 24a–h.
Compound 24a. Triazole 24a was synthesized according to
the general procedure for the preparation of N-triazoles from
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azide 6 (52 mg, 0.06 mmol) and 1-dodecyne 8a (25 mg,
0.12 mmol, 2 equiv.). Flash chromatography (cyclohexane/
EtOAc 7/3) aﬀorded 24a as a white foam (35 mg, 55% yield): Rf
0.61 (cyclohexane/EtOAc 1/1); m.p. 102–106 °C; [α]D −30 (c 0.5,
CH2Cl2); IR (film) 3060m, 2928m, 2856m, 1714s, 1386m;
1H
NMR δ 8.63 (br d, 1H, JNH–H5 = 1.0 Hz, NH), 7.91–7.88 (m, 2H,
H11″), 7.85 (d, 1H, JH6–H5 = 8.0 Hz, H6), 7.79–7.76 (m, 2H, H12″),
7.33 (s, 1H, H7′), 6.16 (dd, 1H, JH5–H6 = 8.0 Hz, JH5–NH = 1.0 Hz,
H5), 5.92 (d, 1H, JH1′–H2′ = 5.0 Hz, H1′), 5.34 (s, 1H, H1″), 5.02
(dd, 1H, JH6′a–H6′b = 13.0 Hz, JH6′a–H5′ = 5.0 Hz, H6′a), 4.77 (d,
1H, JH2″–H3″ = 6.0 Hz, H2″), 4.68 (d, 1H, JH3″–H2″ = 6.0 Hz, H3″),
4.58 (dd, 1H, JH4″–H5″a = 5.5 Hz, JH4″–H5″b = 10.0 Hz, H4″), 4.44
(dd, 1H, JH6′b–H6′a = 13.0 Hz, JH6′b–H5′ = 10.5 Hz, H6′b), 4.26
(ddd, 1H, JH5′–H6′a = 5.0 Hz, JH5′–H6′b = 10.5 Hz, JH5′–H4′ = 1.0 Hz,
H5′), 4.17 (t, 1H, JH2′–H1′ = JH2′–H3′ = 5.0 Hz, H2′), 4.02 (t, 1H,
JH3′–H2′ = JH3′–H4′ = 5.0 Hz, H3′), 3.84 (dd, 1H, JH5″a–H5″b = 14.0
Hz, JH5″a–H4″ = 5.5 Hz, H5″a), 3.80 (dd, 1H, JH5″b–H5″a = 14.0 Hz,
JH5″b–H4″ = 10.0 Hz, H5″b), 3.60 (dd, 1H, JH4′–H3′ = 5.0 Hz, JH4′–H5′ =
1.0 Hz, H4′), 2.74–2.64 (m, 2H, H9′), 1.74–1.61 (m, 4H, H10′,
H7″), 1.58–1.50 (m, 2H, H7″), 1.38–1.25 (m, 14H, H11′, H12′,
H13′, H14′, H15′, H16′, H17′), 0.91–0.86 (m, 6H, H8″, H18′), 0.87 (s,
9H, –C(CH3)3), 0.84 (s, 9H, –C(CH3)3), 0.83–0.82 (m, 3H, H8″),
0.11, 0.08, 0.06, −0.01 (4s, 12H, –Si–t-Bu–(CH3)2); 13C NMR
δ 168.2 (C9″), 163.1 (C4), 150.4 (C2), 142.9 (C8′), 139.6 (C6),
134.6 (C12″), 131.9 (C10″), 123.9 (C11″), 122.1 (C7′), 118.1 (C6″),
112.7 (C1″), 103.1 (C5), 88.3 (C1′), 86.3 (C3″), 84.6 (C4″), 82.4
(C4′), 82.1 (C2″), 79.0 (C5′), 75.4 (C2′), 71.7 (C3′), 50.5 (C6′), 40.5
(C5″), 32.9 (C7″), 29.8, 29.8, 29.7, 29.7, 29.5, 29.5, 28.9 (C7″, C9′,
C10′, C11′, C12′, C13′, C14′, C15′, C16′), 25.8, 25.7 (–C(CH3)3), 22.8
(C17′), 18.1, 18.0 (–C(CH3)3), 14.2 (C18′), 8.5, 7.5 (C8″), −4.1,
−4.4, −4.6, −4.7 (–Si–t-Bu–(CH3)2); HRMS, ESI+ calcd for
C52H83N6O11Si2
+ (M + H)+ 1023.5653, found 1023.5671.
Compound 24b. Triazole 24b was synthesized according to
the general procedure for the preparation of N-triazoles from
azide 6 (40 mg, 0.47 mmol) and 12-phenyl-dodec-1-yne 8b
(17 mg, 0.07 mmol, 1.5 equiv.). Flash chromatography (cyclo-
hexane/EtOAc 7/3) aﬀorded 24b as a white foam (31 mg, 60%
yield): Rf 0.11 (cyclohexane/EtOAc 7/3); m.p. 106–110 °C; [α]D
−34 (c 0.5, CH2Cl2); IR (film) 2928m, 2848w, 2163m, 1693s,
1394m, 1090w, 837m; 1H NMR δ 8.61 (br s, 1H, NH), 7.92–7.88
(m, 2H, H11″), 7.85 (d, 1H, JH6–H5 = 8.0 Hz, H6), 7.79–7.76 (m,
2H, H12″), 7.32 (s, 1H, H7′), 7.28–7.25 (m, 2H, H20′), 7.18–7.15
(m, 3H, H21′, H22′), 6.16 (dd, 1H, JH5–H6 = 8.0 Hz, JH5–NH = 2.5
Hz, H5), 5.92 (d, 1H, JH1′–H2′ = 5.0 Hz, H1′), 5.35 (s, 1H, H1″),
5.03 (dd, 1H, JH6′a–H6′b = 13.0 Hz, JH6′a–H5′ = 5.0 Hz, H6′a), 4.77
(d, 1H, JH2″–H3″ = 6.0 Hz, H2″), 4.69 (d, 1H, JH3″–H2″ = 6.0 Hz,
H3″), 4.58 (dd, 1H, JH4″–H5″a = 5.5 Hz, JH4″–H5″b = 10.0 Hz, H4″),
4.45–4.41 (m, 1H, H6′b), 4.28–4.25 (m, 1H, H5′), 4.17 (t, 1H,
JH2′–H1′ = JH2′–H3′ = 5.0 Hz, H2′), 4.02 (t, 1H, JH3′–H2′ = JH3′–H4′ =
5.0 Hz, H3′), 3.84 (dd, 1H, JH5″a–H5″b = 13.5 Hz, JH5″a–H4″ = 5.5
Hz, H5″a), 3.80 (dd, 1H, JH5″b–H5″a = 13.5 Hz, JH5″b–H4″ = 10.0
Hz, H5″b), 3.60–3.59 (m, 1H, H4′), 2.73–2.68 (m, 2H, H9′), 2.59
(t, 2H, JH18′–H17′ = 7.5 Hz, H18′), 1.73–1.58 (m, 6H, H10′, H17′,
H7″), 1.57–1.52 (m, 2H, H7″), 1.38–1.24 (m, 12H, H11′, H12′,
H13′, H14′, H15′, H16′), 0.90 (t, 3H, JH8″–H7″ = 7.5 Hz, H8″), 0.87 (s,
9H, –C(CH3)3), 0.85–0.82 (m, 12H, –C(CH3)3, H8″), 0.83–0.82
(m, 3H, H8″), 0.11, 0.08, 0.06, −0.01 (4s, 12H, –Si–t-Bu–(CH3)2);
13C NMR δ 168.2 (C9″), 163.1 (C4), 150.4 (C2), 143.1 (C19′), 139.5
(C8′), 134.6 (C6), 134.6 (C12″), 131.9 (C10″), 128.5 (C21′), 128.3
(C20′), 125.7 (C22′), 123.9 (C11″), 121.9 (C7′), 118.1 (C6″), 112.7
(C1″), 103.1 (C5), 88.3 (C1′), 86.3 (C3″), 84.6 (C4″), 82.4 (C4′), 82.1
(C2″), 79.0 (C2′), 75.4 (C5′), 71.7 (C3′), 49.9 (C9′), 40.4 (C5″), 36.1
(C18′), 31.6 (C10′), 29.8, 29.8, 29.7, 29.7, 29.6, 29.5, 29.5 (C7″, C6′,
C11′, C12′, C13′, C14′, C15′, C16′, C17′), 25.9, 25.9 (–C(CH3)3), 18.1,
18.0 (–C(CH3)3), 8.5, 7.5 (C8″), −4.1, −4.4, −4.6, −4.7 (–Si–t-Bu–
(CH3)2); HRMS, ESI
+ calcd for C58H87N6O11Si2
+ (M + H)+
1099.5966, found 1099.5994.
Compound 24c. Triazole 24c was synthesized according to
the general procedure for the preparation of N-triazoles from
azide 6 (40 mg, 0.047 mmol) and 5-heptyne-1-ol 8c (8 mg,
0.07 mmol, 1.5 equiv.). Flash chromatography (cyclohexane/
EtOAc 3/7) aﬀorded 24c as a white foam (24 mg, 53% yield): Rf
0.12 (cyclohexane/EtOAc 3/7); m.p. 110–112 °C; [α]D −22 (c 0.5,
CH2Cl2); IR (film) 2931w, 2857w, 1715s, 1523w, 1256m,
1159m, 838w; 1H NMR δ 8.76–8.66 (br m, 1H, NH), 7.94–7.89
(m, 2H, H11″), 7.83 (d, 1H, JH6–H5 = 8.5 Hz, H6), 7.79–7.76 (m,
2H, H12″), 7.34 (s, 1H, H7′), 6.15 (dd, 1H, JH5–H6 = 8.5 Hz,
JH5–NH = 2.0 Hz, H5), 5.92 (d, 1H, JH1′–H2′ = 5.0 Hz, H1′), 5.34 (s,
1H, H1″), 5.02 (dd, 1H, JH6′a–H6′b = 13.5 Hz, JH6′a–H5′ = 5.5 Hz,
H6′a), 4.77 (d, 1H, JH2″–H3″ = 6.0 Hz, H2″), 4.69 (d, 1H, JH3″–H2″ =
6.0 Hz, H3″), 4.57 (dd, 1H, JH4″–H5″a = 6.0 Hz, JH4″–H5″b = 10.0
Hz, H4″), 4.43 (dd, 1H, JH6′b–H6′a = 13.5 Hz, JH6′b–H5′ = 10.0 Hz,
H6′b), 4.27 (ddd, 1H, JH5′–H6′a = 5.5 Hz, JH5′–H6′b = 10.0 Hz,
JH5′–H4′ = 1.0 Hz, H5′), 4.17 (t, 1H, JH2′–H1′ = JH2′–H3′ = 5.0 Hz,
H2′), 4.02 (t, 1H, JH3′–H2′ = JH3′–H4′ = 5.0 Hz, H3′), 3.83 (dd, 1H,
JH5″a–H5″b = 13.5 Hz, JH5″a–H4″ = 6.0 Hz, H5″a), 3.80 (dd, 1H,
JH5″b–H5″a = 13.5 Hz, JH5″b–H4″ = 10.0 Hz, H5″b), 3.65 (t, 2H,
JH13′–H12′ = 6.5 Hz, H13′), 3.59 (dd, 1H, JH4′–H3′ = 5.0 Hz, JH4′–H5′ =
1.0 Hz, H4′), 2.76–2.66 (m, 2H, H9′), 1.73–1.66 (m, 4H, H10′,
H7″), 1.61 (qt, 2H, JH12′–H13′ = JH12′–H11′ = 6.5 Hz, H12′),
1.56–1.54 (m, 2H, H7″), 1.44 (qt, 2H, JH11′–H12′ = JH11′–H10′ = 6.5
Hz, H11′), 0.89 (t, 3H, JH8″–H7″ = 7.0 Hz, H8″), 0.86 (s, 9H,
–C(CH3)3), 0.85–0.82 (m, 12H, –C(CH3)3, H8″), 0.10, 0.08, 0.07,
−0.01 (4s, 12H, –Si–t-Bu–(CH3)2); 13C NMR δ 168.2 (C9″), 163.1
(C4), 150.4 (C2), 148.3 (C8′), 139.6 (C6), 134.6 (C12″), 131.9 (C10″),
123.9 (C11″), 122.2 (C7′), 118.1 (C6″), 112.6 (C1″), 103.2 (C5), 88.2
(C1′), 86.3 (C3″), 84.6 (C4″), 82.6 (C4′), 82.1 (C2″), 79.0 (C5′), 75.3
(C2′), 71.2 (C3′), 62.8 (C13′), 49.9 (C6′), 40.4 (C5″), 32.5 (C12′), 29.5
(C7″), 29.3 (C10′), 28.9 (C7″), 25.8, 25.8 (–C(CH3)3), 25.6 (C9′),
25.5 (C11′), 18.1, 18.1 (–C(CH3)3), 8.5, 7.5 (C8″), −4.1, −4.4,
−4.6, −4.7 (–Si–t-Bu–(CH3)2); HRMS, ESI+ calcd for
C47H73N6O12Si2
+ (M + H)+ 969.4820, found 969.4824.
Compound 24d. Triazole 24d was synthesized according to
the general procedure for the preparation of N-triazoles from
azide 6 (50 mg, 0.06 mmol) and 12-dodecyne-1-ol 8d (20 mg,
0.12 mmol, 2 equiv.). Flash chromatography (cyclohexane/
EtOAc 1/1) aﬀorded 24d as a white foam (43 mg, 66% yield): Rf
0.21 (cyclohexane/EtOAc 1/1); m.p. 110–112 °C; [α]D −23 (c 0.5,
CH2Cl2); IR (film) 2929br, 2853w, 1712s, 1459w, 1396m;
1H
NMR δ 8.70 (br s, 1H, NH), 7.91–7.89 (m, 2H, H11″), 7.84 (d,
1H, JH6–H5 = 8.5 Hz, H6), 7.79–7.76 (m, 2H, H12″), 7.32 (s, 1H,
H7′), 6.15 (d, 1H, JH5–H6 = 8.5 Hz, H5), 5.92 (d, 1H, JH1′–H2′ = 5.0
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Hz, H1′), 5.35 (s, 1H, H1″), 5.02 (dd, 1H, JH6′a–H6′b = 13.0 Hz,
JH6′a–H5′ = 5.0 Hz, H6′a), 4.77 (d, 1H, JH2″–H3″ = 6.0 Hz, H2″), 4.68
(d, 1H, JH3″–H2″ = 6.0 Hz, H3″), 4.58 (dd, 1H, JH4″–H5″a = 6.0 Hz,
JH4″–H5″b = 10.0 Hz, H4″), 4.43 (dd, 1H, JH6′b–H6′a = 13.0 Hz,
JH6′b–H5′ = 10.5 Hz, H6′b), 4.27 (ddd, 1H, JH5′–H6′a = 5.0 Hz,
JH5′–H6′b = 10.5 Hz, JH5′–H4′ = 1.0 Hz, H5′), 4.17 (t, 1H, JH2′–H1′ =
JH2′–H3′ = 5.0 Hz, H2′), 4.02 (t, 1H, JH3′–H2′ = JH3′–H4′ = 5.0 Hz,
H3′), 3.85 (dd, 1H, JH5″a–H5″b = 13.5 Hz, JH5″a–H4″ = 6.0 Hz, H5″a),
3.80 (dd, 1H, JH5″b–H5″a = 13.5 Hz, JH5″b–H4″ = 10.0 Hz, H5″b),
3.64 (t, 2H, JH18′–H17′ = 6.5 Hz, H18′), 3.59 (dd, 1H, JH4′–H3′ = 5.0
Hz, JH4′–H5′ = 1.0 Hz, H4′), 2.73–2.64 (m, 2H, H9′), 1.74–1.63 (m,
4H, H10′, H7″), 1.58–1.52 (m, 4H, H17′, H7″), 1.38–1.25 (m, 13H,
H11′, H12′, H13′, H14′, H15′, H16′, OH), 0.89 (t, 3H, JH8″–H7″ = 7.0
Hz, H8″), 0.86 (s, 9H, –C(CH3)3), 0.85–0.82 (m, 12H, –C(CH3)3,
H8″), 0.11, 0.08, 0.06, −0.02 (4s, 12H, –Si–t-Bu–(CH3)2); 13C
NMR δ 168.2 (C9″), 163.1 (C4), 150.4 (C2), 148.6 (C8′), 139.5 (C6),
134.6 (C12″), 131.8 (C10″), 123.9 (C11″), 121.9 (C7′), 118.1 (C6″),
112.7 (C1″), 103.1 (C5), 88.2 (C1′), 86.3 (C3″), 84.6 (C4″), 82.4
(C4′), 82.1 (C2″), 79.1 (C5′), 75.4 (C2′), 71.8 (C3′), 63.0 (C18′), 49.5
(C6′), 40.4 (C5″), 32.9 (C7″), 29.7, 29.6, 29.5, 29.5, 29.5, 29.4,
29.4, 28.9 (C7″, C9′, C10′, C11′, C12′, C13′, C14′, C15′, C16′), 25.8,
25.8 (–C(CH3)3), 25.7 (C17′), 18.1, 18.0 (–C(CH3)3), 8.5, 7.5 (C8″),
−4.1, −4.4, −4.6, −4.7 (–Si–t-Bu–(CH3)2); HRMS, ESI+ calcd for
C52H83N6O12Si2
+ (M + H)+ 1039.5602, found 1039.5624.
Compound 24e. Triazole 24e was synthesized according to
the general procedure for the preparation of N-triazoles from
azide 6 (40 mg, 0.047 mmol) and alkyne 8e (7.2 mg,
0.031 mmol, 1 equiv.). Flash chromatography (EtOAc/MeOH
100/0 to 90/10) aﬀorded 24e as a pale red film (22 mg, 44%
yield): Rf 0.10 (EtOAc/MeOH 90/10); [α]D −22 (c 0.5, CH2Cl2); IR
(film) 3744br, 2677m, 2160s, 1712s, 1096m, 830m; 1H NMR
δ 8.31 (br s, 1H, NH), 7.91–7.88 (m, 2H, H11″), 7.82 (d, 1H,
JH6–H5 = 8.0 Hz, H6), 7.79–7.77 (m, 2H, H12″), 7.69 (s, 1H, H8′),
6.13 (dd, 1H, JH5–H6 = 8.0 Hz, JH5–NH = 1.5 Hz, H5), 5.91 (d, 1H,
JH1′–H2′ = 5.0 Hz, H1′), 5.35 (s, 1H, H1″), 5.00 (dd, 1H, JH6′a–H6′b =
13.5 Hz, JH6′a–H5′ = 5.5 Hz, H6′a), 4.77 (d, 1H, JH2″–H3″ = 6.0 Hz,
H2″), 4.69–4.66 (m, 3H, H9′, H3″), 4.57 (dd, 1H, JH4″–H5″a = 6.5
Hz, JH4″–H5″b = 9.5 Hz, H4″), 4.51 (d, 1H, JH6′b–H6′a = 13.5 Hz,
JH6′b–H5′ = 9.5 Hz, H6′b), 4.33 (ddd, 1H, JH5′–H6′a = 5.5 Hz, JH5′–H6′b =
9.5 Hz, JH5′–H4′ = 1.0 Hz, H5′), 4.18 (t, 1H, JH2′–H1′ = JH2′–H3′ = 5.0
Hz, H2′), 4.03 (t, 1H, JH3′–H2′ = JH3′–H4′ = 5.0 Hz, H3′), 3.85 (dd,
1H, JH5″a–H5″b = 13.5 Hz, JH5″a–H4″ = 6.0 Hz, H5″a), 3.79 (dd, 1H,
JH5″b–H5″a = 13.5 Hz, JH5″b–H4″ = 10.0 Hz, H5″b), 3.72–3.59 (m,
17H, H4′, H10′, H11′, H12′, H13′, H14′, H15′, H16′, H17′), 1.73–1.63
(m, 3H, H7″, OH), 1.56–1.51 (m, 2H, H7″), 0.89 (t, 3H, JH8″–H7″ =
7.0 Hz, H8″), 0.87 (s, 9H, –C(CH3)3), 0.85–0.82 (m, 12H,
–C(CH3)3, H8″), 0.10, 0.08, 0.07, −0.01 (4s, 12H, –Si–t-Bu–
(CH3)2);
13C NMR δ 168.2 (C9″), 162.9 (C4), 150.3 (C2), 145.3
(C8′), 139.6 (C6), 134.6 (C12″), 131.8 (C10″), 124.2 (C7′), 123.9
(C11″), 118.1 (C6″), 112.6 (C1″), 103.1 (C5), 88.2 (C1′), 86.3 (C3″),
84.6 (C4″), 82.7 (C4′), 82.1 (C2″), 78.9 (C5′), 75.3 (C2′), 72.6
(CH2PEG), 71.9 (C3′),70.6, 70.3, 69.8 (CH2PEG), 64.7 (C9′), 61.8
(CH2PEG), 50.5 (C6′), 40.5 (C5″), 29.5, 28.9 (C7″), 25.9, 25.8 (–
C(CH3)3), 18.1, 18.1 (–C(CH3)3), 8.5, 7.5 (C8″), −4.1, −4.4, −4.5,
−4.6 (–Si–t-Bu–(CH3)2); HRMS, ESI+ calcd for C51H81N6O16Si2+
(M + H)+ 1089.5242, found 1089.5260.
Compound 24f. Triazole 24f was synthesized according to
the general procedure for the preparation of N-triazoles from
azide 6 (40 mg, 0.047 mmol) and alkyne 8f (22 mg, 0.07 mmol,
1.5 equiv.). Flash chromatography (cyclohexane/EtOAc 6/4)
aﬀorded 24f as a white foam (37.5 mg, 68% yield): Rf 0.11
(cyclohexane/EtOAc 6/4); m.p. 120–124 °C; [α]D −21 (c 0.5,
CH2Cl2); IR (film) 2923m, 1713s, 1273m, 1253w, 1075w, 746m;
1H NMR δ 8.57 (brs, 1H, NH), 7.90–7.88 (m, 2H, H11″),
7.88–7.81 (m, 3H, H21′, H6), 7.79–7.75 (m, 2H, H22′), 7.72–7.69
(m, 2H, H12″), 7.32 (s, 1H, H7′), 6.16 (dd, 1H, JH5–H6 = 8.0 Hz,
JH5–NH = 2.0 Hz, H5), 5.92 (d, 1H, JH1′–H2′ = 5.0 Hz, H1′), 5.34 (s,
1H, H1″), 5.02 (dd, 1H, JH6′a–H6′b = 13.0 Hz, JH6′a–H5′ = 5.0 Hz,
H6′a), 4.77 (d, 1H, JH2″–H3″ = 6.5 Hz, H2″), 4.68 (d, 1H, JH3″–H2″ =
6.5 Hz, H3″), 4.58 (dd, 1H, JH4″–H5″a = 5.5 Hz, JH4″–H5″b = 10.5
Hz, H4″), 4.43 (dd, 1H, JH6′b–H6′a = 13.0 Hz, JH6′b–H5′ = 10.5 Hz,
H6′b), 4.26 (ddd, 1H, JH5′–H6′a = 5.0 Hz, JH5′–H6′b = 10.5 Hz,
JH5′–H4′ = 1.0 Hz, H5′), 4.16 (t, 1H, JH2′–H1′ = JH2′–H3′ = 5.0 Hz,
H2′), 4.01 (t, 1H, JH3′–H2′ = JH3′–H4′ = 5.0 Hz, H3′), 3.84 (dd, 1H,
JH5″a–H5″b = 13.5 Hz, JH5″a–H4″ = 5.5 Hz, H5″a), 3.80 (dd, 1H,
JH5″b–H5″a = 13.5 Hz, JH5″b–H4″ = 10.5 Hz, H5″b), 3.67 (t, 2H,
JH18′–H17′ = 7.0 Hz, H18′), 3.59 (dd, 1H, JH4′–H3′ = 5.0 Hz, JH4′–H5′ =
1.0 Hz, H4′), 2.72–2.63 (m, 2H, H9′), 1.69–1.60 (m, 6H, H10′,
H17′, H7″), 1.57–1.51 (m, 2H, H7″), 1.37–1.23 (m, 12H, H11′,
H12′, H13′, H14′, H15′, H16′), 0.89 (t, 3H, JH8″–H7″ = 7.0 Hz, H8″),
0.87 (s, 9H, –C(CH3)3), 0.85–0.82 (m, 12H, –C(CH3)3, H8″), 0.10,
0.07, 0.05, −0.02 (4s, 12H, –Si–t-Bu–(CH3)2); 13C NMR δ 168.6,
168.2 (C19′, C9″), 163.1 (C4), 150.3 (C2), 148.7 (C8′), 139.5 (C6),
134.6 (C12″), 133.9 (C22′), 132.4 (C20′), 131.2 (C10″), 123.8 (C11″),
123.3 (C21′), 121.9 (C7′), 118.1 (C6″), 112.7 (C1″), 103.1 (C5), 88.2
(C1′), 86.3 (C3″), 84.6 (C4″), 82.4 (C4′), 82.1 (C2″), 79.1 (C2′), 75.4
(C5′), 71.8 (C3′), 49.9 (C9′), 40.5 (C5″), 38.2 (C18′), 29.8, 29.6, 29.6,
29.5, 29.4, 29.4, 29.3, 28.9, 28.7, 27.1, 26.9 (C7″, C6′, C10′, C11′,
C12′, C13′, C14′, C15′, C16′, C17′), 25.8, 25.7 (–C(CH3)3), 18.1, 18.0
(–C(CH3)3), 8.4, 7.5 (C8″), −4.1, −4.1, −4.6, −4.7 (–Si–t-Bu–
(CH3)2); HRMS, ESI
+ calcd for C60H86N7O13Si2
+ (M + H)+
1168.5817, found 1168.5838.
Compound 24g. Triazole 24g was synthesized according to
the general procedure for the preparation of N-triazoles from
azide 6 (21 mg, 0.024 mmol) and alkyne 8g (16.0 mg,
0.049 mmol, 2.0 equiv.). Flash chromatography (cyclohexane/
EtOAc 6/4 to 3/7) aﬀorded 24g as a white foam (19 mg, 64%
yield): Rf 0.30 (cyclohexane/EtOAc 3/7); m.p. 112–116 °C; [α]D
−34 (c 1.0, CH2Cl2); IR (film) 2928br, 2550w, 1718s, 1696s,
1655m, 1463w, 1253m, 839m; 1H NMR δ 8.56 (br s, 1H, NH),
7.92–7.88 (m, 2H, H11″), 7.84–7.80 (m, 3H, H17′, H6), 7.78–7.43
(m, 4H, H12″, H21′), 7.57 (t, 1H, JH23′–H22′ = 8.0 Hz, H23′),
7.48–7.45 (m, 2H, H22′), 7.41–7.39 (br s, 1H, H7′), 7.36 (d, 2H,
JH11′–H12′ = 8.0 Hz, H11′), 7.27 (d, 2H, JH12′–H11′ = 8.0 Hz, H12′),
7.03–7.01 (m, 2H, H16′), 6.11 (dd, 1H, JH5–H6 = 8.5 Hz, JH5–NH =
1.5 Hz, H5), 5.88 (d, 1H, JH1′–H2′ = 5.0 Hz, H1′), 5.32 (s, 1H, H1″),
5.14 (m, 2H, H14′), 4.96 (dd, 1H, JH6′a–H6′b = 13.5 Hz, JH6′a–H5′ =
5.5 Hz, H6′a), 4.75 (d, 1H, JH2″–H3″ = 6.0 Hz, H2″), 4.68 (d, 1H,
JH3″–H2″ = 6.0 Hz, H3″), 4.56 (dd, 1H, JH4″–H5″a = 6.0 Hz, JH4″–H5″b =
9.5 Hz, H4″), 4.45 (dd, 1H, JH6′b–H6′a = 13.0 Hz, JH6′b–H5′ = 10.0
Hz, H6′b), 4.27 (ddd, 1H, JH5′–H6′a = 5.5 Hz, JH5′–H6′b = 10.0 Hz,
JH5′–H4′ = 1.0 Hz, H5′), 4.17 (t, 1H, JH2′–H1′ = JH2′–H3′ = 5.0 Hz,
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H2′), 4.13 (d, 1H, JH9′a–H9′b = 16.0 Hz, H9′a), 4.06 (d, 1H, JH9′b–H9′a =
16.0 Hz, H9′b), 4.02 (t, 1H, JH3′–H2′ = JH3′–H4′ = 5.0 Hz, H3′), 3.80
(dd, 1H, JH5″a–H5″b = 13.5 Hz, JH5″a–H4″ = 6.0 Hz, H5″a), 3.80 (dd,
1H, JH5″b–H5″a = 13.5 Hz, JH5″b–H4″ = 9.5 Hz, H5″b), 3.61 (dd, 1H,
JH4′–H3′ = 5.0 Hz, JH4′–H5′ = 1.5 Hz, H4′), 1.71–1.62 (m, 2H, H7″),
1.57–1.49 (m, 2H, H7″), 0.94–0.80 (m, 24H, H8″, –C(CH3)3),
0.10, 0.08, 0.08, −0.02 (4s, 12H, –Si–t-Bu–(CH3)2); 13C NMR
δ 13C NMR δ 195.6 (C19′), 168.2 (C9″), 163.0 (C4), 162.5 (C15′),
150.3 (C2), 147.4 (C8′), 139.5 (C6), 139.1 (C20′), 138.4 (C13′),
135.8 (C10′), 134.6 (C12″), 132.7 (C17′), 132.0 (C23′), 131.8 (C10″),
130.5 (C18′), 129.8 (C21′), 129.1 (C22′), 128.5 (C11′), 128.3 (C12′),
128.0(C11″), 123.8 (C7′), 118.1 (C6″), 114.5 (C16′), 112.7 (C1″),
103.0 (C5), 88.3 (C1′), 86.2 (C3″), 84.6 (C4″), 82.6 (C4′), 82.0 (C2″),
78.9 (C2′), 75.3 (C5′), 71.8 (C3′), 70.1 (C14′), 50.2 (C9′), 40.4 (C5″),
29.5 (C7″), 29.5 (C7″), 28.9 (C6′), 25.9, 25.8 (–C(CH3)3), 18.1, 18.0
(–C(CH3)3), 8.5, 7.5 (C8″), −4.1, −4.4, −4.6, −4.7 (–Si–t-Bu–
(CH3)2); HRMS, ESI
+ calcd for C63H79N6O13Si2
+ (M + H)+
1183.5238, found 1183.5222.
Compound 24h. Triazole 24h was synthesized according to
the general procedure for the preparation of N-triazoles from
azide 6 (40 mg, 0.047 mmol) and alkyne 8h (25.4 mg,
0.07 mmol, 1.5 equiv.). Flash chromatography (cyclohexane/
EtOAc 6/4) aﬀorded 24h as a white foam (33 mg, 58% yield): Rf
0.20 (cyclohexane/EtOAc 6/4); m.p. 102–106 °C; [α]D −24 (c 0.5,
CH2Cl2); IR (film) 1710s, 1643m, 1602w, 1256m, 835w;
1H
NMR δ 8.68 (br d, 1H, JNH–H5 = 1.5 Hz, NH), 7.92–7.88 (m, 2H,
H11″), 7.85 (d, 1H, JH6–H5 = 8.0 Hz, H6), 7.83–7.80 (m, 2H, H21′),
7.79–7.74 (m, 4H, H12″, H25′), 7.57–7.54 (m, 1H, H27′), 7.48–7.45
(m, 2H, H26′), 7.32 (s, 1H, H7′), 6.96–6.93 (m, 2H, H20′), 6.16
(dd, 1H, JH5–H6 = 8.0 Hz, JH5–NH = 1.5 Hz, H5), 5.92 (d, 1H,
JH1′–H2′ = 5.0 Hz, H1′), 5.35 (s, 1H, H1″), 5.02 (dd, 1H, JH6′a–H6′b =
13.0 Hz, JH6′a–H5′ = 5.0 Hz, H6′a), 4.77 (d, 1H, JH2″–H3″ = 6.0 Hz,
H2″), 4.68 (d, 1H, JH3″–H2″ = 6.5 Hz, H3″), 4.57 (dd, 1H, JH4″–H5″a =
5.5 Hz, JH4″–H5″b = 10.0 Hz, H4″), 4.43 (dd, 1H, JH6′b–H6′a = 13.0
Hz, JH6′b–H5′ = 10.5 Hz, H6′b), 4.27 (ddd, 1H, JH5′–H6′a = 5.0 Hz,
JH5′–H6′b = 10.5 Hz, JH5′–H4′ = 1.5 Hz, H5′), 4.16 (t, 1H, JH2′–H1′ =
JH2′–H3′ = 5.0 Hz, H2′), 4.04 (t, 1H, JH18′–H17′ = 7.0 Hz, H18′), 4.02
(t, 1H, JH3′–H2′ = JH3′–H4′ = 5.0 Hz, H3′), 3.84 (dd, 1H, JH5″a–H5″b =
13.5 Hz, JH5″a–H4″ = 5.5 Hz, H5″a), 3.80 (dd, 1H, JH5″b–H5″a = 13.5
Hz, JH5″b–H4″ = 10.0 Hz, H5″b), 3.59 (dd, 1H, JH4′–H3′ = 5.0 Hz,
JH4′–H5′ = 1.5 Hz, H4′), 2.74–2.64 (m, 2H, H9′), 1.81 (qt, 2H,
JH17′–H18′ = JH17′–H16′ = 7.0 Hz, H17′), 1.71–1.62 (m, 4H, H10′,
H7″), 1.56–1.52 (m, 2H, H7″), 1.50–1.44 (m, 2H, H16′), 1.38–1.26
(m, 10H, H11′, H12′, H13′, H14′, H15′), 0.89 (t, 3H, JH8″–H7″ = 7.5 Hz,
H8″), 0.86 (s, 9H, –C(CH3)3), 0.85–0.82 (m, 12H, –C(CH3)3, H8″),
0.11, 0.08, 0.06, −0.02 (4s, 12H, –Si–t-Bu–(CH3)2); 13C NMR
δ 195.8 (C23′), 168.3 (C9″), 163.2 (C4), 163.1 (C19′), 150.5 (C2), 148.8
(C8′), 139.6 (C6), 138.6 (C24′), 134.7 (C12″), 132.8 (C21′), 132.0 (C27′),
131.9 (C21′), 130.1 (C10″), 129.9 (C25′), 128.4 (C26′), 123.9 (C11″),
122.1 (C7′), 118.2 (C6″), 114.3 (C20′), 112.8 (C1″), 103.2 (C5), 88.3
(C1′), 86.4 (C4′), 84.7 (C2″), 82.5 (C4″), 82.2 (C2′), 79.2 (C3″), 75.5
(C3′), 71.9 (C5′), 68.5 (C18′), 50.0 (C9′), 40.5 (C5″), 29.9, 29.8, 29.7,
29.6, 29.4, 29.1, 27.2, 26.2 (C6′, C10′, C11′, C12′, C13′, C14′, C15′, C16′,
C17′, C7″), 25.9, 25.8 (–C(CH3)3), 18.2, 18.2 (–C(CH3)3), 8.6,
7.6 (C8″), −4.0, −4.3, −4.5, −4.6 (–Si–t-Bu–(CH3)2); HRMS, ESI+
calcd for C65H91N6O13Si2
+ (M + H)+ 1219.6177, found 1219.6198.
General procedure for phthalimide, isopentylidene and TBS
group cleavage
To a solution of triazole 23a–h or 24a–h (1 equiv.), in MeOH
(700 µL) was added dropwise an ethanolic solution of methyl-
amine (8.03 M, 400 equiv.). The solution was stirred at r.t. for
5 h and volatiles were removed in vacuo. To the crude residue
was added pure H2O (700 µL) and the resulting suspension
was cooled to 0 °C. At 0 °C, TFA (2 mL) was added dropwise.
The pale yellow resulting solution was stirred at 0 °C for
10 min and then at r.t. for 18 h and then concentrated to
dryness. The residue was then purified by semi-preparative
reverse phase HPLC to give the corresponding fully depro-
tected tetrols 25a–h or 26a–h. Yields were given after 2 steps
and purification by semi-preparative reverse phase HPLC.
Compound 25a. Compound 25a was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from C-triazole 23a (60 mg, 0.059 mmol).
After semi-preparative reverse phase HPLC (method A) and lyo-
philisation, 25a was obtained as an ammonium trifluoroace-
tate salt (white powder, 25.8 mg, 62% yield): m.p. 138–140 °C;
[α]D +17 (c 0.2, MeOH); IR (film) 2383m, 1715s, 1698s, 1226m;
1H NMR (CD3OD), δ 7.83 (s, 1H, H8′), 7.79 (d, 1H, JH6–H5 = 8.0
Hz, H6), 5.79 (d, 1H, JH1′–H2′ = 3.5 Hz, H1′), 5.71 (d, 1H, JH5–H6 =
8.0 Hz, H5), 5.16 (s, 1H, H1″), 4.37 (t, 2H, JH9′–H10′ = 7.0 Hz,
H9′), 4.16–4.08 (m, 4H, H2′, H4′, H5′, H4″), 4.02 (dd, 1H, JH3″–H2″ =
5.0 Hz, JH3″–H4″ = 7.0 Hz, H3″), 3.98 (d, 1H, JH2″–H3″ = 5.0 Hz,
H2″), 3.91 (dd, 1H, JH3′–H2′ = 6.0 Hz, JH3′–H4′ = 3.5 Hz, H3′),
3.29–3.27 (m, 1H, H5″a), 3.24 (dd, 1H, JH6′a–H6′b = 14.5 Hz,
JH6′a–H5′ = 8.0 Hz, H6′a), 3.17 (dd, 1H, JH6′b–H6′a = 14.5 Hz,
JH6′b–H5′ = 5.5 Hz, H6′b), 2.98 (dd, 1H, JH5″b–H5″a = 13.5 Hz,
JH5″b–H4″ = 9.5 Hz, H5″b), 1.88 (qt, 2H, JH10′–H9′ = JH10′–H11′ = 7.0
Hz, H10′), 1.34–1.26 (m, 14H, H11′, H12′, H13′, H14′, H15′, H16′,
H17′), 0.89 (t, 3H, JH18′–H17′ = 7.0 Hz, H18′);
13C NMR (CD3OD)
δ 166.2 (C4), 152.3 (C2), 144.8 (C7′), 142.3 (C6), 125.1 (C8′), 110.9
(C1″), 102.6 (C5), 91.6 (C1′), 85.5 (C3″), 80.1 (C4″), 79.7 (C4′), 76.5
(C2″), 75.8 (C2′), 73.9 (C5′), 71.5 (C3′), 51.5 (C9′), 44.3 (C5″), 33.2,
31.5, 30.8, 30.7, 30.5, 30.2, 29.8, 27.6, 23.9 (C6′, C10′, C11′, C12′,
C13′, C14′, C15′, C16′, C17′), 14.6 (C18′); HRMS, ESI
+ calcd for
C27H45N6O9
+ (M + H)+ 597.3243, found 597.3248; HPLC,
method D, tR = 12.19 min, 98%.
Compound 25b. Compound 25b was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from C-triazole 23b (25.6 mg,
0.023 mmol). After semi-preparative reverse phase HPLC
(method A) and lyophilisation, 25b was obtained as an
ammonium trifluoroacetate salt (white foam, 9.7 mg, 53%
yield): m.p. 129–132 °C; [α]D +14 (c 0.1, MeOH); IR (film)
2923br, 2852br, 2301w, 1699s, 1592m; 1H NMR (CD3OD),
δ 7.83 (s, 1H, H8′), 7.79 (d, 1H, JH6–H5 = 8.0 Hz, H6),7.24–7.22
(m, 2H, H20′), 7.16–7.11 (m, 3H, H21′, H22′), 5.78 (d, 1H, JH1′–H2′
= 3.0 Hz, H1′), 5.70 (d, 1H, JH5–H6 = 8.0 Hz, H5), 5.16 (s, 1H,
H1″), 4.37 (t, 2H, JH9′–H10′ = 7.0 Hz, H9′), 4.15–4.08 (m, 4H, H2′,
H4′, H5′, H4″), 4.01 (dd, 1H, JH3″–H2″ = 4.5 Hz, JH3″–H4″ = 7.0 Hz,
H3″), 3.97 (d, 1H, JH2″–H3″ = 4.5 Hz, H2″), 3.91 (dd, 1H, JH3′–H2′ =
6.0 Hz, JH3′–H4′ = 3.0 Hz, H3′), 3.30–3.25 (m, 1H, H5″a), 3.25 (dd,
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1H, JH6′a–H6′b = 14.5 Hz, JH6′a–H5′ = 8.0 Hz, H6′a), 3.16 (dd, 1H,
JH6′b–H6′a = 14.5 Hz, JH6′b–H5′ = 5.5 Hz, H6′b), 2.98 (dd, 1H,
JH5″b–H5″a = 13.0 Hz, JH5″b–H4″ = 9.5 Hz, H5″b), 2.59 (t, 2H,
JH18′–H17′ = 7.5 Hz, H18′), 1.87 (qt, 2H, JH10′–H9′ = JH10′–H11′ = 7.0
Hz, H10′), 1.63–1.57 (m, 2H, H17′), 1.35–1.25 (m, 12H, H11′,
H12′, H13′, H14′, H15′, H16′);
13C NMR (CD3OD) δ 166.2 (C4),
152.3 (C2), 144.8 (C7′), 144.1 (C19′), 142.3 (C6), 129.5 (C21′),
129.4 (C20′), 126.8 (C22′), 125.1 (C8′), 111.0 (C1″), 102.6 (C5), 91.7
(C1′), 85.5 (C3″), 80.2 (C4″), 79.7 (C4′), 76.5 (C2″), 75.8 (C2′), 73.9
(C5′), 71.5 (C3′), 51.5 (C9′), 44.3 (C5″), 37.1 (C18′), 32.9 (C17′), 31.4
(C10′), 30.7, 30.6, 30.6, 30.6, 30.4, 30.2, 29.8, 27.6 (C6′, C10′, C11′,
C12′, C13′, C14′, C15′, C16′); HRMS, ESI
+ calcd for C33H49N6O9
+
(M + H)+ 673.3556, found 673.3544; HPLC, method D, tR =
13.80 min, 98%.
Compound 25c. Compound 25c was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from C-triazole 23c (35.4 mg, 0.036 mmol).
After semi-preparative reverse phase HPLC (flow rate: 15 mL
min−1, H2O–TFA 0.1%/MeOH (100/0 to 40/60% v/v in 25 min))
and lyophilisation, 25c was obtained as an ammonium tri-
fluoroacetate salt (white foam, 9.2 mg, 38% yield):
m.p. 121–125 °C; [α]D +16 (c 0.2, MeOH); IR (film) 2911br,
2842br, 2319w, 1699s, 1552w; 1H NMR (CD3OD), δ 7.84 (s, 1H,
H8′), 7.79 (d, 1H, JH6–H5 = 8.0 Hz, H6), 5.79 (d, 1H, JH1′–H2′ = 3.5
Hz, H1′), 5.71 (d, 1H, JH5–H6 = 8.0 Hz, H5), 5.15 (s, 1H, H1″),
4.41–4.36 (m, 2H, H9′), 4.16–4.07 (m, 4H, H2′, H4′, H5′, H4″),
4.02–3.99 (m, 1H, H3″), 3.98–3.97 (m, 1H, H2″), 3.91 (dd, 1H,
JH3′–H2′ = 6.0 Hz, JH3′–H4′ = 3.0 Hz, H3′), 3.54 (t, 2H, JH13′–H12′ =
6.5 Hz, H13′), 3.29–3.27 (m, 1H, H5″a), 3.24 (dd, 1H, JH6′a–H6′b =
14.5 Hz, JH6′a–H5′ = 8.0 Hz, H6′a), 3.16 (dd, 1H, JH6′b–H6′a = 14.5
Hz, JH6′b–H5′ = 6.0 Hz, H6′b), 3.02–2.94 (m, 1H, H5″b), 1.96–1.88
(m, 2H, H10′), 1.82–1.76 (m, 1H, H11′a), 1.58–1.52 (m, 1H, H11′b),
1.42–1.33 (m, 2H, H12′);
13C NMR (CD3OD) δ 166.3 (C4), 152.3
(C2), 144.9 (C7′), 142.3 (C6), 125.2 (C8′), 110.9 (C1″), 102.6 (C5),
91.7 (C1′), 85.4 (C3″), 80.1 (C4″), 79.7 (C4′), 76.5 (C2″), 75.8 (C2′),
73.9 (C5′), 71.5 (C3′), 62.7 (C13′), 51.5 (C9′), 44.3 (C5″), 33.0 (C12′),
31.2 (C11′), 29.8 (C6′), 24.0 (C10′); HRMS, ESI
+ calcd for
C22H35N6O10
+ (M + H)+ 543.2409, found 543.2396; HPLC,
method D, tR = 13.80 min, 98%.
Compound 25d. Compound 25d was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from C-triazole 23d (40.3 mg,
0.039 mmol). After semi-preparative reverse phase HPLC
(method B) and lyophilisation, 25d was obtained as an
ammonium trifluoroacetate salt (white foam, 18.3 mg, 65%
yield): m.p. 127–132 °C; [α]D +14 (c 0.1, MeOH); IR (film)
2919br, 2301br, 1699s, 1697s, 1540m; 1H NMR (CD3OD), δ 7.83
(s, 1H, H8′), 7.78 (d, 1H, JH6–H5 = 8.5 Hz, H6), 5.79 (d, 1H,
JH1′–H2′ = 3.0 Hz, H1′), 5.70 (d, 1H, JH5–H6 = 8.5 Hz, H5), 5.16 (s,
1H, H1″), 4.37 (t, 2H, JH9′–H10′ = 7.0 Hz, H9′), 4.16–4.08 (m, 4H,
H2′, H4′, H5′, H4″), 4.02 (dd, 1H, JH3″–H2″ = 4.5 Hz, JH3″–H4″ = 7.0
Hz, H3″), 3.97 (d, 1H, JH2″–H3″ = 4.5 Hz, H2″), 3.91 (dd, 1H,
JH3′–H2′ = 6.0 Hz, JH3′–H4′ = 3.0 Hz, H3′), 3.54 (t, 2H, JH18′–H17′ =
7.0 Hz, H18′), 3.29–3.27 (m, 1H, H5″a), 3.24 (dd, 1H, JH6′a–H6′b =
14.5 Hz, JH6′a–H5′ = 7.5 Hz, H6′a), 3.16 (dd, 1H, JH6′b–H6′a = 14.5
Hz, JH6′b–H5′ = 5.0 Hz, H6′b), 2.98 (dd, 1H, JH5″b–H5″a = 13.0 Hz,
JH5″b–H4″ = 10.0 Hz, H5″b), 1.88 (qt, 2H, JH10′–H9′ = JH10′–H11′ = 7.0
Hz, H10′), 1.52 (qt, 2H, JH17′–H18′ = JH17′–H16′ = 7.0 Hz, H17′),
1.38–1.26 (m, 12H, H11′, H12′, H13′, H14′, H15′, H16′);
13C NMR
(CD3OD) δ 166.2 (C4), 152.3 (C2), 144.8 (C7′), 142.3 (C6), 125.2
(C8′), 111.0 (C1″), 102.6 (C5), 91.7 (C1′), 85.5 (C3″), 80.1 (C4″),
79.7 (C4′), 76.5 (C2″), 75.8 (C2′), 73.9 (C5′), 71.5 (C3′), 63.1 (C18′),
51.5 (C9′), 44.3 (C5″), 33.8, 31.4, 30.7, 30.6, 30.6, 30.2, 29.8,
27.6, 27.1 (C6′, C10′, C11′, C12′, C13′, C14′, C15′, C16′, C17′); HRMS,
ESI+ calcd for C27H45N6O10
+ (M + H)+ 613.3192, found
613.3178; HPLC, method D, tR = 9.82 min, 98%.
Compound 25e. Compound 25e was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from C-triazole 23e (21.2 mg, 0.019 mmol).
After semi-preparative reverse phase HPLC (flow rate: 15 mL
min−1, H2O–TFA 0.1%/MeOH 100/0 to 40/60 in 60 min) and
lyophilisation, 25e was obtained as an ammonium ditrifluoro-
acetate salt (white foam, 7.9 mg, 52% yield): [α]D +19 (c 0.1,
H2O); IR (film) 3384br, 2951br, 1685s, 1258m;
1H NMR (D2O +
50 µL CD3OD, 500 MHz), δ 7.96 (s, 1H, H8′), 7.78 (d, 1H, JH6–H5 =
8.0 Hz, H6), 5.88 (d, 1H, JH5–H6 = 8.0 Hz, H5), 5.79 (d, 1H,
JH1′–H2′ = 3.5 Hz, H1′), 5.21 (s, 1H, H1″), 4.61 (t, 2H, JH9′–H10′ =
5.0 Hz, H9′), 4.31 (t, 1H, JH2′–H1′ = JH2′–H3′ = 3.5 Hz, H2′), 4.25 (t,
1H, JH3′–H2′ = JH3′–H4′ = 3.5 Hz, H3′), 4.21 (ddd, 1H, JH5′–H4′ = 5.5
Hz, JH5′–H6′a = 7.0 Hz, JH5′–H6′b = 6.0 Hz, H5′), 4.14–4.72 (m, 3H,
H2″, H3″, H4″), 3.98 (dd, 1H, JH4′–H5′ = 5.5 Hz, JH4′–H3′ = 3.5 Hz,
H4′), 3.95 (t, 2H, JH10′–H9′ = 5.0 Hz, H10′), 3.72–3.61 (m, 16H,
H11′, H12′, H13′, H14′, H15′, H16′, H17′, H18′), 3.36–3.34 (m, 1H,
H5″a), 3.22 (dd, 1H, JH6′a–H6′b = 14.5 Hz, JH6′a–H5′ = 7.0 Hz, H6′a),
3.21 (dd, 1H, JH6′b–H6′a = 14.5 Hz, JH6′b–H5′ = 6.0 Hz, H6′b), 2.93
(dd, 1H, JH5″b–H5″a = 13.0 Hz, JH5″b–H4″ = 8.5 Hz, H5″b);
13C NMR
(D2O + 50 µL CD3OD) δ 167.2 (C4), 164.0 (CO-TFA), 152.5 (C2),
140.1 (C7′), 142.9 (C6), 126.4 (C8′), 109.8 (C1″), 102.9 (C5), 91.1
(C1′), 84.9 (C4′), 79.3 (C2″), 78.9 (C5′), 75.6 (C3″), 74.8 (C2′), 73.2
(C4″), 72.8, 70.8, 70.8, 70.7, 70.7, 70.7, 70.6, 70.6 (CPEG, C3′),
69.9 (C10′), 61.5 (C9′), 43.9 (C5″), 29.1 (C6′); HRMS, ESI
+ calcd
for C27H45N6O14
+ (M + H)+ 677.2988, found 677.2999; HPLC,
method D, tR = 3.15 min, 96%.
Compound 25f. Compound 25f was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from C-triazole 23f (37.5 mg, 0.032 mmol).
After semi-preparative reverse phase HPLC (method: 15 mL
min−1, H2O–TFA 0.1%/MeOH 90/10 to 40/60 in 60 min) and
lyophilisation, 25f was obtained as an ammonium ditrifluoro-
acetate salt (white foam, 11.1 mg, 41% yield): [α]D +8 (c 0.1,
H2O); IR (film) 3265br, 2942br, 1683s, 1487m, 1273m, 1138s;
1H NMR (D2O/CD3OD = 1/1), δ 7.84 (s, 1H, H8′), 7.76 (d, 1H,
JH6–H5 = 8.0 Hz, H6), 5.82 (d, 1H, JH5–H6 = 8.0 Hz, H5), 5.76 (d,
1H, JH1′–H2′ = 2.0 Hz, H1′), 5.20 (s, 1H, H1″), 4.37 (t, 2H, JH9′–H10′ =
7.5 Hz, H9′), 4.21–4.13 (m, 4H, H2′, H4′, H5′, H4″), 4.09–4.02 (m,
2H, H2″, H3″), 3.97–3.93 (m, 1H, H3′), 3.37–3.34 (m, 1H, H5″a),
3.25–3.17 (m, 2H, H6′a, H6′b), 3.02–2.98 (m, 1H, H5″b), 2.95 (t, 2H,
JH18′–H17′ = 7.0 Hz, H18′), 1.87–1.80 (m, 2H, H10′), 1.65–1.62 (m,
2H, H17′), 1.39–1.12 (m, 12H, H11′, H12′, H13′, H14′, H15′, H16′);
13C
NMR (D2O/CD3OD = 1/1) δ 166.7 (C4), 163.5 (CO-TFA), 152.3 (C2),
144.5 (C7′), 142.5 (C6), 125.5 (C8′), 111.4 (C1″), 102.9 (C5), 91.1
(C1′), 85.4 (C3″), 79.6 (C4″), 79.2 (C4′), 76.0 (C2″), 75.2 (C2′), 73.5
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(C5′), 71.1 (C3′), 51.4 (C9′), 43.9 (C5″), 40.8 (C17′), 30.8, 30.0, 29.9,
29.7, 29.6, 29.5, 28.2, 27.1, 27.0 (C6′, C10′, C11′, C12′, C13′, C14′, C15′,
C16′, C17′); HRMS, ESI
+ calcd for C27H46N7O9
+ (M + H)+ 612.3352,
found 612.3357; HPLC, method D, tR = 4.56 min, 98%.
Compound 25g. Compound 25g was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from C-triazole 23g (56 mg, 0.047 mmol).
After semi-preparative reverse phase HPLC (method A) and lyo-
philisation, 25g was obtained as an ammonium trifluoroace-
tate salt (white powder, 26 mg, 64% yield): m.p. 137–140 °C;
[α]D +21 (c 0.2, MeOH); IR (film) 2922br, 1714s, 1276m,
1260m, 830w; 1H NMR (CD3OD), 7.88 (s, 1H, H8′), 7.79–7.77
(m, 2H, H17′), 7.71–7.62 (m, 3H, H6, H21′), 7.64 (t, 1H, JH23′–H22′ =
7.5 Hz, H23′), 7.53 (t, 2H, JH22′–H23′ = JH22′–H21′ = 7.5 Hz, H22′),
7.46 (d, 2H, JH11′–H12′ = 8.0 Hz, H11′), 7.34 (d, 2H, JH12′–H11′ = 8.0
Hz, H12′), 7.13–7.10 (m, 2H, H16′), 5.71–5.69 (m, 2H, H5, H1′),
5.60 (d, 1H, JH9′a–H9′b = 15.0 Hz, H9′a), 5.57 (d, 1H, JH9′b–H9′a =
15.0 Hz, H9′b), 5.20 (s, 2H, H14′), 5.16 (s, 1H, H1″), 4.15–4.09
(m, 4H, H2′, H3′, H5′, H4″), 4.00–3.93 (m, 3H, H2″, H3″, H4′),
3.27–3.23 (m, 2H, H5″a, H6′a), 3.16 (dd, 1H, JH5″b–H5″a = 14.5 Hz,
JH5″b–H4″ = 5.0 Hz, H5″b), 2.92 (dd, 1H, JH6′b–H6′a = 13.5 Hz,
JH6′b–H5′ = 9.5 Hz, H6′b);
13C NMR (CD3OD) δ 198.4 (C19′), 166.4
(C4), 164.2 (C15′), 152.3 (C2), 145.3 (C7′), 142.3 (C6), 139.3 (C20′),
138.6 (C13′), 136.7 (C10′), 133.9 (C17′), 133.7 (C23′), 131.4 (C18′),
130.8 (C21′), 129.7 (C22′), 129.5 (C11′), 129.4 (C12′), 125.6 (C8′),
115.6 (C16′), 110.8 (C1″), 102.6 (C5), 91.6 (C1′), 85.7 (C3″), 80.0
(C4″), 79.4 (C4′), 79.4 (C2″), 75.6 (C2′), 73.7 (C5′), 71.4 (C3′), 70.9
(C14′), 54.8 (C9′), 44.1 (C5″), 29.9 (C6′); HRMS ESI
+ calcd for
C38H41N6O11
+ (M + H)+ 757.2828, found 758.2808; HPLC,
method C, tR = 12.09 min, 99%.
Compound 25h. Compound 25h was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from C-triazole 23h (47 mg, 0.039 mmol).
After semi-preparative reverse phase HPLC (method A) and lyo-
philisation, 25h was obtained as an ammonium trifluoroace-
tate salt (white powder, 24 mg, 69% yield): m.p. 132–136 °C;
[α]D +8 (c 0.2, MeOH); IR (film) 2741w, 2383m, 1698s, 1598m;
1H NMR (CD3OD), 7.83 (s, 1H, H8′), 7.79–7.76 (m, 3H, H21′,
H6), 7.72–7.69 (m, 2H, H25′), 7.63–7.59 (m, 1H, H27′), 7.53–7.49
(m, 2H, H26′), 7.04–7.01 (m, 2H, H20′), 5.79 (d, 1H, JH1′–H2′ = 3.0
Hz, H1′), 5.70 (d, 1H, JH5–H6 = 8.0 Hz, H5), 5.16 (s, 1H, H1″),
4.36 (t, 2H, JH9′–H10′ = 7.0 Hz, H9′), 4.15–4.06 (m, 6H, H2′, H4′,
H5′, H18′, H4″), 4.02 (dd, 1H, JH3″–H2″ = 5.5 Hz, JH3″–H4″ = 7.0 Hz,
H3″), 3.97 (d, 1H, JH2″–H3″ = 5.5 Hz, H2″), 3.91 (dd, 1H, JH3′–H2′ =
6.0 Hz, JH3′–H4′ = 3.5 Hz, H3′), 3.29–3.27 (m, 1H, H5″a), 3.24 (dd,
1H, JH6′a–H6′b = 14.5 Hz, JH6′a–H5′ = 8.0 Hz, H6′a), 3.16 (dd, 1H,
JH6′b–H6′a = 14.5 Hz, JH6′b–H5′ = 5.5 Hz, H6′b), 2.99 (dd, 1H,
JH5″b–H5″a = 13.5 Hz, JH5″b–H4″ = 9.5 Hz, H5″b), 1.87 (qt, 2H,
JH10′–H9′ = JH10′–H11′ = 7.0 Hz, H10′), 1.80 (qt, 2H, JH17′–H18′ =
JH17′–H16′ = 7.0 Hz, H17′), 1.52–1.46 (m, 2H, H16′), 1.40–1.25 (m,
10H, H11′, H12′, H13′, H14′, H15′);
13C NMR (CD3OD) δ 197.8
(C23′), 166.2 (C4), 164.8 (C19′), 152.3 (C2), 144.8 (C7′), 142.3 (C6),
139.7 (C24′), 133.8 (C21′), 133.4 (C27′), 131.0 (C22′), 130.8 (C25′),
129.6 (C26′), 125.2 (C8′), 115.4 (C20′), 111.0 (C1″), 102.6 (C5), 91.6
(C1′), 85.5 (C4′), 80.5 (C2″), 79.7 (C4″), 76.5 (C2′), 75.8 (C3″), 73.9
(C3′), 71.5 (C5′), 69.6 (C18′), 50.4 (C9′), 44.3 (C5″), 31.4, 30.6, 30.6,
30.5, 30.3, 30.2, 29.9, 27.6, 27.2 (C6′, C10′, C11′, C12′, C13′, C14′,
C15′, C16′, C17′); HRMS ESI
+ calcd for C40H53N6O11
+ (M + H)+
793.3767, found 793.3768; HPLC, method C, tR = 15.19 min,
98%.
Compound 26a. Compound 26a was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from N-triazole 24a (35.2 mg, 0.034 mmol).
After semi-preparative reverse phase HPLC (method A) and lyo-
philisation, 26a was obtained as an ammonium trifluoroace-
tate salt (white powder, 13.3 mg, 56% yield): m.p. 142–146 °C;
[α]D +21 (c 0.4, MeOH); IR (film) 2926m, 1677s, 1465w, 1202m,
1134m, 801w; 1H NMR (CD3OD), δ 7.79 (s, 1H, H7′), 7.65 (d,
1H, JH6–H5 = 8.0 Hz, H6), 5.74 (d, 1H, JH1′–H2′ = 2.5 Hz, H1′), 5.69
(d, 1H, JH5–H6 = 8.0 Hz, H5), 5.14 (s, 1H, H1″), 4.80 (dd, 1H,
JH6′a–H6′b = 14.5 Hz, JH6′a–H5′ = 6.0 Hz, H6′a), 4.70 (dd, 1H,
JH6′b–H6′a = 14.5 Hz, JH6′b–H5′ = 6.0 Hz, H6′b), 4.32 (dt, 1H,
JH5′–H6′a = 6.0 Hz, JH5′–H6′b = 6.0 Hz, JH5′–H4′ = 3.5 Hz, H5′),
4.18–4.15 (m, 2H, H2′, H3′), 4.06 (ddd, 1H, JH4″–H5″a = 2.5 Hz,
JH4″–H5″b = 9.5 Hz, JH4″–H3″ = 7.0 Hz, H4″), 3.96–3.91 (m, 3H, H4′,
H2″, H3″), 3.23 (dd, 1H, JH5″a–H5″b = 13.0 Hz, JH5″a–H4″ = 2.5 Hz,
H5″a), 2.98 (dd, 1H, JH5″b–H5″a = 13.0 Hz, JH5″b–H4″ = 9.5 Hz,
H5″b), 2.69 (t, 2H, JH9′–H10′ = 7.5 Hz, H9′), 1.68–1.62 (m, 2H,
H10′), 1.37–1.26 (m, 14H, H11′, H12′, H13′, H14′, H15′, H16′, H17′),
0.89 (t, 3H, JH18′–H7′ = 6.5 Hz, H18′);
13C NMR (CD3OD) δ 166.2
(C4), 162.5 (CO-TFA), 152.2 (C2), 149.5 (C8′), 142.4 (C6), 125.1
(C7′), 110.9 (C1″), 102.7 (C5), 92.5 (C1′), 84.7 (C4′), 80.2 (C4″),
78.4 (C5′), 76.4 (C2″), 75.4 (C2′), 73.9 (C3″), 71.4 (C3′), 52.6 (C6′),
44.3 (C5″), 33.2, 30.9, 30.8, 30.8, 30.6, 30.4, 26.4, 23.9 (C9′, C10′,
C11′, C12′, C13′, C14′, C15′, C16′, C17′), 14.6 (C18′); HRMS, ESI
+
calcd for C27H45N6O9
+ (M + H)+ 597.3243, found 597.3254;
HPLC, method C, tR = 12.09 min, 99%.
Compound 26b. Compound 26b was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from N-triazole 24b (30.0 mg,
0.027 mmol). After semi-preparative reverse phase HPLC
(method A) and lyophilisation, 26b was obtained as an
ammonium trifluoroacetate salt (white foam, 11.2 mg, 52%
yield): m.p. 132–135 °C; [α]D +14 (c 0.1, MeOH); IR (film)
2926br, 2855br, 2303w, 1697s, 1594m; 1H NMR (CD3OD) δ 7.79
(s, 1H, H7′), 7.65 (d, 1H, JH6–H5 = 8.0 Hz, H6), 7.24–7.22 (m, 2H,
H20′), 7.16–7.11 (m, 3H, H21′, H22′), 5.74 (d, 1H, JH1′–H2′ = 2.0
Hz, H1′), 5.69 (d, 1H, JH5–H6 = 8.0 Hz, H5), 5.14 (s, 1H, H1″),
4.80 (dd, 1H, JH6′a–H6′b = 14.0 Hz, JH6′a–H5′ = 5.5 Hz, H6′a), 4.70
(dd, 1H, JH6′b–H6′a = 14.0 Hz, JH6′b–H5′ = 5.5 Hz, H6′b), 4.32 (dt,
1H, JH5′–H6′a = 5.5 Hz, JH5′–H6′b = 5.5 Hz, JH5′–H4′ = 3.5 Hz, H5′),
4.18–4.15 (m, 2H, H2′, H3′), 4.06 (ddd, 1H, JH4″–H5″a = 3.0 Hz,
JH4″–H5″b = 9.5 Hz, JH4″–H3″ = 7.0 Hz, H4″), 3.96–3.92 (m, 3H, H4′,
H2″, H3″), 3.23 (dd, 1H, JH5″a–H5″b = 13.0 Hz, JH5″a–H4″ = 3.0 Hz,
H5″a), 2.99 (dd, 1H, JH5″b–H5″a = 13.0 Hz, JH5″b–H4″ = 9.5 Hz,
H5″b), 2.69 (t, 2H, JH9′–H10′ = 7.5 Hz, H9′), 2.59 (t, 2H, JH18′–H17′ =
7.5 Hz, H18′), 1.67–1.57 (m, 4H, H10′, H17′), 1.37–1.23 (m, 12H,
H11′, H12′, H13′, H14′, H15′, H16′);
13C NMR (CD3OD) δ 166.2 (C4),
152.2 (C2), 149.5 (C8′), 144.1 (C19′), 142.4 (C6), 129.5 (C21′),
129.4 (C20′), 126.8 (C22′), 125.1 (C7′), 110.9 (C1″), 102.7 (C5), 92.4
(C1′), 84.8 (C4′), 80.2 (C4″), 78.4 (C5′), 76.4 (C2″), 75.4 (C2′), 73.9
(C3″), 71.4 (C3′), 52.6 (C6′), 44.3 (C5″), 37.1 (C18′), 32.9 (C17′),
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30.8, 30.8, 30.7, 30.7, 30.6, 30.5, 30.3, 26.4 (C9′, C10′, C11′, C12′,
C13′, C14′, C15′, C16′); HRMS, ESI
+ calcd for C33H49N6O9
+ (M +
H)+ 673.3556, found 673.3552; HPLC, method D, tR =
13.29 min, 99%.
Compound 26c. Compound 26c was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from N-triazole 24c (35.1 mg, 0.036 mmol).
After semi-preparative reverse phase HPLC (method B) and lyo-
philisation, 26c was obtained as an ammonium trifluoroace-
tate salt (white foam, 8.0 mg, 34% yield): m.p. 130–134 °C; [α]D
+13 (c 0.2, MeOH); IR (film) 2914br, 2843br, 2317w, 1692s,
1552w; 1H NMR (CD3OD), δ 7.81 (s, 1H, H7′), 7.66 (d, 1H,
JH6–H5 = 8.0 Hz, H6), 5.76 (d, 1H, JH1′–H2′ = 2.0 Hz, H1′), 5.69 (d,
1H, JH5–H6 = 8.0 Hz, H5), 5.14 (s, 1H, H1″), 4.78 (dd, 1H,
JH6′a–H6′b = 14.0 Hz, JH6′a–H5′ = 6.0 Hz, H6′a), 4.70 (dd, 1H,
JH6′b–H6′a = 14.0 Hz, JH6′b–H5′ = 8.5 Hz, H6′b), 4.34–4.31 (m, 1H,
H5′), 4.18–4.16 (m, 2H, H2′, H3′), 4.05 (ddd, 1H, JH4″–H5″a = 3.0
Hz, JH4″–H5″b = 9.5 Hz, JH4″–H3″ = 7.0 Hz, H4″), 3.96–3.91 (m, 3H,
H4′, H2″, H3″), 3.55 (t, 2H, JH13′–H12′ = 6.5 Hz, H13′), 3.23 (dd,
1H, JH5″a–H5″b = 13.5 Hz, JH5″a–H4″ = 3.0 Hz, H5″a), 2.97 (dd, 1H,
JH5″b–H5″a = 13.5 Hz, JH5″b–H4″ = 9.5 Hz, H5″b), 2.71 (t, 2H,
JH9′–H10′ = 7.5 Hz, H9′), 1.68 (qt, 2H, JH10′–H9′ = JH10′–H11′ = 7.5 Hz,
H10′), 1.56 (qt, 2H, JH12′–H13′ = JH12′–H11′ = 6.5 Hz, H12′), 1.45–1.39
(m, 2H, H11′);
13C NMR (CD3OD) δ 166.2 (C4), 152.2 (C2), 149.4
(C8′), 142.4 (C6), 125.2 (C7′), 110.8 (C1″), 102.8 (C5), 92.4 (C1′), 84.7
(C4′), 80.2 (C4″), 78.4 (C5′), 76.4 (C2″), 75.4 (C2′), 73.9 (C3″), 71.4
(C3′), 63.2 (C13′), 52.6 (C6′), 44.3 (C5″), 33.4 (C12′), 30.5 (C10′), 26.6
(C11′), 26.4 (C9′); HRMS, ESI
+ calcd for C22H35N6O10
+ (M + H)+
543.2409, found 543.2399; HPLC, method D, tR = 2.66 min, 98%.
Compound 26d. Compound 26d was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from N-triazole 24d (34.1 mg,
0.033 mmol). After semi-preparative reverse phase HPLC
(method A) and lyophilisation, 26d was obtained as an
ammonium trifluoroacetate salt (white foam, 10.0 mg, 42%
yield): m.p. 126–129 °C; [α]D +15 (c 0.1, MeOH); IR (film)
2914br, 2851br, 2300m, 1731s, 1259m; 1H NMR (CD3OD),
δ 7.79 (s, 1H, H7′), 7.65 (d, 1H, JH6–H5 = 8.0 Hz, H6), 5.75 (d, 1H,
JH1′–H2′ = 2.0 Hz, H1′), 5.69 (d, 1H, JH5–H6 = 8.0 Hz, H5), 5.14 (s,
1H, H1″), 4.79 (dd, 1H, JH6′a–H6′b = 14.0 Hz, JH6′a–H5′ = 5.5 Hz,
H6′a), 4.70 (dd, 1H, JH6′b–H6′a = 14.0 Hz, JH6′b–H5′ = 5.5 Hz, H6′b),
4.32 (dt, 1H, JH5′–H6′a = 5.5 Hz, JH5′–H6′b = 5.5 Hz, JH5′–H4′ =
3.5 Hz, H5′), 4.18–4.15 (m, 2H, H2′, H3′), 4.06 (ddd, 1H, JH4″–H5″a =
3.0 Hz, JH4″–H5″b = 10.0 Hz, JH4″–H3″ = 6.5 Hz, H4″), 3.96–3.92 (m,
3H, H4′, H2″, H3″), 3.53 (t, 2H, JH18′b–H17′ = 6.5 Hz, H18′), 3.24 (dd,
1H, JH5″a–H5″b = 13.0 Hz, JH5″a–H4″ = 3.0 Hz, H5″a), 3.00 (dd, 1H,
JH5″b–H5″a = 13.0 Hz, JH5″b–H4″ = 10.0 Hz, H5″b), 2.69 (t, 2H,
JH9′–H10′ = 7.5 Hz, H9′), 1.68–1.62 (m, 2H, H10′), 1.52 (qt, 2H,
JH17′–H18′ = JH17′–H16′ = 6.5 Hz, H17′), 1.38–1.26 (m, 12H, H11′, H12′,
H13′, H14′, H15′, H16″);
13C NMR (CD3OD) δ 166.2 (C4), 152.2 (C2),
149.5 (C8′), 142.4 (C6), 125.1 (C7′), 110.9 (C1″), 102.7 (C5), 92.4 (C1′),
84.7 (C4′), 80.2 (C4″), 78.4 (C5′), 76.4 (C2″), 75.4 (C2′), 73.9 (C3″),
71.4 (C3′), 63.2 (C18′), 52.6 (C6′), 44.3 (C5″), 33.8 (C17′), 30.9, 30.7,
30.7, 30.6, 30.3, 27.1, 26.4 (C9′, C10′, C11′, C12′, C13′, C14′, C15′, C16′);
HRMS, ESI+ calcd for C27H45N6O10
+ (M + H)+ 613.3192, found
613.3181; HPLC, method D, tR = 11.10 min, 97%.
Compound 26e. Compound 26e was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from N-triazole 24e (19.7 mg, 0.018 mmol).
After semi-preparative reverse phase HPLC (method: 15 mL
min−1, H2O–TFA 0.1%/MeOH 100/0 to 60/40 in 50 min) and
lyophilisation, 26e was obtained as an ammonium trifluoroa-
cetate salt (white foam, 9.7 mg, 69% yield): [α]D +12 (c 0.1,
MeOH); IR (film) 3058br, 2931br, 1687s, 1462m; 1H NMR
(D2O + 50 µL CD3OD), δ 8.12 (s, 1H, H8′), 7.66 (d, 1H, JH6–H5 =
8.5 Hz, H6), 5.85 (d, 1H, JH5–H6 = 8.5 Hz, H5), 5.75 (d, 1H, JH1′–H2′ =
3.0 Hz, H1′), 5.16 (s, 1H, H1″), 4.84 (dd, 1H, JH6′a–H6′b = 15.0 Hz,
JH6′a–H5′ = 5.0 Hz, H6′a), 4.70–4.69–4.64 (m, 3H, H6′b, H9′),
4.45–4.42 (m, 1H, H5′), 4.30 (dd, 1H, JH2′–H1′ = 3.0 Hz, JH2′–H3′ =
5.5 Hz), 4.27 (dd, 1H, JH3′–H2′ = 5.5 Hz, JH3′–H4′ = 4.5 Hz),
4.11–4.02 (m, 4H, H4′, H2″, H3″, H4″), 3.72–3.61 (m, 14H, H10′,
H11′, H12′, H13′, H14′, H15′, H16′), 3.30–3.29 (m, 3H, H5″a, H17′),
2.91 (dd, 1H, JH5″b–H5″a = 13.0 Hz, JH5″b–H4″ = 9.0 Hz, H5″b);
13C
NMR (CD3OD) δ 167.2 (C4), 152.3 (C2), 145.0 (C8′), 142.7 (C6),
127.5 (C7′), 110.1 (C1″), 102.9 (C5), 91.5 (C1′), 84.4 (C4′), 79.4
(C4″), 77.9 (C5′), 75.7 (C2″), 74.6 (C2′), 73.0 (C3″), 72.9 (CH2PEG),
70.9 (C3′), 70.8, 70.7, 70.7, 70.6, 70.6, 70.2 (CH2PEG), 64.2 (C9′),
61.5 (CH2PEG), 52.7 (C6′), 43.8 (C5″); HRMS, ESI
+ calcd for
C26H43N6O14
+ (M + H)+ 663.2832, found 663.2842; HPLC,
method D, tR = 3.21 min, 96%.
Compound 26f. Compound 26f was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from N-triazole 24f (37.5 mg, 0.032 mmol).
After semi-preparative reverse phase HPLC (method: 15 mL
min−1, H2O–TFA 0.1%/MeOH 100/0 to 60/40 in 50 min) and
lyophilisation, 26f was obtained as an ammonium ditrifluoro-
acetate salt (white foam, 12.2 mg, 45% yield): [α]D +9 (c 0.1,
H2O); IR (film) 3384br, 2951br, 1685s, 1258m;
1H NMR
(D2O : CD3OD = 1 : 1), δ 7.79 (s, 1H, H7′), 7.55 (d, 1H, JH6–H5 =
7.5 Hz, H6), 5.78 (d, 1H, JH5–H6 = 7.5 Hz, H5), 5.72 (sl, 1H, H1′),
5.19 (s, 1H, H1″), 4.87–4.83 (m, 2H, H6′a, H6′b), 4.37–4.32 (m,
1H, H5′), 4.24–4.11 (m, 3H, H2′, H3′, H4″), 4.08–3.98 (m, 3H,
H4′, H2″, H3″), 3.37–3.34 (m, 1H, H5″a), 3.14–3.11 (m, 1H, H5″b),
2.95 (t, 2H, JH9′–H10′ = 6.5 Hz, H9′), 2.66 (t, 2H, JH18′–H17′ = 6.5
Hz, H18′), 1.68–1.62 (m, 2H, H10′), 1.59–1.54 (m, 2H, H17′),
1.41–1.24 (m, 12H, H11′, H12′, H13′, H14′, H15′, H16″);
13C NMR
(D2O : CD3OD = 1 : 1) δ 166.7 (C4), 163.5 (CO-TFA), 152.2 (C2),
149.2 (C8′), 142.3 (C6), 125.7 (C7′), 110.6 (C1″), 102.8 (C5), 91.4
(C1′), 84.9 (C4′), 79.8 (C4″), 77.9 (C5′), 76.0 (C2″), 74.9 (C2′), 73.3
(C3″), 71.3 (C3′), 52.9 (C6′), 43.7 (C5″), 40.7 (C18′), 30.1, 30.1,
30.0, 29.9, 29.7, 29.5, 28.2, 27.1, 25.7 (C9′, C10′, C11′, C12′, C13′,
C14′, C15′, C16′, C17′); HRMS, ESI
+ calcd for C27H45N7O9
+ (M +
H)+ 612.3352, found 612.3361; HPLC, method D, tR = 4.47 min,
96%.
Compound 26g. Compound 26g was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from N-triazole 24g (21.0 mg,
0.018 mmol). After semi-preparative reverse phase HPLC
(method A) and lyophilisation, 26g was obtained as an
ammonium trifluoroacetate salt (white foam, 11.3 mg, 72%
yield): m.p. 156–158 °C; [α]D +13 (c 0.1, MeOH); IR (film)
2925br, 2301br, 1731s, 1691s, 1542m; 1H NMR (CD3OD) δ 7.67
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(s, 1H, H7′), 7.54–7.46 (m, 4H, H17′, H21′), 7.39–7.33 (m, 2H, H6,
H23′), 7.20–7.06 (m, 6H, H11′, H12′, H22′), 6.87–6.80 (m, 2H,
H16′), 5.57 (d, 1H, JH5–H6 = 7.0 Hz, H5), 5.50 (br s, 1H, H1′), 5.18
(s, 1H, H1″), 4.99–4.92 (m, 2H, H9′), 4.89–4.85 (m, 1H, H6′a),
4.69–4.62 (m, 3H, H6′b, H14′), 4.33–4.30 (m, 1H, H5′), 4.16–4.11
(m, 3H, H2′, H3′, H4″), 4.04–4.92 (m, 1H, H3″), 3.99–3.97 (m,
1H, H2″), 3.91–3.87 (m, 1H, H4′), 3.35–3.32 (m, 1H, H5″), 3.12
(dd, 1H, JH5″b–H5″a = 13.0 Hz, JH5″b–H4″ = 10.0 Hz, H5″b);
13C
NMR (CD3OD) δ 190.9 (C19′), 166.7 (C4), 164.0 (C15′), 163.5
(CO-TFA), 151.9 (C2), 147.6 (C8′), 141.6 (C6), 140.1 (C20′), 138.3
(C13′), 135.6 (C10′), 135.2 (C17′), 133.6 (C23′), 130.5 (C18′), 130.4
(C21′), 129.7 (C22′), 129.3 (C11′), 128.8 (C12′), 120.9 (C7′), 116.3
(C16′), 110.3 (C1″), 102.5 (C5), 90.9 (C1′), 84.9 (C3″), 79.6 (C4″),
77.2 (C4′), 75.7 (C2″), 74.9 (C2′), 73.0 (C5′), 71.0 (C3′), 70.6 (C14′),
52.3 (C6′), 43.6 (C5″), 31.3 (C9′); HRMS, ESI
+ calcd for
C38H41N6O11
+ (M + H)+ 757.2828, found 757.2839; HPLC,
method C, tR = 11.99 min, 99%.
Compound 26h. Compound 26h was synthesized according
to the general procedure for phthalimide, isopentylidene and
TBS group cleavage from N-triazole 24h (30.0 mg,
0.025 mmol). After semi-preparative reverse phase HPLC
(method A) and lyophilisation, 26h was obtained as an
ammonium trifluoroacetate salt (white foam, 14.3 mg, 64%
yield): m.p. 135–138 °C; [α]D +10 (c 0.2, MeOH); IR (film)
2921br, 2304br, 1731s, 1699s, 1540m; 1H NMR (CD3OD)
δ 7.79–7.77 (m, 3H, H7′, H21′), 7.73–7.70 (m, 2H, H25′), 7.65 (d,
1H, JH6–H5 = 8.0 Hz, H6), 7.63–7.60 (m, 1H, H27′), 7.53–7.50 (m,
2H, H26′), 7.05–7.02 (m, 2H, H20′), 5.75 (d, 1H, JH1′–H2′ = 2.0 Hz,
H1′), 5.68 (dd, 1H, JH5–H6 = 8.0 Hz, H5), 5.15 (s, 1H, H1″), 4.79
(dd, 1H, JH6′a–H6′b = 14.5 Hz, JH6′a–H5′ = 5.5 Hz, H6′a), 4.70 (dd,
1H, JH6′b–H6′a = 14.5 Hz, JH6′b–H5′ = 5.5 Hz, H6′b), 4.32 (dt, 1H,
JH5′–H6′a = 5.5 Hz, JH5′–H6′b = 5.5 Hz, JH5′–H4′ = 3.5 Hz, H5′),
4.18–4.15 (m, 2H, H2′, H3′), 4.98–4.05 (m, 3H, H18′, H4″),
3.96–3.90 (m, 3H, H4′, H2″, H3″), 3.24 (dd, 1H, JH5″a–H5″b = 13.0
Hz, JH5″a–H4″ = 2.5 Hz, H5″a), 3.01 (dd, 1H, JH5″b–H5″a = 13.0 Hz,
JH5″b–H4″ = 10.0 Hz, H5″b), 2.69 (t, 2H, JH9′–H10′ = 7.5 Hz, H9′),
1.81 (qt, 2H, JH17′–H18′ = JH17′–H16′ = 7.5 Hz, H17′), 1.68–1.62 (m,
2H, H10′), 1.49 (qt, 2H, JH16′–H17′ = JH16′–H15′ = 7.5 Hz, H16′),
1.37–1.23 (m, 10H, H11′, H12′, H13′, H14′, H15′);
13C NMR
(CD3OD) δ 197.9 (C23′), 166.2 (C4), 164.8 (C19′), 152.2 (C2), 149.4
(C8′), 142.4 (C6), 139.7 (C24′), 133.8 (C21′), 133.4 (C27′), 131.1
(C21′), 130.8 (C25′), 129.6 (C26′), 125.1 (C7′), 115.4 (C20′), 110.9
(C1″), 102.7 (C5), 92.4 (C1′), 84.8 (C4′), 80.2 (C4″), 78.4 (C5′), 76.4
(C2″), 75.4 (C2′), 73.9 (C3″), 71.4 (C3′), 69.6 (C18′), 52.6 (C6′), 44.3
(C5″), 30.8, 30.8, 30.7, 30.7, 30.7, 30.5, 30.4, 30.3, 27.2, 26.4
(C9′, C10′, C11′, C12′, C13′, C14′, C15′, C16′, C17′); HRMS, ESI
+ calcd
for C40H53N6O11
+ (M + H)+ 793.3767, found 793.3750; HPLC,
method D, tR = 13.25 min, 99%.
Compounds 27a–n. Compounds 27a–n have been syn-
thesised and fully characterized.24 The corresponding purity
has been determined by analytical HPLC and data have been
included in the ESI.†
Trifluoroacetate salt of 1″,5″-dideoxy-5″-amino-1″-[5′(S)-
acetylenylmethyl-uridinyl]-β-D-ribofuranose 28. Compound 28
was synthesized according to the general procedure for phthal-
imide, isopentylidene and TBS group cleavage from alkyne 5
(50.0 mg, 0.06 mmol). After semi-preparative reverse phase
HPLC (method: 15 mL min−1, H2O–TFA 0.1%/MeOH 100/0 to
60/40 in 50 min) and lyophilisation, 28 was obtained as an
ammonium ditrifluoroacetate salt (white foam, 16.3 mg, 52%
yield): m.p. 147–154 °C; [α]D +19 (c 0.2, H2O); IR (film) 2925br,
2300w, 1643s, 1436m, 1270s; 1H NMR (D2O + 50 µL CD3OD), δ
7.82 (d, 1H, JH6–H5 = 8.0 Hz, H6), 5.86 (d, 1H, JH5–H6 = 8.0 Hz,
H5), 5.81 (d, 1H, JH1′–H2′ = 4.0 Hz, H1′), 5.20 (s, 1H, H1″), 4.28
(dd, 1H, JH2′–H1′ = 4.0 Hz, JH2′–H3′ = 5.0 Hz, H2′), 4.26 (dd, 1H,
JH4′–H3′ = 5.0 Hz, JH4′–H5′ = 3.5 Hz, H4′), 4.20 (t, 1H, JH3′–H2′ =
JH3′–H4′ = 5.0 Hz, H3′), 4.17–4.11 (m, 2H, H2″, H4″), 4.08–4.03
(m, 2H, H3″, H5′), 3.39 (dd, 1H, JH5″a–H5″b = 13.5 Hz, JH5″a–H4″ =
2.0 Hz, H5″a), 3.20 (dd, 1H, JH5″b–H5″a = 13.5 Hz, JH5″b–H4″ = 8.5
Hz, H5″b), 2.81–2.70 (m, 2H, H6′a, H6′b), 2.48–2.47 (m, 1H, H8′);
13C NMR (CD3OD) δ 167.1 (C4), 152.4 (C2), 142.8 (C6), 125.2
(C7′), 110.8 (C1″), 102.8 (C5), 91.2 (C1′), 85.4 (C4′), 81.7 (C7′), 79.4
(C4″), 77.9 (C5′), 75.7 (C2″), 74.8 (C2′), 73.6 (C3″), 72.9 (C8′), 70.9
(C3′), 44.4 (C5″), 23.2 (C6′); HRMS, ESI
+ calcd for C17H24N3O9
+
(M + H)+ 414.1507, found 414.1513; HPLC, method D, tR =
3.32 min, 95%.
Trifluoroacetate salt of 1″,5″-dideoxy-5″-amino-1″-[5′(S)-
azidomethyl-uridinyl]-β-D-ribofuranose 29. Compound 29 was
synthesized according to the general procedure for phthal-
imide, isopentylidene and TBS group cleavage from azide 6
(10.0 mg, 0.012 mmol). After semi-preparative reverse phase
HPLC (method: 15 mL min−1, H2O–TFA 0.1%/MeOH 95/5 to
60/40 in 40 min) and lyophilisation, 29 was obtained as an
ammonium trifluoroacetate salt (white powder, 2.0 mg, 31%
yield): m.p. 142–146 °C; [α]D +14 (c 0.1, MeOH); IR (film)
2926m, 2100m, 1610s, 1462w, 1202m, 1133m,; 1H NMR (D2O +
50 µL CD3OD), δ 7.79 (d, 1H, JH6–H5 = 8.0 Hz, H6), 5.87 (d, 1H,
JH5–H6 = 8.0 Hz, H5), 5.78 (d, 1H, JH1′–H2′ = 3.0 Hz, H1′), 5.19 (s,
1H, H1″), 4.30 (dd, 1H, JH2′–H3′ = 5.0 Hz, JH2′–H1′ = 3.0 Hz, H2′),
4.208 (t, 1H, JH3′–H2′ = JH3′–H4′ = 5.0 Hz, H3′), 4.17–4.07 (m, 4H,
H4′, H5′, H2″, H3″, H4″), 3.76 (dd, 1H, JH6′a–H6′b = 13.5 Hz,
JH6′a–H5′ = 4.5 Hz, H6′a), 3.61 (dd, 1H, JH6′b–H6′a = 13.5 Hz,
JH6′b–H5′ = 5.5 Hz, H6′b), 3.40 (dd, 1H, JH5″a–H5″b = 13.5 Hz,
JH5″a–H4″ = 1.5 Hz, H5″a), 3.18 (dd, 1H, JH5″b–H5″a = 13.5 Hz,
JH5″b–H4″ = 8.5 Hz, H5″b);
13C NMR (D2O + 50 µL CD3OD)
δ 167.0 (C4), 152.3 (C2), 142.8 (C6), 110.1 (C1″), 102.9 (C5), 91.8
(C1′), 84.5 (C4′), 79.5 (C4″), 78.4 (C5′), 75.8 (C2″), 74.7 (C2′), 73.4
(C3″), 70.7 (C3′), 53.0 (C6′), 44.1 (C5″); HRMS, ESI
+ calcd for
C15H23N6O9
+ (M + H)+ 431.1521, found 431.1515; HPLC,
method D, tR = 4.07 min, 99%.
1″,5″-Dideoxy-2″,3″-O-isopentylidene-5″-azido-1″-[2′,3′-O-iso-
propylidene-5′(S)-ethynyl-uridinyl]-β-D-ribofuranose 32. The
fluororibosyl derivative 30 (1.51 g, 6.17 mmol, 2 equiv.) and
propargyl alcohol 31 (951 mg, 3.09 mmol, 1 equiv.) were dried
together by co-evaporation with toluene (3 × 10 mL) and dis-
solved in DCM (80 mL). The flask was flushed with argon and
molecular sieves 4 Å was added (7 g) in one portion. The sus-
pension was stirred at r.t. for 1 h and then cooled to −78 °C.
Boron trifluoride diethyletherate (775 µL, 6.17 mmol, 2 equiv.)
was added at −78 °C and the reaction medium was stirred at
this temperature for 10 min and was then allowed to warm to
r.t. for 16 h. The reaction mixture was filtered on a celite pad
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and the cake was washed with DCM (50 mL). The reaction was
quenched by addition of a saturated aqueous solution of
NaHCO3 (50 mL) and the aqueous phase was extracted with
DCM (5 × 60 mL). The combined organic layers were dried
(Na2SO4), filtered and concentrated in vacuo. The resulting
white foam was purified by flash chromatography (toluene/
acetone 85/15) to give azido alkyne 32 as a β/α mixture (β/α =
13/1) and as a white foam (1.23 g, 75% combined yield). The
major diastereoisomer was isolated with 45% yield: Rf 0.30
(toluene/acetone 7/3); m.p. 136–140 °C; [α]D −32 (c 0.5,
CH2Cl2); IR (film) 3246br, 3070w, 2105s, 1693s, 1458m, 1090s;
1H NMR δ 9.86 (br s, 1H, NH), 7.32 (d, 1H, JH6–H5 = 7.5 Hz, H6),
5.71 (d, 1H, JH5–H6 = 7.5 Hz, H5), 5.64 (d, 1H, JH1′–H2′ = 2.0 Hz,
H1′), 5.26 (s, 1H, H1″), 4.96 (dd, 1H, JH2′–H3′ = 7.0 Hz, JH2′–H1′ =
2.0 Hz, H2′), 4.93 (dd, 1H, JH3′–H2′ = 7.0 Hz, JH3′–H4′ = 4.0 Hz,
H3′), 4.64 (dd, 1H, JH5′–H4′ = 7.5 Hz, JH5′–H7′ = 2.5 Hz, H5′), 4.60
(d, 1H, JH2″–H3″ = 6.5 Hz, H2″), 4.59 (d, 1H, JH3″–H2″ = 6.5 Hz,
H3″), 4.47 (dd, 1H, JH4″–H5″a = 10.0 Hz, JH4″–H5″b = 4.5 Hz, H4″),
4.34 (dd, 1H, JH4′–H5′ = 6.5 Hz, JH4′–H3′ = 2.5 Hz, H4′), 3.96 (dd,
1H, JH5″a–H5″b = 14.0 Hz, JH5″a–H4″ = 10.0 Hz, H5″a), 3.90 (dd,
1H, JH5″b–H5″a = 14.0 Hz, JH5″b–H4″ = 4.5 Hz, H5″b), 2.60 (d, 1H,
JH7′–H5′ = 2.0 Hz, H7′), 1.65–1.61 (m, 2H, H7″), 1.59 (s, 3H, H9′),
1.52 (q, 2H, JH7″–H8″ = 7.5 Hz, H7″), 1.39 (s, 3H, H9′), 0.85 (t, 3H,
JH8″–H7″ = 7.5 Hz, H8″), 0.82 (t, 3H, JH8″–H7″ = 7.5 Hz, H8″);
13C
NMR δ 168.3 (C9″), 162.9 (C4), 150.1 (C2), 142.1 (C6),
134.3 (C12″), 132.1 (C10″), 123.6 (C11″), 117.2 (C6″), 114.7 (C8′),
109.4 (C1″), 102.9 (C5), 94.8 (C1′), 88.6 (C4′), 85.9 (C2″), 84.9
(C4″), 84.2 (C2′), 82.6 (C3″), 81.5 (C3′), 79.7 (C6′), 76.5 (C7′), 68.6
(C5′), 40.7 (C5″), 29.6, 28.9 (C7″), 27.2, 25.4 (C9′), 8.4, 7.4 (C8″);
HRMS ESI+ calcd for C24H32N5O9
+ (M + H)+ 534.2195, found
534.2195.
1″,5″-Dideoxy-2″,3″-O-isopentylidene-5″-amino-1″-[2′,3′-O-iso-
propylidene-5′(S)-ethynyl-uridinyl]-β-D-ribofuranose 33. To a
solution of azide 32 (609 mg, 1.14 mmol, 1 equiv.) in THF
(12 mL) and water (2 mL) was added triphenylphosphine
(598 mg, 2.28 mmol, 2 equiv.). The mixture was stirred at r.t.
for 16 h and volatiles were removed in vacuo. Flash chromato-
graphy of the residue aﬀorded 33 as a white foam (498 mg,
86% yield); m.p. 116–120 °C; [α]D −15 (c 0.5, MeOH); IR (film)
2976w, 2938w, 1694s, 1455m, 1272s; 1H NMR (CD3OD) δ 7.64
(d, 1H, JH6–H5 = 8.5 Hz, H6), 5.72 (d, 1H, JH1′–H2′ = 2.0 Hz, H1′),
5.65 (d, 1H, JH5–H6 = 8.5 Hz, H5), 5.17 (s, 1H, H1″), 5.08 (dd, 1H,
JH2′–H3′ = 6.5 Hz, JH2′–H1′ = 2.0 Hz, H2′), 4.89 (dd, 1H, JH3′–H2′ =
6.5 Hz, JH3′–H4′ = 3.0 Hz, H3′), 4.69 (d, 1H, JH5′–H4′ = 8.0 Hz, H5′),
4.59 (d, 1H, JH2″–H3″ = 6.0 Hz, H2″), 4.57 (d, 1H, JH3″–H2″ = 6.0
Hz, H3″), 4.19 (dd, 1H, JH4′–H5′ = 8.0 Hz, JH4′–H3′ = 3.0 Hz, H4′),
4.15 (dd, 1H, JH4″–H5″a = 9.0 Hz, JH4″–H5″b = 5.0 Hz, H4″), 3.27
(sl, 1H, H7′), 2.77 (dd, 1H, JH5″a–H5″b = 13.0 Hz, JH5″a–H4″ = 9.0
Hz, H5″a), 2.69 (dd, 1H, JH5″b–H5″a = 13.0 Hz, JH5″b–H4″ = 5.0 Hz,
H5″b), 1.60 (q, 2H, JH7″–H8′′′ = 7.5 Hz, H7″), 1.52 (q, 2H, JH7″–H8′′′ =
7.5 Hz, H7″), 1.50 (s, 3H, H9′), 1.31 (s, 3H, H9′), 0.82 (t, 3H,
JH8″–H7″ = 7.5 Hz, H8″), 0.81 (t, 3H, JH8″–H7″ = 7.5 Hz, H8″);
13C
NMR (CD3OD) δ 166.4 (C4), 152.4 (C2), 142.1 (C6), 117.9 (C6″),
115.3 (C8′), 111.4 (C1″), 103.1 (C5), 97.8 (C1′), 91.4 (C4′), 90.5
(C2″), 87.3 (C4″), 85.6 (C2′), 83.8 (C3″), 83.5 (C3′), 80.2 (C7′, C6′),
70.1 (C5′), 45.8 (C5″), 30.5, 30.0 (C7″), 27.5, 25.5 (C9′), 8.8, 7.9
(C8″); HRMS ESI
+ calcd for C24H34N3O9
+ (M + H)+ 508.2290,
found 508.2301.
Trifluoroacetate salt of 1″,5″-dideoxy-5″-amino-1″-[5′(S)-
ethynyl-uridinyl]-β-D-ribofuranose 34. At 0 °C, to a suspension
of amine 33 (40 mg, 0.078 mmol, 1 equiv.), in pure water (600
µL), was dropwise added trifluoroacetic acid (2.4 mL). The
mixture was stirred at 0 °C for 10 min then at r.t. for 90 min.
Trifluoroacetic acid was then removed in vacuo without
heating. The residue was dissolved in water and lyophilised.
The crude foam was recrystallized in dry Et2O to furnish the
corresponding deprotected compound 34 as a trifluoroacetate
salt (white powder, 39.6 mg, 99% yield); m.p. 180–186 °C;
[α]D +15 (c 0.5, MeOH); IR (film) 3250br, 2925w, 2320w, 1678s,
1519w, 1467w, 1275m; 1H NMR (CD3OD) δ 7.73 (d, 1H,
JH6–H5 = 8.5 Hz, H6), 5.88 (d, 1H, JH1′–H2′ = 6.0 Hz, H1′), 5.74 (d,
1H, JH5–H6 = 8.5 Hz, H5), 5.21 (s, 1H, H1″), 4.65 (dd, 1H,
JH5′–H4′ = 5.5 Hz, JH5′–H7′ = 2.0 Hz, H5′), 4.28 (t, 1H, JH2′–H3′ =
6.0 Hz, JH2′–H1′ = 6.0 Hz, H2′), 4.20 (dd, 1H, JH3′–H2′ = 6.0 Hz,
JH3′–H4′ = 3.0 Hz, H3′), 4.14–4.09 (m, 3H, H2″, H3″, H4″),
3.99–3.96 (m, 1H, H4′), 3.31–3.28 (m, 1H, H5″a), 3.17 (dd, 1H,
JH5″b–H5″a = 13.0 Hz, JH5″b–H4″ = 4.0 Hz, H5″b), 3.14 (d, 1H,
JH7′–H5′ = 2.0 Hz, H7′).;
13C NMR (CD3OD) δ 166.1 (C4), 152.5
(C2), 142.5 (C6), 109.0 (C1″), 103.2 (C5), 90.8 (C1′), 87.1 (C4″),
81.3 (C6′), 80.5 (C3″), 77.9 (C7′), 76.0 (C4′), 74.6 (C2′), 74.3 (C2″),
71.7 (C3′), 69.2 (C5′), 44.5 (C5″); HRMS ESI
+ calcd for
C16H22N3O9
+ (M + H)+ 400.1351, found 400.1351; HPLC,
method C, tR = 2.31 min, 98%.
Enzymatic assays
The activities of the compounds against MraY from Bacillus
subtilis were tested as previously described.14b The assay was
performed in a reaction mixture of 10 µL containing, in final
concentrations, 100 mM Tris-HCl, pH 7.5, 40 mM MgCl2,
1.1 mM C55-P, 250 mM NaCl, 0.25 mM UDP-MurNAc-[
14C]-
pentapeptide (337 Bq), and 8.4 mM N-lauroyl sarcosine. The
reaction was initiated by the addition of MraY enzyme (50 ng)
and the mixture was incubated for 30 min at 37 °C under
shaking with a thermomixer (Eppendorf ). The reaction was
stopped by heating at 100 °C for 1 min and the radiolabeled
substrate (UDP-MurNAc-pentapeptide) and reaction product
(lipid I) were separated by TLC on silica gel plates using 2-pro-
panol/ammonium hydroxide/water (6 : 3 : 1; v/v/v) as the
mobile phase. The radioactive spots were located and quanti-
fied with a radioactivity scanner.
Antibacterial activity
Determination of antibacterial activity was done on microtitric
plates, in 200 µL (final volume) of Müeller–Hinton broth
(MHB), following the EUCAST (European Committee on Anti-
microbial Susceptibility testing)/CLSI (Clinical and Laboratory
Standard Institute) recommended procedure.42
Compounds were solubilized in DMSO and then diluted in
MHB just before utilization. Inocula were prepared for each
strain, resuspending isolated colonies from 18 h cultured
plates. Equivalents of 0.5 Mac Farland turbidity standard
(approximately 1 × 108 CFU ml−1) were prepared in saline solu-
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tion (NaCl 0.085%) and then diluted 200 fold in MHB. MIC
values were determined as the lowest dilution of product
showing no visual turbidity.
Molecular docking
All calculations were performed in Discovery Studio 4.0. MraY
structure (PDB code: 4J72) was prepared by the use of the
Prepare Protein protocol of DS 4.0 including the cleaning of
the protein, the optimization of side-chain conformation for
residues with inserted atoms, the removal of water molecules
present in the PDB structure, the modeling of missing loop
regions based on SEQRES information, and the prediction of
titration site pKs and protonation state of the structure at the
specified pH. Flexible ligand/rigid protein docking was per-
formed using CDOCKER.33 Ligands were prepared using the
Prepared Ligand protocol of DS 4.0 including the generation of
canonical tautomers, keeping only largest fragments, the set of
standard formal charges of common functional groups, the
generation of kekule structures, enumeration of ionization
states at a given pH range, enumeration of tautomers and the
generation of a reasonable 3D conformation using Catalyst.
Random ligand conformations were generated from the initial
ligand structure through high-temperature molecular
dynamics. Due to the high flexibility of the MraY ligand, we
docked for each ligand several conformations previously gener-
ated with the BEST algorithm43 to cover the full range of con-
formers. The poses showing the lowest energy were retained
and clustered according to their binding mode. Three-dimen-
sional snapshots of the docked ligands were generated using
Accelrys DS Visualizer.
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